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 Scope of work conducted by the PhD candidate 
This thesis is the work of the principle investigator, Enesia Banda Chaponda. This 
investigator designed the study with the help of the main and the co-supervisors. All 
the standard operation procedure, the questionnaire and all study forms were 
developed by this investigator. The translation of the questionnaire and consent 
forms from English to Bemba and back translation was done by personnel from the 
Zambia National Broadcasting Network with input from the principle investigator 
who ensured that what was communicated in the local language, Bemba, was what 
was intended. This investigator applied for ethical clearance from the London school 
of Hygiene and Tropical Medicine Observational/Interventions Research Ethics 
committee and the University of Zambia Biomedical Research Ethics Committee.  
After obtaining ethical clearance this investigator also sought and obtained written 
permission to conduct the study from the Zambia Ministry of Health. Upon being 
granted permission by the ministry of health this investigator wrote letters (and 
personally delivered them) to the district health office, the office of the district 
commissioner, the administrators of St. Paul’s Mission Hospital (only hospital in 
Nchelenge District)  and administrators of the two health centres (recruitment sites 
for the study) to inform them about the study before commencement. This 
investigator paid a courtesy call on the chief in the area and organised and held pre-
study meetings with community leaders (village headmen). With the help of 
members of the Tropical Disease Research centre study team members who were 
conducting research in the area, this investigator recruited her study team members, 
which included 4 full-time team members and those who were already working in 
the health system. Those who were already in the system were recruited to help out 
with the project activities during routine duty. These included midwives, general 
nurses, traditional birth attendants/counsellors, counsellors who were involved in 
the routine running of the ANC clinic in the two the health centres, a radiographer 
and laboratory technicians.  
This investigator also trained team members on the general aspects of the project 
and specifics of their role in the project. This investigator managed the day to day 
running of the project, coordinated study team members and conducted weekly 
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feedback meetings with team members. This investigator was also involved in some 
of study activities including screening eligibility of participants, obtaining written 
consent and administration of questionnaires while coordinating the rest of the 
activities during the enrolment and sample collection process.  
All the molecular work was conducted by this investigator. Molecular work included 
deoxy-ribonucleic acid extraction from dried blood samples and cervico-vaginal 
swabs for diagnosis of malaria and three sexually transmitted infections and 
diagnoses of malaria, Chlamydia, gonorrhoea and trichomoniasis infection by 
standard polymerase chain reaction. Over 75% of slides for diagnosis of bacterial 
vaginosis were stained by the principle investigator each week during the 
recruitment period. At the beginning of the project, slide staining for diagnosis of 
bacterial vaginosis was carried out by a technician who later left for school. Reading 
of slides for diagnosis of bacterial vaginosis was done by this investigator at the 
University of Zambia at intervals. Data was mainly entered by a data clerk; this 
investigator coordinated data entry, occasionally entered data and conducted 
regular data entry checks. Data cleaning, development of the analysis plan, data 
processing, data analysis and writing up of the thesis were all done by this 
investigator. 
 
 Activities coordinated by the candidate but conducted by hired individuals 
Some study activities were conducted by individuals who were part of the team or 
those hired for a specific function. These included preparation of blood slides for 
diagnosis of malaria and slides reading; processing of placental tissue, slide 
preparation and reading of slides for diagnosis of placental malaria; rapid plasma 
reagin (RPR) and Treponema pallidum haemagglutination (TPHA) assay testing and 
gestational age measurement by ultra-sound. All of these functions were conducted 
by individuals with training and experience in performing these procedures. 
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Abstract  
Introduction 
Malaria and curable sexually transmitted and reproductive tract infections 
(STIs/RTIs) are important causes of adverse birth outcomes (ABO) and are both 
prevalent in most parts of sub-Saharan Africa. From a public health perspective, 
control of these infections requires interventions that are part of an integrated 
antenatal care package. The extent to which there may be coinfection increases the 
importance of such an integrated approach to reduce ABO. 
A systematic review and meta-analysis published in 2012 showed that the 
prevalence of malaria and curable STIs/RTIs among antenatal attendees in sub-
Saharan Africa is considerable. However, the prevalence of malaria and curable 
STI/RTI coinfection has not been reported in any epidemiological setting. 
The primary objective of this thesis is to address this knowledge gap by estimating 
the prevalence of malaria, curable STIs/RTIs and their coinfection and to highlight 
the importance of an integrated approach to control malaria and STIs/RTIs in 
pregnancy. Secondary objectives of the study were to:  
(1) determine risk factors for malaria, curable STIs/RTIs and their coinfection;  
(2) estimate the prevalence of ABO and identify risk factors for ABO;  
(3) measure the in vivo efficacy and the prophylactic effect of sulphadoxine-
pyrimethamine (SP) in pregnant women, and  
(4) characterise the molecular markers associated with parasite resistance to SP 
among pregnant women.  
 
Methods 
A prospective cohort study of 1,086 antenatal attendees was conducted in 
Nchelenge District, Zambia. Consenting women visiting two health centres for their 
first antenatal care (ANC) visit were screened for malaria and curable STIs/RTIs 
(Chlamydia, gonorrhoea, trichomoniasis, bacterial vaginosis [BV] and syphilis). Socio-
demographic data and maternal characteristics were also collected at enrolment. 
Sulphadoxine-pyrimethamine was administrated as intermittent preventive 
treatment to eligible women and they were followed up at day 28 for a second 
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malaria screening to determine the therapeutic and prophylactic failure of SP. At 
delivery participants were screened for placental malaria and data on birth 
outcomes were recorded. Univariate and multivariate analyses were conducted to 
determine the association between the potential risk factors for infection and ABO. 
Results 
Of the 1086 women recruited 729 were successfully followed to delivery. The 
prevalence of malaria infection measured by microscopy was 31.8% (95% CI, 29.1-
34.6) and by PCR was 57.8% (95% CI, 54.9-60.8). The risk of malaria infection was 
higher among pregnant women recruited from Nchelenge health centre compared 
to those attending the Kashikishi health centre (adjusted odds ratio [aOR] = 1.81; 
95% CI, 1.38-2.37, P < 0.001), and HIV-infected women across health centres had a 
greater risk of malaria infection compared to HIV-uninfected women (aOR = 1.46; 
95%, 1.00-2.13, P = 0.045).   
Infection with at least one STI/RTI was observed in 64.8% (95% CI, 61-67.4) of the 
participating women.  With the exclusion of BV the prevalence of infection with at 
least one curable STI was 34.5% (95% CI, 31.7-37.4).  Infection with at least one STI 
was associated with BV. In comparison to uninfected women, women infected with 
BV were at a higher risk of being infected with at least one STI (aOR 1.44; 95% CI, 
1.08-1.92, P = 0.012). HIV-infected women had a higher risk of infection with BV than 
HIV-uninfected women (aOR 1.87; 95% CI, 1.24-2.83, P = 0.003) and women infected 
with at least one STI had a higher risk of BV (aOR 1.40; 95% CI (1.07 -1.84, P = 0.01).  
Among participants with complete results (n=1071), 38.7% (95% CI,35.7-41.6) were 
coinfected with malaria parasites and at least one STI/RTI; 18.9% (95% CI, 16.5-21.2) 
were infected with malaria parasites only; 26.0% (95% CI, 23.5-28.8) were infected 
with at least one STI/RTI but no malaria parasites, and 16.4% (95% CI, 14.1-18.6) had 
no infection.  The risk of malaria and curable STI/RTI coinfection was higher among 
HIV infected women than HIV-uninfected women (OR; 3.59 [95% CI, 1.73-7.48], P < 
0.001).  
The prevalence of composite ABO was 35.1%. Women shorter than 1.5m were at a 
higher risk of experiencing at least one ABO (aOR 1.55; 95% CI, 1.10-2.18, P = 0.02). 
The risk of having ABO among para II was less than half of the risk observed in 
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primiparous women (aOR 0.41; 95% CI, 0.27-0.61, P < 0.001) and much lower among 
multiparous women (aOR 0.32; 95% CI, 0.22-0.48, P < 0.001). Having taken two or 
more doses of SP during pregnancy was protective against ABO (aOR 0.47; 95% CI, 
0.31-0.72, P = 0.001). None of the infections (malaria, curable STIs/RTIs and their 
coinfection) diagnosed at first ANC were associated with ABO.  
The prevalence of highly resistant quintuple mutant was 68.8% among first ANC 
attendees. Despite the moderate prevalence of the quintuple mutant among 
pregnant women, SP cleared parasitaemia in 86% of the asymptomatic malaria cases 
among HIV-negative women 
Conclusion 
The prevalence of malaria, STI/RTI and their coinfection at first ANC in this study 
population was considerable.  However, no association was found between ABO and 
infection with malaria or STI/RTI or their coinfection. This lack of association is 
partially a result of interventions within the ANC package including treatment of 
some STI/RTI, intermittent preventive treatment in pregnancy with SP and iron and 
folic acid supplementation. Sulphadoxine-pyrimethamine retains partial efficacy 
against P. falciparum malaria in this area with moderate prevalence of the quintuple 
mutant. While continuing the policy of offering intermittent preventive treatment 
with SP during pregnancy, an alternative preventive therapy that is effective against 
both malaria and STIs/RTIs needs to be considered. 
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Summary of content 
This thesis aims to address a knowledge gap by measuring malaria and STIs/RTIs and 
their coinfection. Many studies have reported the prevalence of malaria and that of 
STI/RTI in pregnant women but the prevalence of their coinfection has not been 
estimated in an epidemiological setting. Secondary objectives were to: identify risk 
factors for malaria, curable STIs/RTIs and their coinfection; estimate the prevalence 
of ABO and identify risk factors; characterise the mutations that are associated with 
parasite resistance to SP and assess the in vivo efficacy, prophylactic and therapeutic 
failure of SP among pregnant women.  
The thesis is organised as follows: 
 Chapter 1 gives the background to the study by highlighting the burden of 
malaria, curable STIs/RTIs in pregnant women and their effect on birth 
outcome and the antenatal care package for their management. The 
background also highlights the gap in knowledge on malaria and curable 
STI/RTI coinfection and points out the weaknesses of the intermittent 
preventive treatment in pregnancy with SP (IPTp-SP) strategy for the 
alleviation of the consequences of malaria infection in pregnancy in the face 
of emerging parasite resistance to SP. The background also points out the 
inaccuracy of the syndromic approach for the management of STIs/RTIs. The 
chapter also gives the rationale for the study and the objectives. 
 Chapter 2 describes the methods employed including the study design, a 
description of the study area, identification and recruitment of participant; 
and tools used in the collection of data and samples, detection of infections, 
data processing and analyses.  
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 Chapter 3 describes the characteristics of study participants according to 
recruitment sites and the prevalence of malaria, curable STIs/RTIs and their 
coinfection among participants.  
 Chapter 4 describes the risk factors for malaria, curable STIs/RTIs and their 
coinfection in the study population. 
 Chapter 5 describes results on the estimates of dihydrofolate reductase 
(DHFR) and dihydropteroate synthase (DHPS) mutations associated with P. 
falciparum resistance to SP and gives estimates of the in vivo efficacy and the 
therapeutic and prophylactic failure of IPTp-SP. The idea behind this chapter 
is to give details of interest that is give an estimation of the level of SP 
resistance and the efficacy of SP in the study population. 
 Chapter 6 gives estimates of individual and composite adverse birth outcome 
and describes risk factors for ABO. 
 Chapter 7 discusses all the results and gives the limitations of the study, 
conclusions, policy recommendations and reflexivity. 
Note 
 1. The data on malaria prevalence and risk factors for infection have been published 
in the Malaria Journal (2015) 14:380 DOI 10.1186/s12936-015-0866-1 
Chaponda EB, Chandramohan D, Michelo C, Mharakurwa S, Chipeta J, Chico RM, 
2015. High burden of malaria infection in pregnant women in a rural district of 
Zambia: a cross-sectional study. Malar J 14: 380.  
2. The data on malaria and STI/RTI coinfection has been published in the American 
Journal of Tropical Medicine and Hygiene.  
Chaponda EB, Chico RM, Bruce J, Michelo C, Vwalika B, Mharakurwa S, et al. Malarial 
Infection and Curable Sexually Transmitted and Reproductive Tract Infections Among 
Pregnant Women in a Rural District of Zambia. Am J Trop Med Hyg. 2016;95(5):1069-
76. 
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1 Introduction 
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1.1 Background 
Maternal malaria and curable STIs/RTIs remain important causes of adverse birth 
outcomes (ABO). One of the interventions recommended by the World Health 
Organisation (WHO) for reducing the burden of malaria in pregnancy is intermittent 
preventive treatment in pregnancy with sulphadoxine-pyrimethamine (IPTp-SP). 
However, the effectiveness of IPTp-SP has been undermined by the emergence of SP 
resistant parasites [1, 2]. Results from a systematic review and meta-analysis of trials 
showed that administration of three doses of IPTp-SP appear to be beneficial even in 
areas with high SP resistance. However, this does not imply that it may be so in areas 
with very high SP resistance [3]. Nevertheless, there is urgent need to identify 
alternative preventive therapy for SP. 
Testing women for curable STIs/RTIs during ANC visits and providing appropriate 
care has been a public health challenge for decades in resource-poor settings. The 
WHO has developed syndrome-based algorithms for the detection of curable 
STIs/RTIs to assist countries with limited resources [4]. However, syndrome-based 
algorithm for vaginal discharge has poor sensitivity in detecting cervical infections 
[5]. Therefore, a considerable burden of STIs/RTIs in pregnancy remains undetected 
and untreated.  
A systematic review and meta-analysis of studies reporting malaria or curable 
STIs/RTIs in pregnant women attending antenatal clinics in sub-Saharan Africa 
published in 2012 showed that the prevalence of malaria and curable STIs/RTIs 
during pregnancy is considerable [6]. The review also highlighted the paucity of data 
on coinfection of malaria and curable STIs/RTIs during pregnancy. In view of the 
challenges in the current approach, one of the possible ways forward is to find an 
initiative that integrates the prevention and control of malaria and STI/RTI in 
pregnancy. However, initiative for an integrated solution is hampered by a lack of 
information about the burden of their coinfection. This thesis aims to address this 
gap in knowledge and to highlight the importance of an integrated approach to 
control malaria and STIs/RTIs in pregnancy. 
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Malaria and curable STIs/RTIs are both prevalent in most parts of sub-Saharan Africa. 
The overlapping prevalence of malaria and curable STIs/RTIs has important public 
health implications especially in pregnant women.   
Despite the fact that malaria and curable STIs/RTIs are important risk factors for 
ABO, no study identified in the systematic review by Chico et al. had reported the 
prevalence of malaria and STIs/RTIs coinfection, with the exception of one study 
which reported that 48.3% of women who tested positive to rapid plasma reagin 
(RPR) had placental malaria [6].  
 
The primary objective of the current study was to estimate the prevalence of 
malaria, STIs/RTIs, and their coinfection among pregnant women in an area with 
overlapping prevalence of malaria and STIs/RTIs. Secondary objectives were to: 
1. determine risk factors for malaria, curable STIs/RTIs and their coinfection;  
2. estimate the prevalence of ABO and identify risk factors for ABO;  
3. measure the in vivo efficacy and the prophylactic effect of sulphadoxine-
pyrimethamine (SP) in pregnant women, and  
4. characterise the molecular markers associated with parasite resistance to SP 
among pregnant women.  
 
1.2 Risks associated with malaria and curable STIs/RTIs in pregnancy  
1.2.1 Effects of curable STIs/RTIs on pregnancy outcomes 
Curable STIs/RTIs are a major public health problem, especially in developing 
countries [7, 8]. In 2004 Mullick and colleagues reviewed the prevalence of STIs/RTIs 
and the relationship between these infections and pregnancy outcomes [7]. The 
paper reviewed evidence from both developed and developing countries. Although 
there were few studies from developing countries at the time of the review, the 
authors concluded that developing countries have a high prevalence of STIs/RTIs 
which have a significant impact on birth outcomes.  
1.2.1.1 Syphilis 
Mullick et al. identified two studies that looked at the impact of syphilis in pregnancy 
at a population level in Malawi and Tanzania [9, 10]. In Malawi women with active 
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syphilis were 11 times more likely to experience a stillbirth (adjusted odds ratio 
[aOR] 10.89; 95% CI, 6.61-17.93) and 26% of stillbirths were attributed to active 
syphilis [9].  In Tanzania, 17% of all adverse pregnancy outcomes were attributed to 
syphilis. Syphilis was associated with increased risk of stillbirth (adjusted risk ratio 
[aRR] 18.1; 95% CI, 5.5-59.60), low birth weight (LBW) in live born infants (aRR 3.3; 
95% CI, 2.0-5.4), preterm delivery (PD) (aRR 6.1; 95% CI, 2.5-15.3) and intra-uterine 
growth retardation (IUGR) (aRR 2.1; 95% CI, 1.0-4.2) [10].   
1.2.1.2 Chlamydia trachomatis 
Two prospective studies from the United States (US) included in the same review 
showed that Chlamydia trachomatis has significant impact on pregnancy outcomes. 
In the first study researchers found that C. trachomatis infection was associated with 
both IUGR (aOR 2.4; 95% CI, 1.3-4.2) and PD (aOR 1.6; 95% CI, 1.0-4.2) [11]. Authors 
of the second study found that infection with C. trachomatis was associated with 
LBW (aOR 2.7; 95% CI, 1.3 to 5.7), premature rupture of membranes (PROM) (OR 
2.4; 95% CI 1.7 to 5.4)  and < 34 weeks preterm labour (aOR 4.0; 95% CI, 1.7-9.2) 
[12]. However, a third study (also done in the US) showed no such association 
between infection with C. trachomatis and ABO [13]. This lack of association could 
be explained by the fact that some of the infected women received prenatal 
antibiotic treatment. It is highly unlikely that Chlamydial-infected women in the first 
study mentioned above received treatment as this is not mentioned or referred to at 
all [11]. In the second study mentioned above that associated infection with C. 
trachomatis with LBW, PROM and preterm labour, women received treatment for 
gonococcal infections but Chlamydial infections were not treated until after the 
onset of labour or rupture of membranes [12].  
In two studies from Kenya, infection with C. trachomatis was associated with 
postpartum endometritis [14] and 31% of 181 cases of neonatal conjunctivitis were 
found to have been caused by C. trachomatis [15].  
1.2.1.3 Neisseria gonorrhoea 
Three studies on the impact of N. gonorrhoea infection on pregnancy outcome were 
noted in the review by Mullick et al. 2005. One was based on case reports in the 
United Kingdom and documented sequelae of untreated gonorrhoea in pregnancy 
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which included PD, PROM, LBW, postpartum endometritis and gonococcal 
ophthalmia neonatorum [16]. A case control study of women at delivery in Kenya 
found an association between N. gonorrhoeae infection and LBW (aOR 2.9; 95% CI 
1.2 - 7.2) and it was concluded that N. gonorrhoeae was responsible for 14% of LBW 
cases in the study population [17]. In South Africa a prospective study of 167 women 
looked at gonorrhoea diagnosed at first ANC visit and pregnancy outcome [18]. It 
was found that women with gonorrhoea delivered significantly smaller babies (mean 
weight 2252g versus 2970, P < 0.005). 
1.2.1.4 Trichomonas vaginalis 
Among the four studies of Trichomonas vaginalis in pregnancy included in this 
review, only one study was done in Africa [19]. The studies associated infection with 
T. vaginalis in pregnancy with PD and LBW [19-22]. In the Democratic Republic of 
Congo, trichomoniasis infection in pregnancy was associated with LBW in infants 
born to infected mothers (aOR 2.4; 95% CI, 1.2- 4.5) [19]. In the three studies in the 
US, one found that infection with T. vaginalis was associated with LBW among 
adolescents [22]; in the second study, women infected with T. vaginalis were 
significantly more likely to have PROM (P < 0.03) [21]. Trichomoniasis was associated 
with LBW (aOR 1.3; 95% CI, 1.1 to 1.5), PD (aOR  1.3; 95% CI, 1.1 -1.4) and PD of a 
LBW infant (aOR 1.4; 95% CI, 1.1 to 1.6) in the third study  [20].  
1.2.1.5 Bacterial vaginosis 
Studies on the effect of bacterial vaginosis (BV) on birth outcomes identified in the 
review by Mullick et al. included a prospective, controlled treatment trial in the US. 
Bacterial vaginosis was associated with increased risk of both PD (aRR 1.9; 95% CI, 
1.2-3.0) and PROM (aRR 3.5; 95% CI, 1.4-8.9) in women in the observation phase of 
the study [23].  A cohort study in the US found an association between BV and  PD of 
LBW infants (aOR 1.4; 95 % CI, 1.1- 1.8) [24] and a prospective study in Indonesia 
associated BV diagnosed early, between 16  and 20 weeks gestation, with PD (OR 
2.0; 95% CI, 1.0-3.9) but not with  BV diagnosed at 28 to 32 weeks gestation (aOR 
1.5, 95% CI, 0.7-3.0) [25]. 
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1.2.2 Additional evidence for association of STIs/RTIs with ABO 
To explore additional evidence for the effects of STIs/RTIs on pregnancy outcome, a 
literature search was undertaken. The last search was conducted in February 2016. 
The  Pubmed, Medline, Embase and Global Health databases were searched using 
combinations of the following key words: “Pregnancy”, “antenatal/prenatal”, 
“sexually transmitted disease”, “syphilis/Treponema pallidum”, 
“Chlamydia/Chlamydia trachomatis”, “Gonorrhoea/Neisseria 
gonorrhoeae/gonorrhoea”, “trichomoniasis/Trichomonas vaginalis”, “bacterial 
vaginosis” and “birth/pregnancy outcome”. The words “Malaria/Plasmodium 
falciparum” were also used to identify and include studies reporting the effect of 
malaria on pregnancy outcome in the search. The Medline, Embase and Global 
Health databases were searched via Ovid®. Appendix 1.1a shows search terms that 
were used for studies reporting infection with malaria or STI/RTI in pregnancy and 
birth outcomes. There was no restriction of the time when the studies were 
conducted. Titles and abstracts were screened for relevance and full texts were 
screened for those that were relevant to the subject. Articles with full texts 
published in non-English language were excluded.  Studies that reported 
investigating the association between malaria or STI/RTI and ABO were identified. 
Figure 1.1 shows a flow chart of the literature search and identification of articles. 
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 Figure 1. 1: Identification and screening of studies 
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Overall, 32 studies associating STIs/RTIs with ABO (including those that were 
identified in the review by Mullick et al.) and seven studies on malaria and ABO were 
identified. Below are brief details of 16 of the 32 studies on STIs/RTIs and ABO that 
were published after the review by Mullick et al., 2005. 
1.2.2.1 Syphilis 
In a multiple centre record based retrospective study of 368,151 births in Latin 
America and the Caribbean, syphilis was associated with stillbirth (aOR 1.88; 95% CI, 
1.25-2.83) [26]. 
A review and meta-analysis of studies reporting estimates of ABO among untreated 
1,715 women with syphilis and 22,515 women without syphilis, pooled estimates 
showed that among untreated pregnant women with syphilis, fetal loss and stillbirth 
were 21% more frequent, neonatal deaths were 9.3% more frequent and PD or LBW 
were 5.8% more frequent than among women without syphilis [27].  
1.2.2.2 Chlamydia trachomatis 
In a study of 343 pregnant women in South Africa, 36 (10.5%) delivered before 37 
weeks gestation and C. trachomatis was found in 8 (22.2%) of women who had PD in 
contrast to 32 (10.4%) of women who had full-term deliveries (P = 0.037) [28]. 
Results from an unmatched case-control study conducted in Uganda showed no 
association between C. trachomatis infection and PROM (aOR; 2.05, 95% CI, 0.37-
11.49) [29]. In a study of 3,913 pregnant women in the Netherlands C. trachomatis 
infection was associated with PD occurring before 32 weeks (aOR 4.35; 95% CI, 1.3 - 
15.2) and 35 weeks gestation (aOR:  2.66; 95% CI, 1.1- 6.5), but not before 37 weeks 
(aOR 1.17; 95%CI, 0.6-2.4) and not with LBW (P = 0.25) [30]. In a case control study in 
Switzerland, C. trachomatis was associated with PD (aOR; 7.93, 95% CI, 1.34-46.76) 
[31]. A record-based retrospective cohort study conducted in Australia involving 
354,217 participants, showed that women with Chlamydia had increased risk of PD 
(aOR 1.17, 95% CI, 1.01-1.37) and stillbirth (aOR 1.40, 95% CI, 1.00 -1.96) but no 
association was found between infection with Chlamydia and small for gestational 
age (aOR 0.99, 95% CI, 0.89-1.09) [32].  In a retrospective study in the US, electronic 
medical records from a sexually transmitted disease clinic were matched with state 
birth records for 730 women [33] Chlamydia was associated with LBW (aOR 2.07; 
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95% CI: 1.01 - 4.24).  A population based retrospective cohort study in the US found 
that Chlamydial-infected women were at increased risk of PD (aRR 1.4; 95% CI: 1.08 -
1.99) and PROM (aRR 1.5; 95% CI 1.03 -2.17) compared with uninfected women [34]. 
No increased risk of LBW was observed in this study (aRR 1.12; 0.61-1.68). Another 
study done in the US found no association between C. trachomatis infection and PD 
(aOR 0.7; 95% CI 0.4–1.4) [35]. This could be attributed to the fact that 66% of the 
positive diagnoses were done early and treatment was administered before 20weeks 
gestation. 
 
1.2.2.3 Neisseria gonorrhoeae 
In a record-based retrospective cohort study in Australia involving 354,217 
participants, no association was found between infection with gonorrhoea and 
stillbirth (aOR 2.35, 95% CI, 0.58-9.56) or gonorrhoea and small for gestational age 
(aOR 0.98, 95% CI, 0.58-1.68) [32]. Women infected with gonorrhoea had a higher 
risk of experiencing PD (OR 2.50, 95% CI, 1.39-4.50) [32]. Similarly, gonorrhoea was 
associated with PD (aOR 2.01; 95% CI 1.02 - 3.97), particularly when diagnosed in the 
first trimester (aOR 2.95; 95% CI: 1.30 - 6.70) in a study of 730 women in the US [33]. 
1.2.2.4 Trichomonas vaginalis 
No addition studies on the effect of T. vaginalis on ABO were identified in the 
literature search. The only studies that were identified were included in the review 
by Mullick et al., 2005 and are already described above. 
1.2.2.4 Bacterial vaginosis 
In a prospective study of 1,536 Tanzanian women designed to determine risk factors 
for poor birth outcomes, no association was found between treated STIs/RTIs and 
ABO except untreated BV which was associated with PD  (aOR; 2.9 95% CI, 1.3 - 6.6) 
[36]. In a prospective cohort study of 3,262 women in Denmark, BV was associated 
with LBW (aOR 1.95; 95% CI, 1.3-2.9), PD of a LBW infant (aOR 2.5; 95% CI, 1.6-3.9) 
and clinical chorioamnionitis (aOR 2.4; (95% CI, 1.4-4.1) [37].  In the United Kingdom, 
women with BV were not at a higher risk of experiencing PD (aOR 0.9, 95% CI, 0.4-
2.2) but had increased risk of experiencing spontaneous abortion (aOR 4.0, 95% CI, 
1.3-12.1) [38].  
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In a meta-analysis aimed at evaluating BV as a risk factor for PD, BV was associated 
with PD (aOR 2.2; 95% CI, 1.5-3.1) and spontaneous abortion (aOR 9.9; 95% CI, 2.0-
49.3) [39]. The meta-analysis was updated after about four years and BV was still 
associated with PD (aOR 2.2; 95% CI, 1.6-3.9) and spontaneous abortion (aOR 6.3; 
95% CI, 3.7-10.9) [40]. In Switzerland a study of 1,197 pregnant women found that 
BV was associated with preterm delivery (aOR 2.19; 95% CI, 1.2-4.0) [41]. 
 
1.2.3 Effects of malaria on pregnancy outcomes 
Pregnant women in malaria endemic areas are a high risk group for Plasmodium 
falciparum infection and related consequences [42]. Pregnancy results in a transient 
depression of cell-mediated immunity which improves the likelihood of foetal 
allograft retention but also interferes with immune responses to various infectious 
diseases [43]. Red blood cells that have been infected by P. falciparum sequester in 
vascular spaces in the placenta mediated by adhesion to chondroitin sulphate A [44] 
leading to placental inflammation [45] and complications associated with malaria in 
pregnancy [46]. Consequences of malaria in pregnancy include maternal anaemia, 
IUGR [36, 47], PD [36, 48], stillbirth [49, 50] and LBW  [36, 42]. Low birth weight is 
associated with a marked increase in neonatal death [51-54].   
Studies that investigated the effect of malaria on pregnancy outcome identified in 
the literature search mentioned above were all conducted in Africa. In Tanzania a 
study of the effectiveness of syphilis screening and treatment conducted from 1997 
to 2000, women with malaria had an increased risk of experiencing PD (aOR 3.2; 95% 
CI, 1.9-5.2), LBW (aOR 5.4; 95% CI, 3.1-9.5) and IUGR (aOR 2.8; 95% CI, 1.2-6.7) [36]. 
In another study designed to identify risk factors for stillbirth conducted in 
November and December of 2006 in Ghana, women with malaria had increased risk 
of stillbirth (aOR 1.9; 95% CI, 1.2-9.3) [50]. In a hospital based study also aimed at 
identifying risk factors for stillbirth, conducted between November 2007 to February 
2008 in Sudan, infection with malaria was associated with increased risk of stillbirth 
(aOR 3.0; 95% CI, 1.0-8.9) [49]. 
Among 1,766 women in Malawi, placental blood P. falciparum infection was 
independently associated with LBW (aOR: 1.71) [55]. Secondary analysis of data for 
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2,149 women included in a community based randomised placebo controlled trial for 
the prevention of preterm birth. Results showed that persistent malaria (despite 
malaria prophylaxis) increased the risk of late preterm birth (aOR 1.99, 95% CI, 1.05-
3.79) [56]. In a case-control study in Sudan conducted in 2010, a combination of 
histologically determined and sub-microscopic infections was significantly associated 
with LBW (aOR 2.45; 95% CI, 1.2-4.9) [57]. No association was found between 
malaria and LBW (aOR 1.0; 95% CI, 0.4-2.5), PD (aOR 1.7; 95% CI, 0.7-3.9), stillbirth 
(aOR 1.0; 95% CI, 0.3-3.0) and any ABO (aOR 1.3; 95% CI, 0.66-2.38) in a study in 
Sudan [58] . This lack of association was attributed to high IPTp-SP uptake in the 
study population. 
 
Table 1-1 shows a summary of studies associating curable STIs/RTIs and malaria with 
ABO.
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Table1- 1: Summary of studies associating curable STIs/RTIs and malaria with adverse pregnancy outcomes 
Organism/ 
infection 
LBW IUGR PD Stillbirth PROM Spontaneous 
abortion 
Country year Author, publication Year 
Plasmodium 
falciparum 
5.4(3.1-9.5) 2.83 (1.2-6.7) 3.2 (1.9-5.2) NA NR NR Tanzania 1997-2000 Watson-Jones et al., 2007[36] 
NR NR NR 3.0 (1.0-8.9) NR NR Sudan 2007-2008 Bader et al., 2010 [49] 
NR NR NR 1.9 (1.2-9.3) NR NR Ghana 2006 Yatichi et al., 2010 [50] 
1.71, P < 0.05 NR NR NR NR NR Malawi 1987-1990 Steketee et al., 1996 [55] 
2.45 (1.2-4.9) NR NR NR NR NR Sudan 2010 Muhammed et al., 2013 [57] 
NR NR 2.0 (1.1-3.8) NR NR NR Malawi 2004-2005 Van der Brook et al., 2014 [56] 
1.0 (0.4-2.5) NR 1.7 (0.7-3.9) 1.0 (0.3-3.0) NR NR Ghana 2011 Asundep et al., 2014 [58] 
Treponema 
pallidum 
NR NR NR NR NR 42% of cases Zambia 1982 Ratnam et al., NR [59] 
NR NR 1.4 (0.5-4.1) NR NR NR Kenya 1985 Elliot et al., 1990 [17] 
NR NR 33%, 5 of 15 
cases 
NR NR NR South Africa 1988 Donders et al., 1993 [18] 
NR NR NR 11.0 (6.6-17.9) NR NR Malawi 1987-1990 McDermott et al., 1993 [9] 
4.01, P < 0.001 NR NR 3.3
a 
, P = 0.028 NR NR Kenya 1991 Temmerman et al., 1995 [60] 
3.3
a
 (2.0-5.4) 2.1
a
 (1.0-4.2) 6.1
a
 (2.5-15.3) 18.1
a
 (5.5-59.6) NR NR Tanzania 1998-2000 Watson-Jones et al., 2002 [61] 
NR NR NR 1.9 (1.3-2.8) NR NR Multiple 2009-2012 Arnesen et al., 2015[26] 
Neisseria 
gonorrhoeae 
2.9(1.2-7.2) NR NR NR NR NR Kenya 1985 Elliot et al. , 1990 [17] 
P = 0.005
 ‡
 NR 56%, 5 of 9 
cases 
NR NR NR South Africa 1988 Donders et al., 1993 [18] 
0.8 (0.3-2.3) 
NR 
NR 
NR 
2.0 (1.0-4.0) 
2.5 (1.4-4.5) 
NR 
NR 
NR 
NR 
NR 
NR 
USA 
Australia 
1996-2002 
1999-2008 
Johnson et al., 2011 [33] 
Liu et al., 2013 [32] 
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Table 1-1: Summary of studies associating curable STIs/RTIs and malaria with adverse pregnancy outcomes continued 
Organism/ 
infection 
LBW IUGR PD Stillbirth PROM Spontaneous 
abortion 
Country year Author, publication Year 
Chlamydia 
trachomatis 
 
2.7(1.3-5.7) NR NR NR 2.4 (1.7-5.4) NR USA 1983 Gravett et al., 1986 [12] 
NR NR 19.4% versus 
8.0%, P = 0.03 
NR 19.4% versus 
8.0%, P = 0.03 
NR USA NR Sweet et al., 1987 [62] 
NR 2.4 (1.3-4.2) NR NR NR NR USA 1983-1985 IJH, 1989 [11] 
NR NR NR NR NR 1.8 (0.3-10.7) USA 1995-1996 Sozio et al., 1998 [63] 
15.5 versus 13.2 
P > 0.05 
7.3 versus 5.8% 
P > 0.05 
NR 20 versus 21% 
P > 0.05 
NR NR Hungary 1994-1995 Kovacs et al., 1998[64] 
NR NR 22.2% 8 of 36 
cases versus 
10.4% 32 of 307 
cases P = 0.037 
NR NR NR South Africa 2002-2003 Odendaal et al., 2006 [28] 
1.1 (0.7-1.70)
a
 NR 1.5 (1.1-2.0)
 a
 NR 1.5 (1.0-2.2)
 a
 NR USA 2003 Blas et al., 2007 [34] 
0.19 (0.1-1.5)
 
 
0.3 (0.1-1.2) 
0.97 (0.1-7.9)
 
 
3.65 (1.1-12.0) 
0.59 (0.2-2.0)
 
 
1.15 (0.5-2.6) 
NR 
NR 
NR 
NR 
NR 
NR 
Tanzania 1997-2000 Watson-Jones et al., 2007 [36] 
NR NR 0.7 (0.4-1.4) NR NR NR USA 2005-2008 Silveira et al., 2009 [35] 
2.07 (1.01-4.24) NR 1.0 (0.6-2.0) NR NR NR USA 1996-2002 Johnson et al., 2011 [33] 
NA NR 4.4 (1.3-15.2)
b 
2.7 (1.6-6.5)
c
 
NR NR NR Netherlands  2003-2005 Rours et al., 2011 [30] 
NR NR 7.9 (1.3-46.9) NR NR NR Switzerland 2006-2009 Baud et al., 2014 [31] 
NR NR NR NR 2.1 (0.4-11.5) 
 
NR Uganda 2013 Nakubulwa et al., 2015  [29] 
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Table 1-1: Summary of studies associating curable STIs/RTIs and malaria with adverse pregnancy outcomes continued 
Organism/ 
infection 
LBW IUGR PD Stillbirth PROM Spontaneous 
abortion 
Country year Author, publication Year 
Trichomonas 
vaginalis 
NR NR NR NR P < 0.03 NR USA NR Minkoff et al., 1984 [21] 
1.3(1.1-1.5) NR 1.3 (1.1-1.4) NR NR NR USA 1984-1990 Cotch et al., 1997 [20] 
2.1(1.0-4.2.) NR NR NR NR NR Congo DR 1989-1990 Sutton et al., 1999 [19] 
1.11 (0.6-1.9)
 
 
NR 
0.61 (0.2-1.5)
 
 
NR 
1.27 (0.8-2.0)
 
 
2.38 (0.5-12.1) 
2.32 (1.0-5.7)
 
 
5.57 (0.5-66.1) 
NR 
NR 
NR 
NR 
NR 
NR 
1997-2000 Watson-Jones et al., 2007 [36]
 ¥
 
1.5 (0.9-2.6) NR 1.4 (0.7-2.8) NR NR NR USA 1996-2002 Johnson et al., 2011[33] 
Bacterial 
vaginosis 
 
NA   NR NR NR 2.0 (1.1-3.7) NR USA 1983 Gravett et al., 1986  [12] 
NR NR 2.0 (1.0-3.9)
e
 NR NR NR Indonesia  Riduan et al., 1993 [25] 
NR NR 1.9 (1.2-3.0) 
a 
1.5 (0.7-3.0)
f
 
NR 
 
3.5 (1.4-8.9) 
a
 NR USA 1991-1992 Mcgregor et al., 1995 [23] 
NR NR 1.4 (0.9-2.05)  
Week 24,  
1.8 (1.2-3.0)  
Weeks 28 
NR  NR NR Multiple  Multiple Meis et al, 1995 [65] 
1.5 (1.2-1.7) NR 1.4 (1.1-1.8) NR  1.1 (0.8-1.6) NR USA 1984-1989 Hillier et al., 1995 [24] 
NR NR 0.9 (0.4-2.2) NR  NR 4.0 (1.3-12.1 UK 1998-2000 Oakeshott et al., 2004 [38] 
NR NR 2.16 (0.9-3.6)
 a  
 NR  NR NR Sweden 1990-1991 Jacobson et al., 2002 [66] 
NR NR 2.2 (1.5-3.1) NR  NR 9.9 (2.0-49.3) Multiple Multiple  Leitich et al., 2003 [39] 
2.0  (1.3-2.9) NR 2.5 (1.6-3.9)* NR  NR NR Denmark 1998-2002 Svare et al., 2006 [37] 
NR NR 2.2 (1.6-3.0) NR  NR 6.3 (3.7-10.9) Multiple Multiple Leitich et al., 2007 [40] 
NR NR 2.19 (1.2-4.0) NR  NR NR Switzerland NR Daskalakis et al. , 2006 [41] 
1.08 (0.7-1.9)
 
 
2.02 (0.7-5.9) 
1.09 (0.6-2.2)
 
 
NR 
0.91 (0.6-1.4)
 
 
2.95 (1.3-6.6) 
1.79 (0.8-4.2)
 
 
NR 
 NR 
 NR 
NR 
NR 
 
Tanzania 1997-2000 Watson-Jones et al., 2007 [36]
 ¥
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Table 1-1: Summary of studies associating curable STIs/RTIs and malaria with adverse pregnancy outcomes continued 
IJH: Investigators of John Hopkins;  
IUGR: Intrauterine growth retardation 
LBW: Low birth weight 
NR: Not reported 
PROM: Premature rupture of membranes 
PD: Preterm delivery 
a Adjusted risk ratio, the other figures are adjusted odds ratios. Bracketed figures are 95% confidence Intervals for odds ratios. 
b Preterm delivery before 32 weeks  
c Preterm delivery before 35 week  
d preterm delivery before 37 weeks 
eBacterial vaginosis diagnosed at 16 to 20 weeks 
fBacterial vaginosis diagnosed at 28 to 32 weeks 
gAmong treated women  
*preterm delivery of low birthweight infant 
¥first row represents untreated women and second row represents treated women 
†22.2% versus 10.4% prevalence of Chlamydia among women with preterm delivery and full term delivery 
‡Mean birth weight of preterm babies versus full-term, 2252g and 2970g, P = 0.005 
Bold type: statistically significant association 
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1.2.4 Effect of treatment of curable STIs/RTIs in pregnancy  
The benefits of STIs/RTIs treatment on pregnancy outcome have been demonstrated 
in randomised trials.  Three studies on the effects of treatment of STIs/RTIs were 
identified in the review by Mullick and colleagues [67-69]. A randomised trial in the 
US showed that treatment with erythromycin between 26 and 30 weeks gestation 
resulted in reduced frequency of PROM (6%) compared to placebo recipients (16%), 
P < 0.01 [68]. In a double-blind placebo controlled clinical trial, a single dose of 
ceftriaxone given to pregnant women in Kenya between 28 and 32 weeks  led to a 
significant increase in mean birthweight [3.21kg versus 3.06kg, (P < 0.01)] [69]. A 
randomised trial of presumptive sexually transmitted therapy in pregnancy in 
Uganda,  showed that treatment with a single dose of metronidazole combined with 
azithromycin and cefixime reduced rates of neonatal death (rate ratio 0.83; 95% CI, 
0.71-0.97), LBW (rate ratio 0.68; 95% CI, 0.53-0.86), and PD (rate ratio 0.77; 95% CI, 
0.56-1.05) [67].  
Studies focusing on specific infections have shown benefits of treatment of STIs/RTIs 
in pregnancy. A cohort study in the US found an increased risk in the incidence of 
PROM in untreated women with positive Chlamydia cultures compared to those with 
positive cultures who received treatment or those with negative cultures [70].  
Another study in the US showed a decreased risk of PROM in successfully treated 
Chlamydia positive patients compared to patients who were treated but had either 
recurrent or persistent Chlamydia infection at the end of pregnancy (aOR 0.31; 95% 
CI) [71]. In the third study in India the mean duration of gestation for PD was 
significantly higher among Chlamydial-infected women who received treatment in 
comparison to untreated women [35.5 versus 33.1 weeks (P < 0.05)] [72].  
Treatment of syphilis has also been shown to be beneficial, particularly if done in the 
first trimester compared to the third [61].  A study in Tanzania demonstrated that 
there was no increased risk of adverse pregnancy outcomes for women treated for 
high titre active syphilis (OR 0.76; 95% CI, 0.4 -1.4) or low titre active syphilis (OR 
0.95; 95% CI, 0.6 -1.5) compared with sero-negative women. Women were recruited, 
tested for syphilis and treated on the same day (mean recruitment age, 25.8 weeks) 
[61]. However, whilst treatment of women who were RPR (rapid plasma reagin) 
positive at antenatal clinics in Kenya significantly improved pregnancy outcome, it 
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did not eliminate the risk altogether [60]. Indeed, in this study, infected women who 
did not receive treatment had a marked higher risk of ABO (OR 4.1; 95% CI, 2.4-7.2) 
compared to uninfected women; but infected women who received treatment still 
experienced a 2.5-fold higher risk of ABO than uninfected women. Women who were 
treated but were still syphilis positive at delivery had significantly more ABO than 
those without syphilis (14.7 versus 6.2; P < 0.05) but less than untreated women 
(26.2% versus 14.7%; P < 0.05). 
Treatment of BV with clindamycin in the treatment phase of a controlled drug trial in 
the US was associated with reduced PD (RR 0.5; 95% CI, 0.3-0.8) and PROM (RR 0.5; 
95% CI, 0.2-1.4) [23].  Findings in another study in the US showed that women with 
clinically diagnosed BV, and were treated using metronidazole and erythromycin, had 
a lower incidence of PD (31% with treatment versus 49% with placebo, P = 0.006) 
[73].  
Another study in the US designed to evaluate the effect of early BV screening (at < 22 
weeks gestation) and treatment followed by re-screening and re-treatment if 
necessary, found that treatment of BV (with oral metronidazole or intravaginal 
metronidazole or clindamycin) was significantly associated with a reduction in the 
risk of PD (OR 0.5; 95% CI, 0.3-0.8) [74]. Similar results were found in another study 
in the United Kingdom where screening and treatment with intravaginal clindamycin 
were done early (13-20 weeks gestation)[75]. Treated women experienced a 
significant reduction in PD compared with the placebo group [4% versus 10%, (P < 
0.03)] [76].  
In a review of studies on screening, treatment, or ABO data in women with 
asymptomatic BV, no benefit was found in the treatment of  asymptomatic BV [77]. 
Treatment of T. vaginalis infection in pregnancy has been shown to have no effect on 
gestational age and birthweight. A study in South Africa found that gestational age 
and birth weight of infants born to women who were treated with benzoyl-
metronidazole and in those who did not receive treatment were similar [78]. 
Treatment was effective in clearing infection.  A review aimed at determining 
whether antibiotic treatment for BV or T. vaginalis during pregnancy decreases the 
risk of PD and associated ABO concluded that there is no evidence to support the use 
of antibiotic treatment for these infections for the purpose of  reducing the risk of PD 
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and associated ABO [75]. These conclusions were based on two studies. One US 
study evaluating treatment of asymptomatic trichomoniasis (selectively enrolled 
asymptomatic women) with metronidazole suggested that the drug failed to prevent 
PD [79]. In this study women treated with metronidazole were significantly more 
likely to deliver a preterm infant than untreated women (RR 1.8; 95% CI 1.2-2.7). The 
second study was a sub-analysis of a randomised trial in Uganda  which showed that 
women who were treated for trichomoniasis with metronidazole were 2.5 times 
more likely to deliver a LBW infant (RR 2.49; 95% CI 1.12-5.50) [80]. Although the 
original study was not designed to assess the effect of T. vaginalis treatment, the 
authors inferred that this might have been due to metronidazole exposure. However, 
what was observed in this study may be attributable to some other factor rather 
than what was inferred by the authors since the risk of PD was not increased in other 
clinical trials of metronidazole treatment of bacterial vaginosis during pregnancy [73, 
81-83]. Furthermore a sub-analysis of a study of pregnant women in four sub-
Saharan African sites found that treatment of trichomoniasis with metronidazole did 
not influence the risk of PD or LBW, women randomised to the antibiotic arm were 
not more likely to deliver a preterm infant (20.9% versus 19.8%, P = 0.84) or to 
deliver an infant with a lower mean birth weight (2992 versus 2930 P = 0.27) [84]. 
The treatment effectively resolved T. vaginalis infection.  
 
1.3 Prevalence of malaria and STIs/RTIs 
1.3.1 General overview of malaria prevalence in pregnancy  
Several reviews have reported the prevalence of malaria in pregnancy. Brabin 
reviewed 14 studies conducted before 1980 and found peripheral and placental 
parasitaemia ranging from 2-76% and 2-74%, respectively [42]. This review included 
two studies from Panama and 12 conducted in Africa. The wide range of prevalence 
of malaria in pregnancy is partly due to the difference in the level of malaria 
transmission in the study sites. Generally, the prevalence of malaria in pregnancy 
was higher in rural than urban areas. The median prevalence was at 27%.  Another 
review of studies done between 1985 and 2000 in eight countries found maternal 
malaria infection, defined as placental or peripheral, in all gravidae ranged between 
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6 and 65% [54]. The median prevalence of maternal parasitaemia was 27%. A similar 
estimate of 26% was obtained for placental parasitaemia (range 5-52%) from another 
review of studies conducted between 1980 and 2001 [85]. Desai et al., reviewed 13 
studies conducted between 1986 and 2004 of P. falciparum infection in pregnancy in 
areas of low-transmission settings in Africa and found a median prevalence of 
peripheral and placental parasitaemia at 13.7% and 6.7%, respectively [86]. The point 
prevalence estimates in the review by Desai et al., were generally lower since the 
review concentrated on low transmission areas. 
 
The meta-analysis by Chico et al. reviewed studies conducted among antenatal 
attendees in sub-Sahara Africa [6] and reported pooled prevalence estimates for 
malaria and STIs/RTIs. The estimates were reported separately for West and Central 
Africa and for East and Southern Africa.  This review included studies of women 
receiving antenatal care conducted between 1990 and 2011 and excluded studies 
that had selective enrolment, i.e. high risk groups such as HIV-seropositive women. 
These estimates were calculated using a standard method for correcting errors of 
magnitude based on the known specificity and sensitivity of individual diagnostic 
methods [87].  
Pooled prevalence estimates for Eastern and Southern Africa from this review were 
as follows: placental malaria 25.8% (95% CI, 19.7-31.9) and peripheral malaria 32.0% 
(95% CI, 25.9-38.0). Prevalence estimates that were obtained for West and Central 
Africa were higher than those obtained for East and Southern;  placental and 
peripheral parasitaemia was at 39.9% (95% CI, 34.2,-45.7) and 38.2% (95% CI, 32.3-
44.1) respectively [6].  
 At the patient level, placental parasitaemia is almost always higher than measures of 
peripheral parasitaemia [88-90].  When this has not been the case in systematic 
reviews or meta-analyses, this is because not all studies conduct placental histology; 
therefore, fewer data points are often pooled for estimates of placental infection. If 
these happen to be studies where the prevalence of parasitaemia is lower, then the 
overall frequency will be lower than pooled measures of peripheral infection. 
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1.3.2 General overview of STI/RTI prevalence 
The review (mentioned in earlier text) by Mullick et al. 2005 of studies published 
between 1987 and 2004 also examined the prevalence and the impact of STIs/RTIs on 
pregnancy outcomes in developing countries. Results from this review by Mullick et 
al. showed that up to 40% of pregnant women in Africa had trichomoniasis and 
bacterial vaginosis, 2.5–17% had serological evidence of syphilis, 3–6% while the 
prevalence of gonorrhoea and Chlamydia ranged from 2–7% and 3–29%, 
respectively.  Studies conducted between 1990 and 2011 reporting point prevalence 
estimates for malaria and STI/RTIs among pregnant women were identified in a more 
recent review and meta-analysis by Chico et al., 2012. Pooled prevalence estimates 
for West and Central Africa from this meta-analysis are as follows: syphilis, 3.5% 
(95% CI, 1.8%-5.2%), gonorrhoeae, 2.7% (95% CI, 1.7%-3.7%), Chlamydia 6.1% (95% 
CI, 4.0%-8.3%), trichomoniasis 17.8% (95% CI, 12.4%-3.1%), BV, 37.6% (95% CI, 
18.0%-57.2%).  For East and Southern Africa, the estimates were as follows: syphilis 
4.5% (95% CI, 3.9-5.1), gonorrhoea 3.7% (95% CI, 2.8- 4.6), Chlamydia 6.9% (95% CI, 
5.1- 8.6), trichomoniasis 29.1 (95% CI, 20.9-37.2) and BV 50.8% (95% CI, 43.3- 58.4).  
  
1.4 Prevalence of malaria and STIs/RTIs in pregnancy in Zambia and neighbouring 
countries 
The review by Chico et al. covered a broader region in sub-Saharan Africa. In this 
study a review was conducted for a smaller region of sub-Saharan Africa, Zambia and 
neighbouring countries. This was done to focus on areas surrounding the study site 
in which a substantial number of prevalence studies have been conducted. To 
explore studies reporting the prevalence of malaria and STIs/RTIs in pregnancy 
conducted between 1990 and 2015 in Zambia and neighbouring countries, a 
literature search was conducted. Four data bases, Pubmed, Medline, Embase and 
Global Health were searched for studies reporting P. falciparum, T. pallidum, N. 
gonorrhoea, Chlamydia trachomatis, T. vaginalis and BV using medical subject 
headings and free texts.  The Medline, Embase and Global Health data bases were 
searched simultaneously via Ovid® using combinations of the following key words; 
“Pregnancy”, “antenatal/prenatal”, “sexually transmitted disease”, 
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“syphilis/Treponema pallidum”, “Chlamydia/Chlamydia trachomatis”, 
“Gonorrhoea/Neisseria gonorrhoeae/gonorrhoea/gonorrhea”, 
“trichomoniasis/Trichomonas vaginalis”, “bacterial vaginosis”, “malaria”, 
“Plasmodium falciparum” “test”, “screen” and “Africa”. Search terms that were used 
are shown in Appendix 1.1b. The last search was conducted in April 2016. 
If an article reported two or more estimates e.g., if more than one diagnostic method 
was used, the highest/higher estimate was picked. Studies of women seeking 
treatment at STI facilities, non-pregnant women and those reporting estimates in 
high-risk groups such as commercial sex workers and in HIV-positive pregnant 
women were excluded. Multi-year studies reporting prevalence estimates that 
included data collected before 1990 were also excluded. Studies conducted in 
countries that are not Zambia’s immediate geographic neighbours were also 
excluded, hence only studies conducted in Angola, Botswana, Democratic Republic of 
Congo (Congo DR), Malawi, Mozambique, Namibia, Tanzania and Zimbabwe were 
included. All the articles obtained from all the search terms were originally retained 
and duplicates were then removed and other studies were excluded based on the 
criteria stated above. Appendix 1.2a to 1.2g show point prevalence estimates for 
malaria and STIs/RTIs from studies conducted in Zambia and neighbouring countries 
and diagnostic methods used in each study.  Figure 1.2 shows the identification and 
screening of studies in the review.  
 
41 
 
Figure 1. 2: Flow chart 
 
16, 831 Records identified from data base 
searches 
Pubmed, Medline, Embase and Global health 
 
11,782 Duplicate records excluded 
5, 049 Records screened 
4,552 articles excluded 
4,480 Unrelated end-points 
72 Ineligible country 
 
 
 
497 Full texts reviewed 
 
431 articles excluded 
229 Unrelated end points 
136 Ineligible country 
17 Some or all data prior to 1990 
  49 Selective enrolment 
66 Articles identified 
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1.4.1 Prevalence of malaria in pregnancy in Zambia and neighbouring countries 
Studies in Zambia and neighbouring countries conducted between 1990 and 2015 
have reported the prevalence of placental and peripheral malaria in all gravidae 
ranging from 9.8-52.0% and 4.7-51.9%, respectively (Appendix 1.2a and 1.2b). The 
wide range of prevalence of malaria in pregnancy is partly due to the difference in 
the intensity of malaria transmission in the various study sites. The median 
prevalence of placental malaria (from 12 studies) and peripheral parasitaemia (from 
22 studies) was 20.3% and 20.5%, respectively.  
1.4.1.1 Diagnostic methods for malaria and published sensitivity and specificity 
Diagnostic methods for malaria and published sensitivity and specificity are 
presented within Appendix 1.3. The gold standard for malaria diagnosis, Giemsa stain 
microscopy, has sensitivity measures ranging from 50-90% and specificity of 
approximately 95% [91-93]. The sensitivity and specificity of Gram stain microscopy 
are greatly influenced by the skills and workload of microscopists [94] and therefore 
the sensitivity and specificity of the method are expected to be on the higher end 
when the method is carried out by trained individuals with reasonable workload. 
One advantage of standard microscopy is that the method requires a relatively short 
time for diagnosis when used in areas of high transmission and parasites are present 
in high concentrations (approximately 1,000 parasites per microlitre [μL] of blood). 
However, if parasite densities are very low, examination of each slide is labour-
intensive [94]. The use of PCR for the diagnosis of malaria is highly sensitive in the 
detection of parasites. The method has been reported to have 91% sensitivity and 
specificity [95] and has the ability to measure infections where parasite counts are as 
low as five per μL of blood [96, 97], although the sensitivity of PCR has been shown 
to decrease markedly at parasite densities < 500/μL [98]. In a study in Taiwan a high 
proportion (58.2%) of microscope-positive samples were negative by PCR and 98.0% 
of these infections had fewer than 250 parasites/µl of blood [98]. In another study 
PCR failed to detect parasite DNA in two microscopy positive samples [99]. Other 
studies have reported that PCR may occasionally yield false negative results [98, 100, 
101] sometime as a result of  inappropriate DNA isolation [102, 103]. Among the 22 
studies reporting prevalence of peripheral malaria among pregnant women in 
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Zambia and neighbouring countries Giemsa stain microscopy was used in 14, PCR in 
seven and RDT in one study (Appendix 1.2f)  
Since Giemsa stain microscopy was used in the majority of these studies, it would be 
expected that there was some level of underestimation of the actual malaria 
prevalence in the region. However, the estimation can be considered reliable as they 
are expected to lie within acceptable ranges of the actual prevalence provided 
diagnoses were conducted under appropriate conditions. 
The use of placental blood microscopy in placental malaria diagnosis has 63% 
sensitivity and 98-99% specificity [104]. Placental histology is reported to have 91% 
sensitivity and 98-99% specificity [104]. Placental blood microscopy and tissue 
histology (score based on more precise method, i.e. histology), placental histology, 
impression, smears with microscopy (score based on most precise method, i.e. 
histology) and placental impression and blood smears with microscopy (score based 
on more precise method, i.e. impression) have all been reported to have 91% 
sensitivity  and approximately 100% specificity [6, 105].   
In the case of studies that used more than one method for the detection of placental 
malaria the estimate based on the method with higher sensitivity and specificity was 
recorded. The majority of studies (eight out of the 14) that contributed to the range 
of the prevalence estimates were based on histology (five) and impression (three) 
both of which are reported to have the same sensitivity and specificity measures. 
Placental blood microscopy was used in two of the studies and PCR was use in the 
remaining four studies. Based on the published sensitivity and specificities of the 
methods one would expect the estimates to be slightly lower than the situation 
obtaining on the ground. However, these estimates can be considered reliable and 
the wide range between the highest and lowest recorded prevalence estimates are 
mainly due to differences in malaria prevalence in the different areas in which these 
studies were conducted.  
1.4.1.2 The malaria situation in Zambia 
In Zambia, malaria is endemic in all 10 provinces and P. falciparum is responsible for 
approximately 95% of all cases [106]. There are an estimated 4.3 million clinically 
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diagnosed cases of malaria and 6,150 deaths annually [106]. Transmission of malaria 
is year-round but peaks in the rainy season (November-April).  An estimated 716,192 
pregnancies in Zambia were at risk of malaria in 2010 based on projections from the 
2000 census [107]. 
Since 2006, the National Malaria Control Programme has conducted a Malaria 
Indicator Survey (MIS) every two years to measure the prevalence of malaria by 
microscopy in children under five years of age in selected sites. The prevalence of 
malaria parasitaemia decreased in Zambia from 2006 to 2010 in some regions, while 
little change was observed in others [108]. Of concern is that parasitaemia declined 
between 2006 and 2008 in Eastern, Northern, and Luapula Provinces, but was higher 
in the 2010 survey with parasite rates in young children in Luapula Province 
exceeding 50% in 2010.  Although a substantial decline of 66% in patient cases and 
deaths occurred in 2000-2008 following the introduction of multiple interventions, a 
malaria upsurge occurred in 2009-2010 when vector control interventions were 
disrupted following delays in the disbursement of funds [109]. There has been a 
48.3% decline in the national overall malaria prevalence in children under five years 
of age between 2006 and 2012 (22.1% versus 14.9%) [109]. 
1.4.1.3 Malaria treatment policy in Zambia 
Zambia revised its national malaria drug treatment policy between 2000 and 2005 to 
adopt artemisinin combination therapy (ACT) as the first-line treatment for 
uncomplicated malaria [110]. Quinine is the first-line treatment for uncomplicated 
malaria in pregnancy in the first trimester, whereas artemether-lumefantrine (AL) is 
for use in second and third trimesters. For complicated malaria, parenteral quinine is 
recommended in all trimesters; SP is used by policy for IPTp and also serves as a drug 
of choice for people who cannot tolerate AL and during periods of AL stock-outs in 
health facilities [111]. The Zambian malaria policy states that IPTp-SP doses are to be 
administered during pregnancy at scheduled ANC visits, spaced one month apart 
after 16 weeks of gestation. 
1.4.1.4 Prevalence of P. falciparum resistance markers in Zambia   
Monitoring SP resistance markers is important in areas where IPTp-SP is policy as 
these markers have been associated with compromised efficacy of SP for IPTp [1-3]. 
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A few studies conducted in Zambia have estimated the prevalence of SP resistance 
markers in the general population and in pregnant women. In 2006, the frequency of 
dihydropteroate synthase (DHPS) and dihydrofolate reductase (DHFR), mutations 
associated with parasite resistance to SP were found to range from 71-92% for the 
triple mutant DHFR and 39-71% for the double mutant DHPS  in the general 
population in six districts in Zambia  [112]. In another study conducted in 2006 in the 
southern part of Zambia, the prevalence of the DHFR triple mutant was found at 
41.3% and  the DHPS double mutant was at 16% in a random sample of 95 selected 
from 188 malaria positive samples [113]. The frequency of the quintuple mutant was 
at 6.5%. Higher prevalence estimates of the quintuple mutant have been found in 
pregnant women in Northern Zambia. In a study conducted between January 2010 
and May 2011 in Mansa the prevalence of the quintuple mutant among 84 malaria 
positive samples was found in 63.1% (n = 53) and 2.3% (n = 2) of these had an 
additional 581-G mutation [114]. This was the first published record of the sextuple 
mutant in Zambia. Another study also conducted in February to April 2013 in the 
Northern part of Zambia, in Nchelenge District the quintuple mutant in a sample of 
72 malaria positive pregnant women was found in 17% (n = 12) of the samples. The 
sextuple mutant was found in 3% (n = 2) of the samples [115]. 
 
1.4.2 Prevalence of curable STIs/RTIs in pregnancy in Zambia and neighbouring 
countries  
Studies of pregnant women in Zambia and neighbouring countries conducted 
between 1990 and 2015 and identified in the literature search have reported 
prevalence of individual STIs/RTIs with wide ranges between the lowest and highest 
reported figures. From these studies it has been reported that 0-14.6% of pregnant 
women have syphilis; 0.5-18.6% have gonorrhoea and 1.7-17.5% have Chlamydia; 
while the prevalence of trichomoniasis and BV range between 2.4-32.2% and 4.3-
37.6% respectively. The median prevalence of individual STIs/RTIs are as follows: 
syphilis 5.6%, gonorrhoea 2.8%, Chlamydia 6.6%, trichomoniasis 17.4% and BV 
24.9%. Appendices 1.2c to 1.2g show point prevalence estimates of STIs/RTIs 
reported in studies conducted in Zambia and neighbouring countries and includes 
diagnostic methods used to estimate prevalence. 
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1.4.2.1 Diagnostic methods for STI/RTIs and published sensitivity and specificity 
Diagnostic methods for STIs/RTIs employed in the various studies in Zambia and 
neighbouring countries and published sensitivity and specificity measures are shown 
within Appendix 1.3. Methods used for detection of syphilis are rapid plasma reagin 
(RPR) and Venereal Disease Research Laboratory (VDRL) test and confirmation is 
conducted using Treponema pallidum haemagglutination assay (TPHA), Treponema 
pallidum particle agglutination (TPPA), determine Syphilis -Treponema pallidum, 
microhaemagglutination assay-Treponema pallidum (MHA-TP) and immunoglobulin 
G (ELISA) tests. When RPR is used for syphilis diagnosis and a confirmatory test is 
conducted both sensitivity and specificity are approximately 100% [6].  When used 
alone the sensitivity measure is 86-100% for RPR and 78-100% for VDRL and the 
specificity is 93-98% and 98% for RPR and VDRL respectively [116].  
Thirty four prevalence estimates (Appendix 1.2c) of syphilis prevalence were 
reported from 33 studies, one study reported two separate point prevalence 
estimates, one for first ANC attendees and another for delivering women. Of these 
34 estimates four were based on RPR only and one on VDRL test only. The rest of the 
estimates were based on either RPR or VDRL and a confirmatory test (TPHA or ELISA 
or Determine Syphilis TP or MHA-TP) in each case.  Estimates obtained from RPR or 
VDRL only would be expected to be higher than those where a confirmatory test is 
used.  Since the majority of studies used the combination of diagnostic tools known 
to have the highest sensitivity and specificity, one would expect that the reported 
estimates of syphilis prevalence among ANC attendees in Zambia and surrounding 
countries are reliable. Therefore, it can be concluded that the reported prevalence, 
whether low or high, is mainly due to the actual prevalence in the study setting 
rather than in differences in diagnostic methods. 
The prevalence of Chlamydia among pregnant women in Zambia and surrounding 
countries has been reported to range between 1.7 and 17.5% (Appendix 1.2d). 
Cervical swab culture for diagnosis of Chlamydia has been reported to have 
sensitivity ranging between 74 and 94% while specificity is between 98 and 99% 
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[117]. Enzyme immunosorbent assay has been widely used for detection of 
Chlamydia and is reported to have sensitivity ranging from 71-87% and specificity 
ranging from 97-99% [117]. Urine based PCR has 78-89% sensitivity and 99-100% 
specificity and cervical swab based PCR has 99% sensitivity and 99-100% specificity 
[117]. The use of Deoxyribonucleic acid identification assay is reported to have 100% 
sensitivity and specificity [6]. In the 11 studies reporting the prevalence of Chlamydia 
among pregnant women in this region, a variety of methods were used to obtain 
these estimates in these studies as follows; culture was used in one, EIA in four, PCR 
in two, LCR in two, DNA-ID in one and ELISA was used in one. Based on the range of 
sensitivity measures for the methods that were used to measure prevalence, it is 
expected that there was some level of underestimation of the prevalence. However, 
some of the studies used DNA-ID, PCR and LCR which have higher sensitivity and 
specificity.  
It is reported that 0.5-18.6% of pregnant women in Zambia and surrounding 
countries have gonorrhoea (Appendix 1.2e). Detection of gonorrhoea using gram 
stain is reported to have 50-70% sensitivity  and 95-100% specificity [118].  Sensitivity 
and specificity of culture and gram stain (based on mean of culture) have been 
reported to be approximately 80% and 100%, respectively  [6].  Ligase chain reaction 
with cervical swab has been reported to have the highest sensitivity and specificity, 
95-100% and 98-100% respectively, while for PCR with cervical swab sensitivity and 
specificity have been estimated to be at 89-97% and 94-100%, respectively [118]. 
Of the 13 studies conducted in Zambia and surrounding countries, 14 point 
prevalence figures were reported for gonorrhoea among ANC attendees. In these 
studies culture was used in eight (with one study reporting two culture based 
estimates), culture and gram stain were used in two, PCR in two and LCR in one. 
Since the use of culture alone and culture combined with gram stain have lower 
sensitivity and specificity, and were used in the majority of studies, the individual 
prevalence estimates would be expected to be slightly lower than the actual 
prevalence but within acceptable ranges.  
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The prevalence of trichomoniasis is reported to range between 2.4 and 32.2%. 
Diagnosis of trichomoniasis has widely been done using wet mount microscopy 
which has sensitivity ranging from low to moderately high (38-82%) and high 
specificity (100%) [117].  All of the 16 estimates of trichomoniasis prevalence from 15 
studies conducted in Zambia and neighboring countries were obtained using wet 
mount microscopy, except one estimate from a study conducted in Zambia in which 
PCR was used. Based on published sensitivity and specificity measures of the wet 
mount microscopy, it is expected that the actual prevalence of trichomoniasis in 
these settings were generally underestimated.  
Bacterial vaginosis is the most prevalent of the STIs/RTIs with reports of prevalence 
ranging between and 4.3 and 37.6% among pregnant women of Zambia and 
surrounding countries. Over the years diagnosis of BV has been done using clue cell 
count, Amsel criteria [119] and the Nugent score [120]. The sensitivity and specificity 
of the Amsel criteria are reported to be 51% and 98% [121]. The Nugent method has 
higher sensitivity (86-89%) than the Amsel criteria but its specificity is reported to be 
between 94-96% [122-124].  
Of the 12 point prevalence estimates from 11 studies reporting BV prevalence in 
Zambia and neighbouring countries, six were based on the Amsel criteria; four were 
based on the Nugent criteria and two were based on the clue cell count method. 
Based on published sensitivity and specificity, the reported prevalence estimates 
would generally be expected to be lower than the actual prevalence in the study 
population. 
1.4.3 General assessment of prevalence literature 
Sensitivity and specificity measures vary among different diagnostic tests. However, 
a diagnostic test conducted at different times under standard laboratory conditions 
would be expected to have similar sensitivity and specificity measures. It was noted 
that similar diagnosed methods have been used over time in the study period (1990-
2015) within which prevalence studies reviewed in thesis were conducted. No 
particular method predominated a certain period in time (e.g. the first 10 or 15 
years) among the various diagnostic methods used in the detection of the different 
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infections. In this context time has no influence on the prevalence estimates in the 
studies that were reviewed.  It was also noted that the prevalence figures from 
studies conducted in the period between 1990 and 2015 do not show any downward 
or upward trend with time across the various infections from different sites in 
Zambia and surrounding countries.  
 In general, methods with low sensitivity would underestimate and those with low 
specificity would overestimate prevalence.   Overall the methods used in the 
diagnosis of malaria and STIs/RTIs have been widely applied and, therefore, variation 
in estimates are likely due to true differences in the prevalence of the infections in 
the different study sites.  
 The median prevalence estimates obtained from studies in Zambia and neighbouring 
countries were lower across all the infections, in comparison to  pooled prevalence 
estimates obtained from the meta-analysis by Chico et al. [6] This may be explained 
by the fact that Chico et al. corrected point estimates to increase the precision of 
each measure before generating pooled prevalence estimates. The median 
prevalence for each infection obtained from studies in Zambia and neighbouring 
countries either fell within (Chlamydia, gonorrhoea and placental malaria) or outside 
(syphilis, trichomoniasis, BV and peripheral malaria) the 95% CI of the pooled 
prevalence estimates obtained from the meta-analysis by Chico et al., 2012.  This 
could further be explained by notable differences in number of studies included in 
the meta-analysis by Chico et al., and in the review conducted in this thesis i.e., 
syphilis (seven), trichomoniasis (four) and BV (six) and peripheral malaria (12). In the 
case of placental malaria the difference in the number of studies between the two 
was minimal (two) and the number of studies was the same in the case of 
gonorrhoea and Chlamydia. Another possible explanation is that the prevalence of 
some of the infections is simply higher in some regions/study sites than others.  
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1.5 Risk factors for STI/RTI and malaria 
 1.5.1 Risk factors for STIs/RTIs 
Studies conducted in Zambia and neighbouring countries reporting prevalence of 
malaria and STIs/RTIs among pregnant women identified in this thesis were further 
reviewed for predictors of infections.  
It was noted that not all the studies reported risk factors for infection. Some of the 
studies identified risk factors for individual infections while in others predictors of 
infection were identified for different combinations of infections  e.g. Chlamydia and 
gonorrhoea [125-127]; HIV, HSV and syphilis [128]; BV, trichomoniasis and 
candidiasis [128]); syphilis, trichomoniasis and gonorrhoea [129];  HSV-type 2, 
trichomoniasis, Chlamydia, gonorrhoea, syphilis and HIV [130]. Risk factors for 
STIs/RTIs and malaria identified in studies conducted in Zambia and neighbouring 
countries are summarised and presented in Appendix 1.4.  
Among these studies syphilis has been associated with the following factors: HIV 
infection [131], history of stillbirth [132, 133], self-reported previous spontaneous 
abortion [133], history of past STI [131], genital ulcers [131, 134], vaginal discharge 
[131], genital warts [131], married status or living with a partner [131, 135], infection 
with trichomoniasis [134], higher parity and gravidity [132], older age [136], lower 
education [136, 137], having more than one lifetime partner [128, 133], previous 
pregnancies [138] and having a partner who takes  alcohol [128].  
Infection with gonorrhoea was associated with having more than one lifetime 
partner [139]. Infection with gonorrhoea and/or Chlamydia was associated with 
following factors in one study; vaginal discharge, having had a new sexual partner in 
the last three months, being separated from one’s partner for more than 3 months, 
presence of a purulent discharge, lower education, current use of a condom [125]. 
Other predictors of Chlamydial/gonococcal infection are older age group (above 25 
versus ≤ 25 [126] and ≥ 30 compared to 20-29 group [127]), single status, being in a 
polygamous marriage, having more than one sexual partner over the previous year 
and having delivered more than five years earlier [126]. Trichomoniasis has been 
associated with polygamy [129], lower education level of sexual partner, abnormal 
discharge, genital ulcer and genital warts [140]. Infection with trichomoniasis and/or 
BV and/or candidiasis has been associated with early sexual debut (< 20 years) [128].  
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In a study in which risk factors for composite STI (HSV-type 2, trichomoniasis, 
Chlamydia, gonorrhoea, syphilis and HIV) were identified, the presence of any STI 
was associated with being in a long-term relationship as opposed to a short term 
one, increasing age difference between the girl and her partner and history of prior 
pregnancy [130].  
Geographical location has been shown to be an important risk factor for STIs/RTIs 
when one area is compared to another, e.g. semi-urban and rural versus urban [138] 
or one study site versus another [136, 140].  
1.5.2 Risk factors for Malaria infection 
In the studies conducted in Zambia and neighbouring countries identified in this 
thesis, the  following factors were associated with an increased risk of peripheral 
malaria;  younger age  [89, 115, 141], wet season [141] primigravidity/primiparity 
[142, 143], wealth quintile (all categories of wealth below the highest) [144]  and 
malaria infection earlier in pregnancy [89, 145]. Bed net use was found to be 
protective against peripheral malaria infection [1].   
A higher risk of placental parasitaemia has been associated with  younger age [89], 
primiparity [141, 143, 146] and malaria infection earlier in pregnancy [89]. Iron 
deficiency [146], bed net use [1] and receiving IPTp-SP during pregnancy [1, 147] 
have been associated with a reduced risk of placental malaria infection.   
1.5.3 Conceptual frameworks for infection 
In order to identify both distal and proximal risk and protective factors associated 
with malaria and STI/RTI, two conceptual frameworks were constructed based on 
evidence from literature. Under these frameworks (Figures 1.3 and 1.4) it is assumed 
that demographic and socio-economic factors directly or indirectly (via 
maternal/partner characteristics) influence the risk of infection. 
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Figure 1. 3: Conceptual framework for STIs/RTIs 
  
 
 
 
 
 
    
 
 
 
 
 
 
 
 
 
Figure 1. 4: Conceptual framework for malaria infection 
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As earlier mentioned the prevalence of malaria and STI/RTI has not been reported in 
any epidemiological setting therefore risk factors for coinfection are not known. It is 
plausible to assume that distal and proximal risk factors for malaria infection and 
STIs/RTIs play a role in their coinfection. Figure 1.5 shows a conceptual framework 
for malaria and STI/RTI coinfection based on risk factors for malaria and STI/RTI 
identified in literature. Unprotected sex may result in pregnancy and STIs. Pregnancy 
brings about reduced immunity [43]  which makes pregnant women in a malaria 
endemic area susceptible to malaria infection. 
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Figure 1. 5: Conceptual frame work for malaria and STI/RTI coinfection 
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 1.6 Prevalence of malaria and STIs/RTIs coinfection 
It is clear from literature that there is paucity of information on the prevalence 
malaria and STIs/RTIs coinfection in pregnancy. In their review, Chico et al., 
noted that only one study from Tanzania reported the prevalence of malaria 
among women who tested positive for syphilis [6]. In this retrospective cohort 
study, it was found that among 73 women with high-titre (≥ 1:8) active syphilis, 
34% concomitantly had maternal malaria, 18% had past chronic placental 
malaria and 48% had histological evidence of current malaria and chronic 
changes indicative of malaria infection earlier in pregnancy [10]. However, the 
occurrence of other curable STIs/RTIs was not reported in this paper. 
 
1.7 Current antenatal Care package 
1.7.1 Antenatal care package for malaria in pregnancy  
Intermittent preventive treatment in pregnancy with SP is recommended by the 
World Health Organization  for reducing the risks associated with malaria in 
pregnancy [148]. Randomised controlled trials have shown IPTp-SP decreases the 
risk of maternal anaemia, placental parasitaemia, and LBW [149-152]. In a review 
of nine trials conducted in Africa IPTp-SP reduced the risk of placental malaria 
(RR 0.48; 95% CI, 0.35-0.68), LBW (RR 0.71; 95% CI, 0.55-0.92), and anaemia (RR 
0.90; 95% CI, 0.81-0.99) [153]. At least one dose of IPTp-SP has been shown to 
protect against maternal parasitaemia (OR 0.20, 95% CI, 0.12-0.34, P < 0.001) in 
an observational study in Ghana [154] and to protect against LBW in Benin [155]. 
 Administration of three doses instead of two doses of SP has been shown to 
reduce the prevalence of placental malaria, LBW, and preterm delivery by 50% in 
a high malaria transmission area of Mali [156]. In comparison to a 2-dose 
regimen, three doses of IPTp-SP are superior in reducing the effect of malaria in 
pregnancy and appear to be effective even in areas with high levels of SP 
resistance [3]. However, the protective effect of IPTp-SP has been compromised 
[157] and a decline in IPTp-SP efficacy has been reported in Africa [158]. In an 
area in Tanzania where 14 days parasitological SP treatment failure rate was as 
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high as 38.8% (95% CI, 26.8-50.8) [159], IPTp-SP was significantly associated with 
placental parasitaemia (P = 0.03), did not have an effect on LBW [OR 0.71 (95% 
CI 0.33-1.54) P = 0.39] and was significantly associated with foetal anaemia [1.91 
(95% CI 1.14-3.19) P = 0.01] [2]. However, in Malawi the use of IPTp-SP was not 
associated with higher parasite densities, greater placental inflammation, or 
worsened delivery outcomes despite the increasing prevalence of SP-resistant P. 
falciparum haplotypes [160]. A recent systematic review and meta-analysis 
reports no evidence of paucigravidae being protected against delivering a LBW 
baby in areas where the parasite population of Arg-581 is greater than 10.1%. 
[161]. Therefore, an evidence-based policy revision is urgently needed. 
 
1.7.2 Antenatal care package for curable STIs/RTIs in pregnancy 
Screening and treatment of syphilis is recommended as a routine part of 
antenatal care [162, 163]. Detection of STIs/RTIs is most accurately done using 
technologically advanced and expensive diagnostic techniques. These techniques 
require trained staff, laboratory equipment, specific storage and transportation 
conditions [5]. In order to assist countries with limited resources, the WHO has 
developed syndrome-based algorithms for the diagnosis and management of 
gonorrhoea, Chlamydia, trichomoniasis and BV in symptomatic individuals. 
Unfortunately in women high proportions of gonococcal (80%) and Chlamydial 
(70-75%) infections are asymptomatic [164]. Approximately 50% of women 
infected with T. vaginalis are asymptomatic but even higher proportions (60-
70%) of asymptomatic T. vaginalis infection and BV have been reported [165, 
166]. The implication is that the use of syndromic management would lead to 
many asymptomatic cases going unnoticed, and thus, a large proportion of 
STIs/RTIs in pregnancy will remain undetected and untreated.  
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1.7.3 Antenatal care in Zambia 
` In Zambia the ANC package includes the following;  weight measurement, height 
measurement, blood pressure measurement, urine sample collection  for 
analysis, blood sample collection for analysis, voluntary counselling and testing, 
provision of iron supplementation , IPTp-SP, discussion of birth preparedness 
plan, provision of treatment for intestinal parasites and tetanus toxoid 
vaccination [167]. Blood testing for screening of maternal syphilis, HIV and 
anaemia are conducted as part of ANC  [168]. Although syndromic management 
is not documented as part of the ANC package, the syndromic approach for STI 
management is documented in the National HIV/AIDS/STI/TB Policy [169]. 
Therefore in practise the syndromic approach is used for diagnosis of other STIs 
whenever women attending ANC come with complaints of signs and symptoms 
that are indicative of STIs. 
In a study where two national datasets with detailed antenatal care provider and 
user information i.e. the 2005 Zambia Health Facility Census and the 2007 
Zambia Demographic and Health Survey (ZDHS), were analyzed to describe the 
level of ANC service provision at 1,299 antenatal facilities in 2005 and the quality 
of ANC received by 4,148 mothers between 2002 and 2007 [170]. In the study 
mentioned above, criteria were developed to describe quality of ANC and 
different levels of provision of ANC. This included information on ANC use, type 
of ANC provider, place of ANC provision, number of ANC visits, timing of first 
ANC visit and on the interventions received. Having received “good quality ANC” 
was defined as having attended at least the recommended four ANC visits with a 
skilled provider and received at least eight antenatal interventions, while the 
definition of “moderate quality ANC” required four visits with a skilled provider 
and five to seven antenatal interventions [170]. Only 45 antenatal facilities (3%) 
fulfilled their developed criteria for optimum ANC service, while 47% of facilities 
provided adequate service, and the remaining 50% offered inadequate service. 
Although 94% of mothers reported at least one ANC visit with a skilled health 
worker and 60% attended at least four visits, only 29% of mothers received good 
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quality ANC, and only 8% of mothers received good quality ANC and attended in 
the first trimester [170]. Results from this study showed that “effective ANC 
delivery”, as estimated by their indicators, was way below ANC coverage.  
Percent distribution of women aged 15-49 who had a live birth in the five years 
preceding the 2013-14 ZDHS by number of antenatal care (ANC) visits for the 
most recent live birth were slightly different between women in the urban and 
rural areas of Zambia. In the urban areas 0.9%, 1.6%, 40.7%, 55.9% and 1% of 
women aged 15-49 attended none, one, two to three and four or more ANC 
visits respectively. In the rural areas distribution was as follows: 1.7%, 2.0%, 
40.2%, 55.2% attended none, one, two to three and four or more ANC visits 
respectively. The median gestational age at first ANC was 4.8 months and 4.7 
months among urban and rural women [167] respectively.  
The proportions of ANC visits among Zambian women seem to suggest that a 
good number of women do not receive adequate ANC interventions indicating 
lost opportunity for delivering interventions. 
 
1.8 Birthing practices and prevalence of adverse pregnancy outcome in Zambia 
1.8.1 Practices and beliefs about pregnancy and childbirth in Zambia 
In Zambia western religious practices are widespread and Christianity co-exist 
with deep spirituality of local tribes [171].  In general there is belief in the 
Christian God and the spirit realm of ancestors, which has allowed for the 
acceptance of the existence of witchcraft [171]. Beliefs in witchcraft are often 
applied to pregnancy, labour and birthing practices. 
Zambian women often deliver in seclusion or in the company of a few selected 
women at home [172]. Several factors contribute to the preference of a 
secretive home delivery.  In general pregnancy due dates and the start of labour 
are  kept secret for fear of witchcraft harming the child and women deliver with 
a few people present to avoid supernatural harm to the child [173].   
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Some of the beliefs contribute to the proportions of women who deliver at home 
as opposed to making use of health professionals and facilities. A population-
based cross sectional study survey by Mwewa and Michelo conducted among 
women (n= 499) of Nchelenge District  in 2008 to identify factors associated with 
home deliveries showed that the  prevalence of home deliveries was 43%, 95% 
CI (38.62, 47.48) [174]. Among the factors cited for home deliveries were long 
distances to the health facilities coupled with lack of transport, abrupt 
unexpected labour, circumstances beyond control (such as embarrassment due 
to not having the required items that delivering mothers are expected to present 
with at health facilities) and myths and traditional beliefs [174]. 
The study also identified some practices that are a result of myths and traditional 
beliefs that prevent women from delivering at health facilities. Among the 
common traditional beliefs pointed out in the study by Mwewa and Michelo is 
what is locally called “incila”. According to information from a focus group 
discussion most women decided to deliver at home in order to be attended by 
their grandmothers and be treated for “incila”, which according to the 
participants, was a situation where the partner or husband of the pregnant 
woman or the pregnant woman herself engaged in sexual affairs with other 
people during the woman's pregnancy, as a result of which the woman could 
have difficulties at delivery  [174].  
It was stated by a focus group discussion participant aged 56 from Kabuta village 
in the study by Mwewa and Michelo that 'The process of preventing death by 
“incila” requires the woman to divulge confidential information to the women 
assisting her delivery so that she delivers well in addition to taking the 
medication and so some women even go further away from their own villages to 
other villages for confidential reasons because some traditional birth attendants 
(TBAs) do not keep secrets. If there were too many men that the woman may 
have had extramarital affairs with while pregnant and they could not all be 
counted, then she is required to put maize meal into a bowl as a gift, for 
everything to end there and this cannot be done at the clinics'.  
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A 59 years old male focus group discussion participants from Kambwali village 
stated that 'The other reason why women prefer to deliver at home is to have 
their babies protected from “icifutato”, which is a situation where the baby may 
die if the father of the child recommences sex with a different woman other than 
his spouse who has not even recovered and healed after delivery of the child. So 
the women will prefer to deliver at home so that the baby after being born is 
bathed in water that is medicated to prevent death by “icifutato”. There are 
other traditional beliefs identified in this population from the study mentioned 
above (including the use of sorcery out of envy and malice to bring doom upon 
the couple) that prevent women from delivering at health centres as a way of 
ensuring the “wellbeing” of the mother and the child by carrying out certain 
traditional practices which cannot be carried out at health facilities. 
 
In another study conducted in Kalomo, Southern Zambia by Sialubanje et al., a 
negative attitude towards nurses; low risk perception regarding their personal 
susceptibility to pregnancy and labour complications; dependence on husbands 
for financial support and decision making; social cultural norms (unwillingness to 
be delivered by a young nurse or a male staff of the health facility) were cited 
among reasons why women delivered at home [175]. Furthermore trust in the 
TBAs and being familiar with TBAs were given as reasons that encouraged 
women to deliver at home [175].  
 
In contrast to low risk perception regarding pregnancy and labour complications, 
over 80% of young focus group discussion respondents, a few older women 
(mainly those who had given birth at a health facility), and all the midwives 
explained that most young women delivered at the health facility because they 
had no experience giving birth and that they were afraid of labour complications 
if they gave birth at home [175]. Although the study by Mwewa and Michelo did 
not explore reasons that influenced women to deliver at a Health facility as in 
the case of the study by Sialubanje et al., it is likely that women who deliver at 
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health facilities in the northern part of Zambia are encouraged to do so for 
similar reasons. 
In 2010 the Zambian Ministry of Health announced that it had no intention of 
training TBAs because certain situations which expectant mothers faced required 
the attention of qualified medical personnel [176]. The ministry charged that 
TBAs contributed to high levels of maternal mortality rate in the country hence 
the need for expectant mothers to deliver from health centres. The Ministry of 
Health carried out massive sensitisation campaigns on the dangers of delivering 
from home through safe motherhood action groups [176]. In the study by 
Sialubanje et al., all Focus group discussions and in-depth interviews were aware 
of the new policy but some TBAs in the focus discussion groups argued that 
women still delivered at home and some TBAs still conducted deliveries [175].  
1.8.2 Prevalence of adverse birth outcomes in Zambia 
The 2013-14 ZDHS reported the prevalence of LBW among deliveries at 10% in 
Zambia based on figures from Lusaka, Copperbelt and Southern Provinces [167]. 
A similar estimate was found in the Zambia Electronic Perinatal Record System 
(ZEPRS) study conducted across 25 facilities in the Lusaka public health sector 
from June 2007 to January, 2010. Records of 115,552 pregnant women showed 
that the proportion of LBW and PD was 10.8% and 34.0% respectively, and the 
incidence of stillbirth was at 24 per 1000 deliveries [177].  
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Figure 1. 6: Conceptual framework for adverse birth outcomes 
  
 
 
 
 
 
 
 
 
 
 
 
 
  
Adopted from Olusanya and Ofovwe, 2010 [178] 
Adverse birth outcomes that are generally described in literature in relation to 
curable STIs/RTIs and malaria and are of interest in this study are IUGR, PD, 
stillbirth and LBW.  
In order to identify both distal and proximal risk factors associated with adverse 
birth outcomes an approach similar to the conceptual framework described by 
Olusanya and Ofovwe, 2009 [178] (Figure 1.1) was adopted. Under this 
framework it is assumed that demographic and social economic status directly or 
indirectly (via maternal and infant characteristics) influence birth outcomes. 
Maternal obstetric characteristics have direct impact on infant status. The 
variables of interest have been guided by evidence from published literature. 
Maternal socio-demographics included age, marital status, education, economic 
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anaemia, infection with curable STIs/RTIs, malaria and HIV. Infant factors 
included IUGR and sex. The sex of the baby is an independent determinant of 
ABO. 
 
1.9 Rationale and objectives 
1.9.1 Rationale 
The individual prevalence of malaria and curable STIs/RTIs among antenatal care 
attendees in sub-Saharan Africa is considerable with the combined prevalence of 
curable STIs/RTIs being equal to, if not greater than malaria [6]. However, the 
prevalence of curable STIs/RTIs and malaria coinfection in pregnancy is entirely 
unknown. Despite the interest in the associations between malaria and birth 
outcomes, and also between curable STIs/RTIs and birth outcomes, no study has 
assessed the occurrence of malaria and curable STIs/RTIs coinfection and 
identified its risk factors.  
Currently, the recommended antenatal care package includes IPTp with SP for 
the control of malaria, screening and treatment of syphilis, and syndromic 
management for other curable STIs/RTIs.  However, in the context of emerging 
malaria parasite resistance to SP and the limited accuracy of the syndromic 
management, new strategies to control these infections in pregnancy are 
needed.  One of the strategies proposed is preventive therapy that is safe and 
effective against malaria and curable STIs/RTIs. Azithromycin–based combination 
therapy offers these properties and is a possible candidate replacement for SP 
[179].  Thus characterising the prevalence of malaria, curable STIs/RTIs and their 
coinfection in pregnant women will not only fill this gap, but will also provide 
evidence in support of an integrated solution for prevention and control of these 
infections in pregnancy. 
Despite the individual public health importance of malaria and curable STIs/RTIs, 
their impact on pregnancy outcomes when they occur together has not been 
assessed.  
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Measuring molecular markers of SP resistance is proposed to monitor the 
efficacy of IPTp-SP.  Although the frequency of SP resistance markers at which 
IPTp would cease to be effective is unknown, monitoring trends of SP resistance 
markers is important, particularly in pregnant women where this information is 
limited [180]. Furthermore this information may support the need for finding 
alternative drugs for IPTp that may be effective against malaria and common 
STIs/RTIs. 
Therefore this study has the potential to contribute to policy revision in the 
interest of reducing the public health impact of malaria and STIs/RTIs in 
pregnancy.   
 
1.9.2 Objectives 
The primary objective of this thesis was to estimate the prevalence of malaria, 
curable STIs/RTIs, and their coinfection among pregnant Zambian women. 
Secondary objectives were as follows: 
1. To identify risk factors for malaria, curable STIs/RTIs and their 
coinfection among pregnant Zambia women. 
2. To determine the prevalence of DHFR and DHPS mutations associated 
with SP resistance among pregnant women. 
3. To measure the in vivo efficacy and therapeutic failure of SP in pregnant 
women over a period of 28 days post-IPT. 
4. To estimate the prevalence of ABO and identify their risk factors among 
pregnant Zambian women.  
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2 Methods 
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2.1 Chapter introduction 
This chapter presents all the methods that were used in the study including 
design, sample size calculation, inclusion and exclusion criteria, enrolment 
procedure, data and sample collection, laboratory procedures and analyses.    
2.1.1 Study design and sample size 
2.1.2 Study design 
This was a prospective cohort study of antenatal attendees. Women were 
enrolled and observed alongside routine ANC activities. The study involved the 
following: (i) Screening of women for malaria and common curable STIs/RTIs at 
first antenatal visit; (ii) screening of women for malaria at day 28 post IPTp-SP, 
and (iii) following them up to delivery to capture delivery characteristics.  
Figure 2.1 shows the flow of research activities that were conducted. 
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Figure 2. 1 Flow-chart of research activities 
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Consenting eligible pregnant women were recruited at their first ANC visit. Samples 
were collected for screening of curable STIs, bacterial vaginosis and malaria. Participants 
(at >16 weeks gestation) were given their first dose of SP for intermittent preventive 
treatment and demographic and socio-economic data was collected. Women were 
followed up after 28 days and screened for malaria and given a second dose of SP. At 
delivery placental tissue was collected for the diagnosis of placental malaria and birth 
characteristics, maternal factors and medical and drug histories were recorded.  
 Recruitment of 1,086 consenting eligible 
antenatal attendees at their first ANC visit               
 Screening of participants for STIs/RTIs and 
malaria 
 IPTp administration (> 16 weeks gestation) 
 Collection of demographic and socio-economic 
data  
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 Administration of IPTp-SP 
 Treatment of RPR positives, and STIs/RTIs 
based on syndromic management 
 
 
 
STI/RTI and malaria negative 
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 Treatment of RPR reactive women (if not 
done within the week of recruitment)  
 Collection of samples for second 
screening for  peripheral malaria 
 Administration of second dose of IPTp-SP 
 Collection of samples for second 
screening of peripheral malaria 
 Administration of second dose of IPTp-SP 
 Eligibility screening 
 Obtained consent from eligible women 
 Collection of maternal factors 
  Collection of birth Characteristic 
 Diagnosis of placental malaria  
 Medical and drug history 
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 Medical and drug history 
 
 
 Adverse birth 
outcomes 
Normal birth 
outcomes 
Adverse birth 
outcomes 
Normal birth 
outcomes 
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2.1.3 Sample size calculation 
The systematic review and meta-analysis by Chico et al. reported the following 
pooled prevalence estimates of curable STIs/RTIs and malaria from East and 
Southern Africa : syphilis 4.5%; gonorrhoea 3.7%; Chlamydia 6.9%; 
trichomoniasis 29.1%; BV 50.8%; placental malaria 25.8%; and peripheral malaria 
32.0% [6]. As there were no data on the prevalence of malaria and curable 
STIs/RTIs coinfection from previous studies, it was assumed that the prevalence 
of malaria and any one curable STI/RTI is 10%. To measure a 10% prevalence 
with a 95% confidence limit around a +/-3% precision, a sample size of 843 
women is required to estimate the proportion of pregnant women coinfected 
with malaria and at least one of the curable STIs/RTIs.  
The 2013-14 Zambia Demographic Health Survey reported that the prevalence of 
LBW among deliveries in Zambia was 9% [181]. A similar estimate was found in 
the Zambia Electronic Perinatal Record System study conducted across 25 facilities 
in the capital city (Lusaka) public health sector from June 2007 to January, 2010. 
Records of 115,552 pregnant women showed that the proportion of LBW was 
10.8%, PD was 34%, and the incidence of stillbirth was at 24 per 1000 deliveries 
[177]. Thus, to explore the determinants of ABO, it was assumed that 10% of the 
women would experience at least one ABO (PD, LBW, IUGR and stillbirth).   
The incidence of ABO among women detected to have curable STIs/RTIs or 
malaria during antenatal period was expected to be higher than that among 
uninfected women. Thus the incidence of ABO in the unexposed women was 
assumed to be 7.5%. A study with 80% power and 95% confidence to detect risk 
factors that have an OR > 2 requires 984 women. To account for losses to follow 
up and withdrawals from the study, the sample size was increased by 10% [182]. 
Therefore, 1,086 women were recruited. Table 2-1 shows different assumptions 
and sample size calculations for the determination of risk factors for ABO. 
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Table 2- 1: Sample size calculation for determination of risk factors for adverse 
birth outcomes 
 
Power 
 
Proportion 
of 
unexposed 
with ABO 
 
 
Odds ratios 
1.5 2.0 2.5 
Unexp. exp total Unexp. exp total Unexp. exp Total 
70% 5 2688 896 3584 825 275 1100 438 148 584 
7.5 1866 622 2480 579 193 722 309 103 412 
10 1458 486 1944 459 153 612 249 83 322 
80% 5 3423 1141 4564 1053 351 1404 558 186 744 
7.5 2373 791 3164 738 246 984 393 131 524 
10 1854 618 2472 582 194 776 315 105 420 
90% 5 4599 1533 6132 1416 472 1888 750 250 1000 
7.5 3186 1062 4248 990 330 1320 528 176 704 
10 2487 829 3316 780 260 1,040 420 140 560 
Unexp: Unexposed 
Exp: Exposed 
Sample size was calculated with 95% confidence and a 3:1 ratio of unexposed to 
expose. Exposure was infection with malaria, any STI/RTI or both. 
 
To estimate the prevalence of SP resistance markers among pregnant women 
the sample size was estimated assuming that the prevalence of the quintuple 
mutation among pregnant women was 50% due to limited data. To detect a 
prevalence of 50% with 95% CIs of +/-10%, a sample size of 96 malaria positive 
women was needed. 
The sample size needed to measure therapeutic outcomes in pregnant women 
receiving IPTp-SP was calculated based on the WHO treatment efficacy protocol 
which calculates sample size based on the expected proportion of treatment 
failures [183]. The proportion of treatment failure among pregnant Zambian 
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women is unknown.  It was assumed that the proportion of therapeutic failures 
was 10%. To detect a 10% failure with 95% CIs of +/-5%, 138 asymptomatic 
malaria positive women were required. 
2.2 Study area and sampling  
2.2.1 Study area 
Nchelenge is a rural district located in the Northern part of Zambia in the Luapula 
Province on the shores of Lake Mweru (Figure 2.2A) and has a population of 
173,680 [184]. The district has a tropical climate with a rainy season (November 
to April) and a dry season (May to October).  
Nchelenge District has 10 health centres, three health posts and one first level 
hospital [185]. The district was selected on the basis that it has a high prevalence 
of malaria and the prevalence of the individual STIs/RTIs of interest was 
expected to be moderate to high based on indications from RPR seropositives 
and HIV-infected women [186]. Luapula province has the highest prevalence of 
malaria in children under the age of five years with a prevalence of 38% by 
microscopy and 56% by rapid diagnostic test [187]. In a study conducted in 
March to April, 2012 in Nchelenge District among 782 children less than 10 years 
of age parasite prevalence by microscopy was reported at 30.2% (n = 236) [188]. 
Between 1990 and 2015, only two published studies both conducted in Luapula 
Province, have estimated the prevalence of malaria among pregnant women.  
One is a study conducted in Mansa in 2009 to 2010 and placental tissue samples 
of 37% (162/435) of delivering women showed histological evidence for malaria 
infection during pregnancy [90].  In another study conducted in 2013 in 
Nchelenge District, 22% of ANC attendees were positive for peripheral malaria by 
PCR [115].The prevalence of RPR-positive women at first ANC attendance was 
estimated at 10.0% [186]. The prevalence of HIV among ANC attendees at 
Kashikishi and Nchelenge health centres, in 2013 was 13.0% and 13.3%, 
respectively [186]. These estimates combined new cases and already known HIV 
positive cases.  
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Although other economic activities exist in Nchelenge District, the inhabitants 
are mainly fishermen and/or farmers. The population focuses on farming during 
periods of the fishing ban which is in effect from 1st December to 1st March each 
year.  
The study was conducted in a catchment area of two health centres, Kashikishi 
and Nchelenge Health centres, with a total catchment population of 44,115 
[185]. The community in the catchment area of two health centres, which served 
as recruitment sites, was selected due to the close location of the two health 
centres to the only hospital in the district. Figure 2.2B shows the location and the 
catchment area of the two health centres.  
  
According to the 2013-14 Zambia Demographic and Health Survey, 94.6% of 
women aged between 15 and 49 in Luapula Province reported having received 
ANC from a skilled health care provider during pregnancy for their most recent 
birth in the preceding five-year period [167].  The coverage of IPTp-SP reported 
in the MIS at Provincial level was as follows;  89.7%, 76.6% and 57.6 % of women 
took at least one dose, two or more doses, and 3 or more doses of IPTp-SP, 
respectively  [189].  At the time of the study, Kashikishi health centre offered 
laboratory, ANC and maternity services while Nchelenge Health Centre offered 
ANC services but not maternity services and depended on Kashikishi Health 
Centre for laboratory services.   
The only hospital in the area is Saint Paul’s Missionary Hospital. In 2013, 2620 
deliveries were recorded at the hospital, 306 (11.7%) by caesarean section and 
2314 were normal births. Of the recorded births, 2556 were live births and 64 
(2.4%) were stillbirths, 29 (1.1%) macerated and 35 (1.3%) fresh stillbirths.  Of 
the 2556 live births 564 (21.5%) were born with a LBW (≤ 2500). The system does 
not capture the number of preterm deliveries.  
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Figure 2. 2: Map showing the position of Nchelenge district in Zambia and the study area 
Key: A-Blue area indicates the area within the borders of Zambia covered by Lake Mweru. Purple area indicates the location of 
Nchelenge District. B-Blue triangles indicates homes of women recruited at Kashikishi Health Centre, red dots indicate homes of 
women recruited at Nchelenge Health Centre, the two purple squares indicate the location of Kashikishi and Nchelenge health centres. 
Locations of participant homes and health centres were plotted using global positioning system coordinates. Maps: Courtesy of 
Ministry of Lands, Lusaka, Zambia 
 
A B 
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2.2.2 Sampling 
Women visiting the two selected Health Centres for their first antenatal care visit 
between November 2013 and April 2014 were invited to join the study and enrolled 
consecutively until the desired sample size was reached. The participants who took 
IPTp-SP at enrolment were followed up at day 28 and screened for peripheral 
malaria. All women enrolled in the cohort were then followed to delivery. 
 
2.3 Inclusion and exclusion criteria 
2.3.1 Inclusion criteria 
 Women of all ages attending the ANC for their first visit  
 Gestational age ≤ 32 weeks 
 Willing to take part in the study and give consent  
 Agree to have their HIV test result from routine counselling and testing 
recorded by a member of the research team 
2.3.2 Exclusion criteria  
 Women reporting to have taken antimalarial and/or antibiotic treatment 
within the previous 4 weeks 
 Women aged below 18 years without a guardian present to give written 
consent 
 
2.4 Enrolment and antenatal care package 
Enrolment and biological sample collections were conducted alongside the provision 
of routine ANC. Booking and ANC revisits were done once each on different days of 
the week at each health centre. Each week the ANC clinic for booking started with a 
health talk which covered various aspects of ANC including nutrition, curable STIs, 
HIV and malaria. At the end of the health talk the study was introduced to the whole 
group of first ANC attendees and their partners. It is worth noting that in the 
community where this study was conducted, attending ANC booking with 
spouses/partners has been encouraged over the years as a way of improving 
maternal health especially when dealing with issues relating to HIV and this was 
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generally accepted by community members. Therefore, women and their partners 
commonly undergo counselling and testing together. 
Height, weight and blood pressure of each participant were measured and recorded 
on the ANC cards. HIV testing was routinely conducted using finger-prick blood with 
two rapid test kits (Determine® HIV-1/2 [Abbott Diagnostic Division, Hoofddorp, The 
Netherlands] and Uni-Gold™ Recombigen® HIV-1/2 [Trinity Biotech USA Inc. New 
York, USA]). Women were generally tested together with their spouses/partners. 
Individuals found to be seropositive using Determine® HIV-1/2 were then tested with 
Uni-Gold™; HIV status was concluded based on the result of the second test. Before 
determination of gestational age, ANC attendees were individually given copies of 
the information sheet which had been translated into Bemba (Appendix 2.1). Upon 
determination of a gestational age ≤ 32 weeks by last menstrual period and fundal 
height assessment, eligibility screening was completed by filling out the eligibility 
screening form (Appendix 2.2).  Eligible women were then requested to give written 
consent, which they did after their assent, by signing two copies of the consent form 
(Appendix 2.3) or appending a thumbprint. In the case of women aged below 18 
years, written consent was sort from their guardian if present after their assent. One 
copy was kept by the research team and a second copy was given to the participant 
together with a copy of the information sheet. Participants were at this point 
assigned an identification number which was used to anonymize all the paperwork 
and samples collected from a particular participant. A record of the participants’ 
names and Identification number was kept separately by the study team. All study 
materials were kept in a private office and were only accessible to authorised 
research team members. 
As part of the antenatal care package, all ANC attendees were given iron and folic 
acid supplements to last them up to their next ANC visit. First ANC attendees who 
had complaints indicative of STI/RTI were further assessed by a clinician for decisions 
on treatment. Women and/or their partners who tested positive for HIV for the first 
time were also assessed for eligibility to receive antiretroviral therapy by their 
regular clinician. All women with ≥ 16 weeks gestation were given IPTp-SP except 
those on cotrimoxazole prophylaxis due to toxicity concerns. 
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2.5 Data and sample collection 
2.5.1 Data and sample collection at recruitment 
One vaginal swab and one cervico-vaginal swab were collected from each participant 
by a trained midwife. Non-lubricated vaginal specula were used to collect the 
samples. The vaginal swab was collected using a dry cotton swab. The swab was 
placed in the vaginal cavity for 10 seconds and immediately rolled onto a slide for 
diagnosis of BV. A Dacron® (Medical Wire & Equipment, Wiltshire, England, United 
Kingdom) was used to collect a cervico-vaginal sample for the detection of C. 
trachomatis, N. gonorrhoea and T. vaginalis by PCR. The cervico-vaginal swabs for 
PCR were placed in cryo vials (Narang Medical Limited, New Delhi, India), labelled 
with each participant’s ID and date of collection. The swabs from each participant 
were transported and stored at -200C for a few hours pending extraction which was 
conducted within 24 hours.   
A questionnaire (Appendix 2.4) was administered to each of the enrolled women by 
a trained field worker in a private room. Gestational age was then measured by 
ultrasound using crown-rump length in first trimester pregnancies and a combination 
of biometric parameters (biparietal diameter, head circumference, abdominal 
circumference, and femur length) in the second and third trimester pregnancies. 
Women with a gestational age > 32 weeks were excluded at this point and counted 
among those who were ineligible. Peripheral and venous blood (approximately 4ml) 
was collected from each participant for malaria and syphilis screening, respectively. 
Peripheral blood was collected via finger pricking and venous blood was collected 
from the arm. Approximately 160μl of peripheral blood was placed on four circles of 
Whatman® filter paper and labelled with the participant ID number. The thick smear 
and blood spots were later used for the diagnosis of malaria by microscopy and 
polymerase chain reaction (PCR), respectively.  
2.5.2 Collection of global position system coordinates 
Landmarks near the homes of participating women and home addresses of all the 
participants were collected at enrolment. Members of the research team visited the 
homes of participants guided by the information collected at recruitment. 
Permission to visit a participant’s home was obtained at recruitment. The reason for 
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the visit was to collect global positioning system coordinates of participants’ homes 
for the purpose of locating women at the time of delivery if they required 
transportation to the hospital.  
2.5.3 Follow-up at day 28 
This part of the study required 138 asymptomatic malaria-positive women in order 
to determine prophylactic and therapeutic failure of IPTp-SP over a period of 28 days 
after SP administration under direct observation. Only women who were eligible to 
receive SP i.e., those who presented with a gestational age ≥ 16 weeks and were not 
currently receiving cotrimoxazole were included in this part of the study. At the 
follow up visit at day 28, peripheral blood for a thick smear and for PCR diagnosis of 
malaria was collected from participants who had taken SP at day 0. Blood sample 
collection was only done after verbal confirmation that a participant had not 
received anti-malarial treatment besides the IPTp-SP given at the time of enrolment.  
The second dose of SP was administered and efforts to collect samples from 
participants who did not show up 28 days post-IPT were made through home visits 
on the same day. Participants who developed malaria symptoms before 28 days 
were tested and treated by the health centre staff following national guidelines as 
routinely done. Such cases were not followed up at day 28 post-IPTp-SP.  
 2.5.4 Data and sample collection at delivery 
Participants were followed to delivery and placental blood and tissue were collected 
by midwives.  The midwives at the Kashikishi Health centre and Saint Paul’s 
Missionary Hospital were informed of the study from the start and were trained on 
how to identify participants from their ANC cards/records and collect placental 
samples and delivery characteristics. Instructions on sample collection were also 
made available to the maternity ward staff. Placental blood for the measurement of 
haemoglobin was collected by making an incision in placental tissue using a blade 
and blood was drawn using a syringe and immediately placed in 
Ethylenediaminetetraacetic acid tubes for determination of haemoglobin level. 
Haemoglobin was read using an ABX Micros ES60 (HORIBA ABX SAS). Placental tissue 
samples were collected as follows: A 2cm x 2cm x 1cm specimen was taken from the 
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maternal side, and placed in 10% formalin filled bottles labelled with the patient’s ID 
number and date of collection. Delivery characteristics and drug history were 
collected at delivery using the second part of the questionnaire (Appendix 2.4). 
New born babies were weighed and birth characteristics recorded. Stillbirth was 
defined as foetal death at ≥ 28 weeks gestation [190], PD  as delivery at < 37 weeks, 
LBW as birthweight < 2500 grams and IUGR was defined as an infant with LBW born 
at ≥ 37 weeks gestation [36, 61]. Gestational age after birth was recorded based on 
earlier assessment at enrolment by ultrasound.  
To ensure that major outcomes were captured in most of the deliveries, two mobile 
phone numbers belonging to team members were given to participants to call at the 
time they went into labour and required transport to the hospital/health centre. 
Those who called for transport were located with the help of global positioning 
system coordinates collected earlier in the study.  Participants were also urged to call 
if they experienced a delivery, late miscarriage or stillbirth at home. A driver and a 
fieldworker followed-up such cases to collect samples and data at delivery and/or 
provide transport to the hospital where the mothers were attended to and samples 
and data were collected. A study completion form was filled out for each participants 
and their completion of the study or loss to follow-up was documented (Appendix 
2.5)    
 
2.6 Laboratory testing and quality control  
2.6.1 Syphilis testing and treatment of seropositives 
Diagnosis of syphilis by rapid plasma reagin (RPR) for samples collected at both 
Nchelenge and Kashikishi Health centres was conducted at Kashikishi Health Centre 
laboratory. Syphilis testing was done using rapid plasma reagin (RPR) (Omega 
Diagnostics Limited, Alva, Scotland, United Kingdom). Since it was not possible to 
have RPR test results on the same day, results for syphilis test were ready the day 
after sample collection. Seropositive women were followed up (incorporated within 
the global positioning coordinate collection exercise explained above) within three 
days and presented with a note to return to the health centre with their partner for 
treatment with benzathine penicillin G (2.4 million units IM weekly x 3 doses) 
according to the national STI policy. Those who did not show up were started on 
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treatment at the day 28 follow-up if they returned to the health centre. A second 
note was delivered to those or the homes of those who did not return at day 28 for 
them to return to the health centre with their partner for treatment.  
For quality control 55/1077 (5%) serum samples were taken to the national STI 
reference laboratory at the University Teaching Hospital (UTH). Testing of all RPR 
seropositive samples with Treponema pallidum haemagglutination assay (TPHA) for 
confirmation of syphilis and RPR reactivity at 1:8 titre were also conducted at the 
national STI laboratory.  
 
2.6.2 Malaria diagnosis by microscopy 
Thick blood films were stained using 10% Giemsa at Kashikishi Health Centre 
Laboratory. Slides were there after transported to the National Malaria Control 
Centre for reading by two independent microscopists. Parasite density was 
determined by assuming 8000 white blood cells (WBCs) per µl and counting the 
number of parasites per 200 WBCs.  In cases where fewer than nine parasites were 
counted against 200WBCs, parasites were counted against 500WBCs. Two-hundred 
high power fields were read before declaring a slide negative. In the event that 
discrepant results were observed between the two microscopists, a third observer 
read the slide to reach an agreement on diagnosis and parasite count.  
 
2.6.3 Diagnosis of placental malaria by histology  
Formalin fixed placental tissue specimens were sent to the UTH histopathology 
laboratory for processing. Fixed placental biopsies were wax embedded, and two 
sections were stained with Gurr’s modified Giemsa and another two with 
haematoxylin and eosin. Slides were examined by a qualified pathologist for the 
presence of parasites, pigment or both. Placental histology was classified as 
described by Rogerson et al, 2003 [191]. The classes were as follows: (1) Parasites, 
no pigment in monocytes or fibrin; (2) Parasites, pigment in monocytes +/- fibrin 
Parasites; (3) Parasites, pigment in fibrin, (4) No parasites, pigment only (past 
infection) and (5) No parasites or pigment (no infection). For quality control, the 
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reading of 6.5% (46/702) randomly selected slides was repeated by a second 
observer. Any disagreements were resolved by a third observer. 
 
2.6.4 Diagnosis of bacterial vaginosis by microscopy 
The vaginal smear samples for the diagnosis of BV were air dried and Gram stained 
using safranin as a counter stain. Gram staining of slides was conducted at the St. 
Paul’s Mission Hospital laboratory and thereafter slides were transported to the 
University of Zambia for reading. Results were classified based on the Nugent criteria 
[120] and recorded in the appropriate result record form (Appendix 2.6). For quality 
control (5%) 55/1085 randomly selected slides were transported to the UTH 
Microbiology laboratory for repeat reading.   
 
2.6.5 Nucleic acid amplification  
In this study, in-house standard end-point PCR assays were employed to detect the 
presence of the C. trachomatis, N. gonorrhoea and T. vaginalis in cervico-vaginal 
swabs; and P. falciparum in dried peripheral blood spots. 
DNA extraction from cervico-vaginal swabs was conducted within 24 hours of 
collection and the extracts from each sample were stored at -200C pending 
molecular detection by PCR. Samples were then transported on ice to the Tropical 
Gastroenterology and Nutrition Group laboratory at UTH where molecular detection 
of C. trachomatis, N. gonorrhoea and T. vaginalis was conducted. In the case of P. 
falciparum, dried blood spots were transported to the Tropical Gastroenterology and 
Nutrition Group laboratory for extraction and molecular detection by PCR. 
 
2.6.5.1 PCR primers  
Plasmodium falciparum was detected using the Snounou primers [94]. For the 
detection of N. gonorrhoea, primers targeting the orf1 gene (Ngu1 and Ngu2) were 
employed to amplify a 260 base pair (bp) product specific for N. gonorrhoea [192].  
Primers KL1 and KL2 were used to amplify a Chlamydial plasmid 241 bp fragment for 
the detection of C. trachomatis [193]. Plasmid based PCR reactions for the detection 
of C. trachomatis have been shown to be 10 to 1000 more sensitive than procedures 
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which use the major outer membrane protein and ribosomal DNA as templates for 
PCR amplification [194, 195] and have been used for the detection of C. trachomatis 
in clinical samples [196]   
Primers based on T. vaginalis repeated DNA target for PCR identification have been 
used for the molecular detection of T. vaginalis [197, 198]. The primer pair, TV3 and 
TV7, was used to amplify a 300bp piece of the genome. This primer set has been 
demonstrated to have higher sensitivity than other primer sets [199].  The primer 
names and sequences for these four organisms are as shown in Appendix 2.7. 
 
2.6.5.2 DNA extraction and PCR for malaria parasite detection 
Filter paper containing blood spots were air dried and individually stored in envelops 
at room temperature pending DNA extraction for the diagnosis of malaria by PCR. 
Parasite DNA extraction was carried out using the chelex method as described 
previously [200]. The extract was transferred in approximately 100 µl aliquots to 
storage vials and were stored -20 0C pending PCR. 
The detection of P. falciparum was carried out using a nested PCR method as 
described by Snounou et al., [201] with modifications to the PCR parameters [202]. 
Briefly, all PCR reactions were carried out in total volumes of 25µl using Thermo 
Scientific® Dream Taq PCR Master Mix (2X) and 0.5µM of each primer and 2µl of 
template. A 2µl of the primary amplicon was used as a template in the secondary 
reaction.  The PCR parameters used for both the primary and secondary reactions 
were as shown in Appendix 2.8.  
 
2.6.5.3 Detection of SP resistance markers 
To estimate the prevalence of SP resistance among first ANC attendees, a random 
sample of 96 was selected from among the P. falciparum malaria positive samples 
detected by PCR. Ninety-six was the required sample size for the characterisation of 
SP resistance markers in the study area. Therefore, only 96 samples were processed 
for this part of the study. 
Parasite DNA template extracted earlier for malaria detection was used for this part 
of the study. Nested PCR and enzyme restriction digestion as previously described 
[203] were employed to detect antifolate polymorphisms in the DHFR and DHPS 
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genes. Names and sequences of the primers that were used are shown in Appendix 
2.9.  The names of the enzymes that were employed and their expected activity 
depending on the whether the amplicon carried the wild type or mutant strain were 
as shown in the Appendix 2.10. 
Negative and positive controls were included in every batch and put through the 
entire process from amplification electrophoresis. Secondary PCR amplicons were 
analysed by gel electrophoresis to confirm amplification and band intensity before 
enzyme digestion. Amplicon and restriction fragments were analysed on ethidium 
bromide agarose gels and visualised under UV light on a Biosens (Genescope V1.76) 
digital imaging system. 
 
2.6.5.4 Determination of in vivo efficacy and prophylactic effect of sulphadoxine-
pyrimethamine 
The pair of blood samples collected at recruitment and 28 days post-IPT visit were 
used to determine the in vivo efficacy to clear parasitaemia and the post-IPT 
prophylactic effect of SP.  The sample size required for this part of the study was 138 
asymptomatic malaria positive pregnant women. A woman with a malaria positive 
blood smear at first ANC visit and found to have a malaria positive blood slide at day 
28 post-IPT visit, was classified as a case of therapeutic failure of SP. It was assumed 
that after a participant with parasitaemia initially receives SP, subsequent detection 
of parasitaemia 28 days post-IPT was caused by either parasite strains present 
before SP administration (recrudescence) or parasite strains acquired after 
treatment (reinfection). Therefore, therapeutic failure cases were further classified 
as re-infection or recrudescence by PCR analysis. To differentiate between 
recrudescence and re-infection in women who tested positive at both the initial (day 
0) and second screening (day 28), genotyping was done to examine genes coding for 
the merozoite surface protein 2 (MSP2) [204, 205]. Women who had a negative 
blood slide at visit one and became slide positive at day 28 post-IPT were classified 
as cases of prophylactic failure of IPTp-SP.  
Polymorphic regions of MSP2 were amplified by nested PCR. The primary PCR 
primers corresponding to the conserved sequence flanking this region and the 
secondary PCR primers were used to amplify the IC3D7 and FC27 allelic families of 
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msp-2. For controls DNA from HB3 and 3D7 laboratory strains was used. Appendix 
2.11 presents the sequences of the primers that were used for this part of the study.  
The secondary amplicon from each sample was analysed using electrophoresis on 2% 
ethidium bromide stained agarose gels. Samples from an individual participant were 
loaded in adjacent lanes. In cases where there was no amplification, PCR was 
repeated using 3 times the quantity of template DNA. In cases where no amplicon 
was detected after the second reaction, amplification was classified unsuccessful. 
Alleles were considered the same for day 0 and day 28 within 10 base pairs.   
Reinfection was defined as having completely different alleles between parasites 
from day 0 and day 28. If a similar allele was found between parasites at 0 and at day 
28 this was classified as recrudescence. Comparisons of band sizes were done using a 
manual method by two different qualified molecular biologists and any discrepancies 
were settled by a third person. 
 
2.6.5.5 DNA Extraction and detection of curable STIs/RTIs by PCR 
Extraction of DNA from cervico-vaginal swabs was done within 24 hours of sample 
collection using the Quick-gDNA™ (Zymo Research Corp, California, USA) Miniprep kit 
following the manufacturer’s instructions. The extract was stored at -200C awaiting 
nucleic acid amplification. 
PCR reactions for the detection of the three organisms, C trachomatis, N. gonorrhoea 
and T. vaginalis were set up separately for each sample. All PCR reactions were 
carried out in total volumes of 25µl using Thermo Scientific® Dream Taq PCR Master 
Mix (2X) and 1µM of each primer and 4µl of template. Amplicon was resolved on 2% 
ethidium bromide agarose gels and visualised under UV light.  
All the PCR parameters that were employed in this study are as indicated in 
Appendix 2.8. 
 
2.6.6 Quality control of PCR methods 
All the PCR assays were tried on known positive samples before they were used on 
research samples. Positive and negative controls were included at the extraction, 
amplification and electrophoresis stages. A negative and a positive control were 
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included in every batch of 46 samples.  Five percent (55 samples) of the samples 
were randomly selected and processed using the Seeplex® STI Master Panel 1 (V2.0) 
[Seegene Technologies Inc. California, USA]. The Seeplex® STI Master Panel 1 by 
Seegene is a multiplex conventional PCR system for the detection of seven organisms 
including C. trachomatis, N. gonorrhoea and T. vaginalis from urine, vaginal swabs 
and liquid based cytology specimens.  
 
2.6.7 Quality assurance of data and sample collection  
The questionnaire was translated into Bemba, the language that is commonly spoken 
in the study district. The questionnaire was pretested among 30 eligible participants 
at an ANC booking to determine pattern of response and clarity of the questions. 
Questions were rephrased, removed or added where necessary.  
To ensure that good quality data was collected, research assistants were trained in 
data collection. Assistants were urged to ensure that questionnaires were checked 
for missing data before releasing the participant. The collection of cervico-vaginal 
samples was restricted to midwives after training on how samples were to be 
collected for diagnosis of BV and other STIs/RTIs. Other biological samples were 
collected by trained laboratory technicians who routinely carry out procedures such 
as venous and peripheral blood collection and slide preparation.  
 
2.7 Ethical consideration 
The study protocol was reviewed and approved by the University of Zambia 
Biomedical Research Ethics Committee, reference number 004-02-13 (Appendix 
2.12) and the London School of Hygiene and Tropical Medicine 
Observational/Interventions Research Ethics Committee (reference number 6292) 
before the research was carried out. In addition, the Ministry of Health (MoH) in 
Zambia also reviewed the research proposal after the ethical approval had been 
granted. The research project was then discussed with relevant local authorities in 
the study district such as the district health management team, community leaders 
and the in-charge personnel at the two health centres.  
At the beginning of each ANC booking session an explanation of the project was 
given to the group of first ANC attendees and their spouses/guardians/partners in 
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addition to the routine weekly health talk. The information included the aims of the 
study, the methods of data and sample collection, number of participants required, 
potential advantages and disadvantages of participation and the expected benefits 
of carrying out the research. The study population was also assured of 
confidentiality. After the details of the project had been explained potential 
participants were informed that participation was voluntary and participants could 
withdraw at any time. There was no age cut off for exclusion because inclusion of 
younger pregnant women was considered to be important in order to have better 
representation of pregnant women. Written consent was sort from guardians of 
women aged below 18 years if present after their assent. To ensure confidentiality 
interviews were conducted privately and each participant was assigned a unique 
identity number that was used to anonymise biological samples, questionnaires, and 
result record forms.  
Participating women received everything that the ANC package routinely offered at 
the time of the study including iron and folic acid tablets. Women who were found 
RPR reactive were given a note to return to the health centre with their sexual 
partner for treatment. Pregnant women who had complaints of symptoms 
associated with STI/RTI were assessed by the regular clinician and managed based on 
their symptoms as part of the recommended ANC package. Women and/or their 
partners who tested HIV positive for the first time underwent assessment for 
eligibility to receive antiretroviral therapy and cotrimoxazole prophylaxis as per 
routine procedures.  All women, except those who were receiving cotrimoxazole 
prophylaxis at the time, were provided IPTp-SP according to national guidelines.  In 
the rare event that a woman showed up for ANC booking with symptomatic malaria, 
routine laboratory testing was done using a rapid diagnostic test kit (SD Bioline 
Malaria Ag P.f/Pan brand; Standard Diagnostics, Inc.) and treatment was 
administered based on national policy guidelines.  Molecular diagnosis of Chlamydia, 
trichomoniasis and gonorrhoea was done in the latter part of the project and results 
were only available after the participants had delivered. Results were sent back to 
the two health centres and participants were who were traced were given a note to 
return to the health centres with their partners for treatment.  
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2.8 Data Processing and Analysis  
Data were double-entered in EpiData version 3.1 software [206] , cleaned, processed 
and analysed using Stata Software version 13 [207]. Cleaning involved visual checks 
of entered data for consistence and valid values. Frequencies of all variables were 
generated to check for missing data. Variables were recoded and composite 
variables were generated. Data on sources of income, level of education and fixed 
and durable assets were used to create an index of household wealth using principal 
components analysis [208]. The malaria and STI/RTI coinfection variable was 
generated from a combination of six outcomes, five curable STIs/RTIs and malaria. 
Coinfection was defined as infection with malaria and at least one of the five 
STIs/RTIs. High blood pressure (BP) was defined as systolic blood pressure ≥ 140mm 
Hg and/or diastolic BP ≥ 90 mm Hg. Hypertension was defined as two high BP 
readings [209].  A variable was created from BP readings collected at recruitment 
and before delivery but during labour. Adverse birth outcomes that were captured in 
this study were LBW, IUGR, stillbirth and PD. A new variable for composite ABO was 
generated from the four outcome variables and was defined as experiencing at least 
one of the four birth outcomes mentioned above. New variables were generated for 
the DHFR triple (Ile-51 + Arg-59 + Asn-108), DHPS double mutant (Gly-437 + Glu-540), 
quintuple (DHFR triple + DHPS double) and sextuple (quintuple + Gly-581) mutants. 
Therapeutic efficacy was defined as aparasitaemia in a previously parasitaemic 
woman 28 days post-IPTp-SP without recrudescence. Women who were 
parasitaemic upon enrolment and were screened for malaria at day 28 were 
included in this analysis. Women who tested positive at day 0 and at day 28 were 
further separated into cases of recrudescence and reinfection. Therapeutic failure 
was defined as testing positive at day 0 and at day 28 due to recrudescence.  
Prophylactic failure was defined as parasitaemia in a previously aparasitaemic 
woman 28 days after IPTp-SP administration. Women found aparasitaemic at 
recruitment and were tested for malaria at day 28 and those who tested positive at 
day 0 and were re-infected by day 28 were included in this analysis.  
Quantitative variables (age and parasite count) were summarised using means and 
median. Characteristics of study participants were described using percentages and 
the Chi-squared test was used to assess differences in proportions between women 
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recruited at the two sites and between women followed up to delivery and those 
who were lost to follow-up.  Standard statistical tests (i.e. Mann-Whitney U test, 
kruskal-wallis test, t-tests and analysis of variance were used to assess significance (P 
< 0.05) of differences in the distribution of continuous variables and comparison of 
means. Non-normally distributed variables were log-transformed before conducting 
t-tests or analyses of variance. The prevalence of malaria infection, determined by 
microscopy or by PCR, and their 95% CIs were estimated. The prevalence of the main 
outcomes (malaria, curable STIs/RTIs, malaria and curable STI/RTI coinfection, and 
ABO) and their 95% CIs were estimated. The prevalence of these outcomes was also 
estimated according to HIV status. The prevalence of malaria and coinfection was 
also estimated according to parity. 
For malaria, the pre-specified outcome was malaria prevalence as determined by 
PCR.  Results obtained from PCR diagnosis were used to assess potential risk factors 
for malaria infection. Potential predictors identified from literature were used to 
determine risk factors for infection in this study. Univariate analyses of potential 
predictors of: (i) Malaria infection; (ii) Infection with at least one STI; (iii) infection 
with BV, and (iv) coinfection with malaria and at least one STI/RTI, were conducted 
using logistic regression. Crude odds ratios were estimated. Potential predictors that 
showed significance at 10% were entered into a multivariable model and assessed 
using a likelihood ratio test. Factors that were found to be independently associated 
with infection at P < 0.05 were entered in a final model and adjusted odds ratios 
were obtained.  Independent variables in final models were checked for interaction 
using a likelihood ratio test. The criterion for interaction was P < 0.01. 
Mean birth weight, mean Hb and median gestational age were compared between 
the uninfected class and each of the other three pathology classes. Proportions of 
different ABO were estimated among the different placental pathology Chi-squared 
test was used to check for association between pathology class and ABO.  
The prevalence of individual ABO and composite ABO among delivering participants 
and their 95%CIs were estimated. Risk factors for composite ABO were explored 
using univariate and multivariate logistic regression as described above. The 
variables for recruitment site, malaria, STIs/RTIs and their coinfection were included 
in the final model to assess whether their individual effect on birth outcome was 
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modified by the site of recruitment. Risk factors for individual ABO (PD, LBW and 
IUGR) were also explored using univariate and multivariate logistic regression as 
described above.  
The prevalence estimates of the DHFR triple, DHPS double; DHFR + DHPS quintuple 
and sextuple mutants and their 95% CIs were calculated. Proportions of women in 
whom parasitaemia at day 0 was cleared by day 28 and those who experienced 
therapeutic and prophylactic failure were quantified. 
 
 
 
 
88 
 
3 Results (1): Maternal characteristics and prevalence estimates of 
malaria, STIs/RTIs and their coinfection 
89 
 
3.1 Chapter introduction 
This chapter presents the participation distribution and socio-demographic 
characteristics of study participants. Characteristics are presented according to 
recruitment sites for assessment of any differences in proportions between the two 
sites. The chapter also describes prevalence of malaria, STIs/RTIs and their 
coinfection and HIV infection. The prevalence of malaria only and malaria and 
STI/RTI coinfection are presented according HIV infection as well as gravidity. 
STIs/RTIs are presented according to HIV status. Results are presented in this manner 
for the assessment of whether these factors modulate the prevalence malaria, 
STIs/RTIs and their coinfection in this study population.  
3.2 Participation distribution 
A total of 1086 women were recruited and 67.1% (n = 729) were successfully 
followed up to delivery. Details of the distribution of participants at recruitment and 
follow-up to delivery are presented in Figure 3.1.  
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Figure 3. 1: Participation flow-chart 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note: The loss to follow-up on the actual sample size (984) was 24%.   
Screened for 
eligibility = 1237 
Ineligible (n = 142) 
Not pregnant   = 6 
> 32    =116 
Antimalarial use =13 
Antimalarial use & > 32 = 5 
Antibacterial use  = 2 
 
Followed up to delivery  
(67.1%, 729/1086)  
 
 
 
 
 
 
 
Lost to follow-up 
 (32.9%, 357/1086) 
Relocated = 7 
Withdrawal of consent = 1 
Moved away for delivery = 9 
Unknown = 340 
 
 
Enrolled women 
=1086 
Eligible = 1095 Refusals = 9 
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3.3 Socio-demographic characteristics of participants 
Table 3-1 presents characteristics of study participants and their respective 
frequencies. The youngest participant was 14 and the oldest was 47 years old. The 
median age of participants was 25 years (Interquartile range [IQR], 20-30) and the 
median gestational age was 22 weeks (IQR, 19-25.5). Almost a quarter (24.1%) of 
women who were enrolled were primigravidae, 15.2% were secundigravidae and 
more than half (60.7%) were multigravidae.  
The majority of these women, 80.6% (n = 874) were married and 40.7% (n = 426) 
reported six or fewer years of schooling. Nearly half of the 49.2% (n = 534) of the 
women reported ownership of a bed net (treated or untreated). Of 531 bed net 
owners, 78.3% (n = 416) reported to have slept under a bed net the previous night. 
Overall only 38.5% (416/1082) of participants slept under a bed net on the previous 
night. Indoor residual spraying had been applied to the homes of 20.9% (n = 226) of 
women at least once in the previous 12 months.  
There were no significant differences in the socio-demographic characteristics (age, 
marital status, years of schooling, bed net use and wealth index) between women 
recruited at Kashikishi and at Nchelenge health centre. The pregnancy related 
factors (gravidity, past experience of miscarriage, past history of stillbirth or PD) and 
clinical symptoms and treatments (symptoms of STI/RTI, HIV status, and use of 
antimalarial drugs prior to ANC visit) also did not differ between the two sites. 
However, Nchelenge site had a higher prevalence of peripheral malaria parasitaemia 
than Kashikishi (PCR positive malaria 67.4% versus 53.5%, P < 0.001; microscopy 
positive malaria 37.6% versus 29.1%, P = 0 .006).   
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Table 3- 1: Baseline characteristics of first ANC attendees of Nchelenge District, Zambia,    
according to recruitment site  
variable All (N = 1085) 
n (%) or median 
(IQR) 
Kashikishi (n = 747) 
n (%) or median 
(IQR) 
Nchelenge (n = 338) 
n (%) or median 
(IQR) 
P-value 
Age (median) 25 (20-30) 24 (20-30) 25 (20-31) 0.133 
Marital status 
  Single  
  Married 
  Widowed/divorced     
 
203 (18.7) 
874 (80.6) 
8 (0.7) 
 
134 (17.9) 
607 (81.3) 
6 (0.8) 
 
69 (20.4) 
267 (80.0) 
2 (0.6) 
 
0.591 
Years of schooling 
   None to 6 
   7 and above 
 
426 (39.3) 
659 (60.7) 
 
287 (38.4) 
460 (61.6) 
 
139 (41.1) 
199 (58.9) 
 
0.398 
Gravidity 
   Primigravidae 
   Secundigravidae 
   Multigravidae 
 
261 (24.1) 
165 (15.2) 
659 (60.7) 
 
183 (24.5) 
117 (15.6) 
447 (59.8) 
 
78 (23.1) 
48 (14.2) 
212 (62.7) 
 
0.657 
 
Bed net ownership  
   No 
   Yes 
 
551 (50.8) 
534 (49.2) 
 
367 (49.1) 
380 (50.9) 
 
184 (54.4) 
154 (45.6) 
 
0.105 
Bed net usage 
   No 
   Yes     
   Missing* 
 
666 (61.6) 
416 (38.4) 
3 
 
451 (60.6) 
293 (39.4) 
3 
 
215 (63.6) 
123 (36.4) 
0 
 
0.349 
IRS in previous 12 
months  
   No 
   Yes 
   Missing* 
 
808 (78.1) 
226 (21.9) 
51 
 
563 (75.7) 
156 (21.0) 
28 
 
245 (72.7) 
70 (20.8) 
26 
 
0.851 
Wealth quintile 
   Lowest 
   Second 
   Middle 
   Fourth 
   Highest 
   Missing* 
 
217 (20.0) 
221 (20.4) 
214 (19.8) 
215 (19.9) 
216 (19.9) 
2 
 
135 (18.1) 
151 (20.3) 
155 (20.8) 
158 (21.20 
146 (19.6) 
2 
 
82 (24.3) 
70 (20.7) 
59 (17.5) 
57 (16.9) 
70 (20.7) 
0 
 
 0.089 
Past experience of 
miscarriage 
    No  
    Yes 
    NA (Primigravidae)* 
 
 
708 (85.1) 
116 (14.1) 
261 
 
 
482 (85.3) 
83 (14.7) 
182 
 
 
226 (87.3) 
33 (12.7)  
79 
 
 
0.455 
Past experience of PD  
   No  
   Yes 
   NA (Primigravidae)* 
   Missing* 
 
784 (95.3) 
39 (4.7) 
261 
1 
 
538 (95.4) 
26 (4.6) 
182 
1 
 
246 (95.0) 
13 (5.0) 
79 
0 
 
 
0.797 
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Table 3-1: Baseline characteristics of first ANC attendees of Nchelenge District, Zambia,    
according to recruitment site continued 
 
Variable All (N = 1085) 
n (%)  
Kashikishi (n = 747) 
n (%)  
Nchelenge (n =338) 
n (%)  
P-value 
Prior delivery of  a still 
born   
   No 
   Yes 
   NA (Primigravidae)* 
 
755 (91.6) 
69 (8.4) 
261 
 
521 (92.2) 
44 (7.8) 
182 
 
234 (90.4) 
25 (9.7) 
79 
 
 
0.370 
Prior delivery of  a still 
born   
   No 
   Yes 
   NA (Primigravidae)* 
 
755 (91.6) 
69 (8.4) 
261 
 
521 (92.2) 
44 (7.8) 
182 
 
234 (90.4) 
25 (9.7) 
79 
 
 
0.370 
Prior delivery of a 
Preterm baby  
   No  
   Yes 
   NA (Primigravidae)* 
   Missing* 
 
 
784 (95.3) 
39 (4.7) 
261 
1 
 
 
538 (95.4) 
26 (4.6) 
182 
1 
 
 
246 (95.0) 
13 (5.0) 
79 
0 
 
 
0.797 
Antimalarial treatment ‡  
  No 
  Yes 
  Missing*   
 
1005 (93.1) 
74 (6.9) 
6 
 
693 (93.2) 
51 (6.9) 
3 
 
312 (93.1) 
23 (6.9) 
3 
 
0.995 
STI/RTI symptoms 
complaints among all 
  No 
  Yes 
 
 
951 (87.7) 
134 (12.4) 
 
 
650 (87.0) 
97 (13.0) 
 
 
301 (89.1) 
37 (10.9) 
 
0.345 
STI/RTI symptoms 
complaints among 
infected 
  No 
  Yes 
  NA (Negative)*   
 
 
 
602 (88.0) 
98 (14.0) 
384 
 
 
 
415 (85.4) 
57 (14.6) 
260 
 
 
 
187 (87.4) 
27 (12.6) 
124 
 
 
 
0.487 
HIV status  
   Negative 
   Positive  
   Missing*  
 
941 (86.8) 
143 (13.2) 
1 
 
643 (86.2) 
103 (13.8) 
1 
 
298 (88.2) 
40 (11.8) 
0 
 
0.374 
ART among HIV Positives 
   No 
   Yes 
   NA (HIV-negative)* 
 
82 (57.7) 
60 (42.7) 
941 
 
58 (56.9) 
44 (43.1) 
643 
 
24 (60.0) 
16 (40.0) 
298 
 
0.734 
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Table 3-1: Baseline characteristics of first ANC attendees of Nchelenge District, Zambia,         
according to recruitment site continued 
 
Variable All (N = 1085) 
n (%)  
Kashikishi (n = 747) 
n (%)  
Nchelenge (n =338) 
n (%)  
P-value 
Microscopy  
  Negative 
  Positive 
  Missing* 
 
736 (68.2) 
343 (31.8) 
6 
 
525 (70.9) 
216 (29.1) 
6 
 
211 (62.4) 
127 (37.6) 
0 
 
0.006 
STI/RTI 
  Negative 
  Positive 
  Missing 
 
384 (35.4) 
700 (64.6) 
1 
 
260 (34.9) 
486 (65.1) 
1 
 
124 (36.7) 
214 (63.3) 
0 
 
0.599 
Malaria & STI/RTI  
  Coinfection† 
  No infection 
  Single infection¥ 
  Coinfection 
Missing* 
 
 
 
177 (16.5) 
480 (44.8) 
414 (38.7) 
14 
 
 
128 (17.4) 
339 (46.2) 
267 (36.4) 
13 
 
 
49 (14.6) 
141 (41.8) 
147 (43.6) 
1 
 
 
0.071 
 
NA: Not applicable, IQR: interquartile range, IRS: Indoor residual spraying 
* Missing and NA values are only presented as numbers and were not included in the calculation of 
percentages and in the Chi-squared test for association 
†Infection with at least one STI/RTI and malaria 
¥Single infection: Infection with at least one STI/RTI or malaria 
‡Antimalarial treatment during pregnancy taken more than four weeks before recruitment 
Less than 5 women took antibacterial agents during pregnancy but more than a month before 
recruitment 
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3.4 Malaria and HIV Burden 
 3.4.1 The Prevalence of HIV infection 
The prevalence of HIV infection among participants was 13.2% (95% CI, 11.3–15.3) 
and the highest burden was observed in multigravidae (15.9%) followed by 
secundigravidae (13.9%) and was lowest in primigravidae (8.0%), P = 0.018. A higher 
proportion of infection was noted among women aged above 25 years than women 
aged ≤ 25 years (17.9% versus 9.4%, P < 0.001). 
3.4.2 The prevalence of peripheral malaria 
The prevalence of malaria infection at first ANC attendance measured by microscopy 
and by PCR was 31.8% (95% CI, 29.1-34.6) and 57.8% (95% CI, 54.9-60.8) 
respectively. Parasite density ranged from 64–24,760 parasites per µl of blood with a 
geometric mean of 1,082 (95% CI, 962-1,217) asexual parasites per µl of blood. 
Parasite density was highest among primigravidae with the geometric mean being 
significantly different across gravidae (P < 0.001). Of the 343 malaria positive 
samples detected by microscopy, seven were negative for P. falciparum by PCR 
(Table 3-2). 
Of the 1,074 women whose results were available for malaria detected by PCR, 8.4% 
(n = 90, 95% CI, 6.7-10.2) were coinfected with HIV. The prevalence of malaria 
among HIV-infected and HIV-uninfected women detected by PCR was 65.2% 
(90/138) and 56.7% (531/936), respectively (P = 0.059). Among women who tested 
positive for HIV, combined with those with known HIV positive status, 42.7% were 
receiving antiretroviral therapy at the time of recruitment. The proportions of 
malaria infection detected by PCR among HIV-infected women on ARV treatment 
and those who were not on ARV treatment were 71.8% (56/78) and 56.7% (34/60) 
respectively, P = 0.064. 
In the case of microscopy, 31.3% (294/939) of HIV-uninfected had parasitaemia 
compared to 35.0% (49/140) among HIV-infected women (P = 0.382). HIV-uninfected 
women had significantly lower parasite densities than HIV-infected women, 990 
(95% CI, 876-1120) versus 1836 (95% CI, 1306-2580), P < 0.001. A lower proportion 
of malaria infection diagnosed by microscopy was observed among HIV-infected 
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women on ARV therapy than among those who were not on therapy, 24.6% (15/61) 
versus 43.0% (34/79) respectively, P = 0.023.  Parasite density among HIV-infected 
women receiving ARV therapy was lower than that observed among those who were 
not on therapy at recruitment, 1,310 (95% CI, 693-2,476, n = 15) versus 2,131 (95% 
CI, 1,408-3,224, n = 34), respectively but this was not statistically significant (P = 
0.189). 
3.4.3 Placental malaria infection 
Of the 729 women who were followed to delivery, placental tissue was successfully 
processed for 96% (n = 702) participants and 40.9% (n=287) of these had 
histopathological evidence of placental malaria (Table 3-3). The highest proportion 
(30.4%) was past infections detected by the presence of the pigment without the 
presence of parasites. The frequency of placental infection, past or active or both, 
was higher in primigravidae than multigravidae and this difference was statistically 
significant (52.7% versus 33.6%; P < 0.001). Further results on placental malaria 
infection and histopathology classes are presented in chapter six (section 6.2).   
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Table 3- 2: Prevalence of HIV and Plasmodium falciparum malaria infection at first antenatal attendance and at delivery among women of 
Nchelenge district according to gravidity/parity 
Infection 
Diagnostic method 
All gravidae 
N = 1085 
n(%) or n, geometric 
mean 
95% 
Confidence 
Interval 
Primigravidae 
n=261 
n(%) or n, geometric 
mean (95% CI)  
Secundigravidae 
n=165 
n(%) or n, geometric 
 mean (95% CI) 
Multigravidae 
n=659 
n (%) or n, geometric 
mean (95% CI) 
P-value 
HIV (serology) 
Negative 
Positive 
Missing* 
 
941 (86.8) 
143 (13.2) 
1 
 
86.8-84.8 
11.3-15.3 
 
 
240 (92.0) 
21 (8.0) 
0 
 
14286.1) 
23 (13.9) 
0  
 
559 (84.9) 
99 (15.1) 
1 
 
0.018 
Malaria (PCR) 
Negative 
Positive 
Missing* 
 
 
453 (42.2) 
621 (57.8) 
11  
 
39.2-45.1 
54.8-60.7 
 
 
81 (31.3)  
I78 (68.7) 
2 
 
 63 (38.2) 
102 (61.8) 
 
309 (47.5) 
341 (52.5)  
9 
 
< 0.001 
Microscopy  
Negative 
Positive 
Missing* 
Geometric mean of 
Parasite density  
  
736 (68.2) 
343 (31.8) 
6 
 
65.4-71.0 
29.1-34.6 
  
127 (49.3) 
132 (51.0) 
2  
 
104 (63.0) 
61 (37.0) 
1 
 
505 (77.1) 
150 (22.9)  
3 
 
< 0.001 
343, 1082 
 
962-1217 132, 1378  
(1133-1677) 
61, 1164 
 (897-1509) 
150, 848 
 (714-1010) 
 
< 0.001 
Placental malaria 
Negative 
Positive 
Missing* 
Lost to follow-up* 
 
415 (59.1) 
287 (40.9) 
27 
356 
 
55.5-62.8 
37.3-44.6 
 
89 (47.3) 
199 (52.7)  
6 
67 
 
46 (50.0) 
46 (50.0) 
6 
67 
 
280 (66.4) 
142 (33.6) 
15 
222 
 
< 0.001 
Of the 343 malaria positive samples detected by microscopy 7 were found negative by PCR specific for P. falciparum detection 
The overall prevalence (40.9%) is a combination of different classes of pathology as follows: Presence of parasites only - 2.4%; Presence of parasites and 
pigment - 8.1%; Presence of pigment only – 30.4%. 
*Missing and lost to follow-up. P-values are only presented as numbers and were not included in the calculation of percentages and in the Chi-squared 
test for association 
Of the expected samples from 1085 participants, 4 dry blood spots and 4 slides were not collected. In addition to this 5 dry blood spots were misplaced 
98 
 
3.4.4 Monthly peripheral malaria infection among first ANC attendees 
Figure 3.2 shows the prevalence of malaria infection among study participants each 
calendar month during the six-month recruitment period from November 2013 to 
April 2014.  The malaria prevalence was slightly higher between February and April 
compared to the period between November and January.  
 
Figure 3. 2: Prevalence of malaria in pregnant women of Nchelenge District and 
total monthly rainfall during the study recruitment period. 
 
PCR: Polymerase chain reaction 
             Mm: Millimetres 
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3.5 Reproductive tract and curable sexually transmitted infections  
The prevalence of STIs/RTIs among pregnant women in this study was high.  Overall, 
infection with at least one STI/RTI was observed in 64.8% (95% CI, 61-67.4) of the 
participating women. The most prevalent infection was BV (48.3%) and the least 
prevalent was gonorrhoea (3.1%). With the exclusion of BV the prevalence of 
infection with at least one curable STI was 34.5% (95% CI, 31.7-37.4).  
 Contrary to what was observed in the case of HIV infection, a higher prevalence of 
STIs was observed among women aged ≤ 25 years than women aged above 25 years 
(38.7% versus 29.2%, P = 0.001). The prevalence of BV was higher among women 
aged ≤ 25 years than among older women, but this was not statistically significant 
(50.1 versus 45.8%, P = 0.130). 
Table 3-4 presents the prevalence of individual and composite STIs/RTIs among 
participants according to HIV status. The prevalence of curable STIs/RTIs was higher 
among HIV-infected women than among HIV-uninfected women. The prevalence of 
BV, Chlamydia, gonorrhoea and syphilis was higher among HIV-infected women than 
among HIV-uninfected women. This was statistically significant in the cases of 
gonorrhoea, BV and syphilis but not in the case of Chlamydia. There was no 
statistically significant difference in the prevalence of trichomoniasis between HIV-
uninfected women and HIV-infected women, 25.0% verse 23.8% (P = 0.752). With 
the exclusion of BV, prevalence of any STI was higher among HIV-infected than HIV 
uninfected women but this was not statistically significant (41.3 versus 33.5%, P = 
0.069).  
Of the 700 women who were infected with at least one STI/RTI at first ANC visit 
14.0% (n = 98) complained of at least one symptom associated with curable STIs/RTIs 
(itching, discharge, burning session during urination or presence of sores/ulcers). 
About 9.4% (36/384) had similar complaints among uninfected women.  A similar 
proportion was observed when only curable STIs were considered. Of the 374 
women who tested positive to at least one STI, 14.2% (n = 53) indicated that they 
were experiencing at least one symptom indicative of infection with an STI at the 
time of recruitment. 
100 
 
Table 3- 3: Prevalence of curable STIs/RTIs among first ANC attendees of Nchelenge 
district according to HIV status 
Infection All 
 (N = 1084) 
n (%)  
95% 
Confidence 
interval‡ 
 
HIV-uninfected 
(n = 941) 
n (%)  
HIV-infected  
(n = 143) 
n (%)  
P-value 
Bacterial vaginosis 
 Normal 
 Intermediate 
 BV 
 Missing* 
 
375 (34.7) 
184 (17.0) 
524 (48.3) 
4 
 
31.8-37.5 
14.9-19.4 
45.2-51.2 
 
 
342 (36.5) 
169 (18.0) 
429 (45.8) 
4 
 
33 (23.1) 
15 (10.5) 
95 (66.4) 
0 
 
< 0.001 
Trichomoniasis 
 Negative 
 Positive 
 Missing* 
 
814 (75.2) 
269 (24.8) 
1 
 
72.6-77.8 
22.3-27.5 
 
705 (75.0) 
235 (25.0) 
1 
 
109 (76.2) 
34 (23.8) 
0 
 
0.752 
 Chlamydia 
 Negative 
 Positive 
 Missing* 
 
1027 (94.8) 
56 (5.2)  
1 
 
93.5-96.2 
3.9-6.7 
 
894 (95.1) 
46 (4.9) 
1 
 
133 (93.0) 
10 (7.0) 
0 
 
0.291 
Gonorrhoea 
 Negative 
 Positive 
 Missing* 
 
1049 (96.9) 
34 (3.1) 
1 
 
95.8-97.9 
2.2-4.4 
 
915 (97.3) 
25 (2.7) 
1 
 
134 (93.7) 
9 (6.3) 
0 
 
0.020 
Confirmed syphilis 
 Negative 
 Positivea 
 Missing* 
 
1001 (92.9) 
76 (7.1) 
7 
 
91.4-94.5 
5.6-8.7 
 
884 (94.2) 
54 (5.8) 
3 
 
117 (84.2) 
22 (15.8) 
4 
 
< 0.001 
Composite STI 
Negative 
Positive 
Missing* 
 
710 (65.5) 
374 (34.5) 
1 
 
62.7-68.3 
31.7-37.4 
 
625(66.5) 
315 (33.5) 
1 
 
84 (58.7) 
59 (41.3) 
0 
 
0.069 
Composite STI/RTI 
 Negative 
 Positive  
 Missing* 
 
381 (35.2) 
702 (64.8) 
1 
 
32.6-38.3 
61.7-67.4 
 
348 (37.0) 
592 (63.0) 
1 
 
33 (23.1) 
110 (76.9) 
0 
 
0.001 
HIV: Human Immunodeficiency Virus 
Composite STI/RTI: sexually transmitted and reproductive tract infections (included bacterial 
vaginosis, Chlamydia, gonorrhoea, trichomoniasis and TPHA confirmed syphilis) 
Composite STI: included Chlamydia, gonorrhoea, trichomoniasis and TPHA confirmed syphilis 
* Missing values are only presented as numbers and were not included in the calculation of 
percentages and in the Chi-squared test for association 
aThe figure represents the number of samples that were TPHA reactive among those who were 
seropositive by RPR calculated out of all the participants who were tested with RPR (1077). 
Note: Among the participants who were RPR reactive, 65% (76/117) were found reactive with 
TPHA 
Overall the total number was 1084 instead of 1085 because the HIV status of one participant was 
not determined.  
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3.6 Malaria and curable STI/RTI coinfection 
Out of the 1071 women tested for malaria and all the five curable STI/RTI, 38.7% (n= 
414) were coinfected with malaria and STI/RTI (Table 3-5). The prevalence of 
coinfection was lower in the case of malaria diagnosed by microscopy (21.4%, 
230/1076). 
3.6.1 Malaria and STI/RTI coinfection according to parity 
 Mono-infection with malaria diagnosed by PCR did not differ significantly among the 
three gravidity groups (primigravidae, secundigravidae and multigravidae) but 
infection with at least one curable STI/RTI increased slightly with increasing gravidity 
(19.4%, 25.5% and 29.0%, respectively, P = 0.012). However, the prevalence of 
coinfection decreased with increasing gravidity (49.6%, 44.2% and 32.9% 
respectively, P < 0.001. This trend in the frequency of coinfection across gravidity 
groups persisted even when the malaria diagnosis was done by microscopy (33.7%, 
28.5% and 14.7% respectively, P < 0.001).  
The median ages of women in the three groups of infection were as follows; 
coinfection 22.5 years (IQR, 19-28), mono-infection (at least one STI/RTI or malaria) 
25 years (IQR, 21-30) and uninfected 27 years (IQR, 21-31) (P < 0.001, kruskal-wallis 
equality-of-population rank test).  
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Table 3- 4: Prevalence of malaria and STI/RTI coinfection according to gravidity  
Coinfection¥ based on malaria diagnosed by PCR 
Category of 
infection 
 
All (N =1085) 
n (%) 
  All  
95% CI 
Primigravidae 
n = 261 
n (%) 
Secundigravidae 
n = 165  
n (%) 
Multigravidae 
(n = 648)  
n (%) 
P-value 
Coinfection¥ 414 (38.7)  35.7 - 41.6 128 (49.6) 73 (44.2) 213 (32.9) < 0.001 
Malaria only  202 (18.8)  16.5 - 21.2 47 (18.2) 29 (17.5) 126 (19.4) 0.822 
STI/RTI only 278 (26.0) 23.5 - 28.8 50 (19.4) 42 (25.5) 188 (29.0) 0.012 
No infection 177 (16.5) 14.1 - 18.6 33 (12.8) 21 (12.7) 121 (18.7) 0.038 
Missing* 14  3 0 11  
Coinfection¥ based on malaria diagnosed by microscopy 
Category of 
infection 
 
All (N =1085) 
n (%) 
  All  
95% CI 
Primigravidae 
n = 261 
n (%) 
Secundigravidae 
n = 165  
n (%) 
Multigravidae 
(n = 648)  
n (%) 
P-value 
Coinfection¥ 230 (21.4) 18.9 - 23.8 87 (33.7) 47 (28.5) 96 (14.7) < 0.001 
Malaria only 93 (8.6) 6.9 -10.3 39 (15.1) 13 (7.7) 41 (6.3) < 0.001 
STI/RTI only 469 (43.5) 40.6 - 46.5 91 (35.3) 69 (41.8) 309 (47.3) 0.004 
No infection 285 (26.4) 23.8 - 29.1 41 (15.9) 36 (21.8) 208 (31.8) < 0.001 
Missing* 9  3 0 6  
¥Coinfection: Infection with malaria and at least one STI/RTI 
*Missing values are only presented as numbers and were not included in the calculation of percentages and in the Chi-squared test for association 
Missing values were due missing samples, 14 samples could not be classified due to some missing results.  
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3.5.2 Malaria and STI/RTI coinfection according to HIV status 
Table 3-5 presents the prevalence of individual STI/RTI and malaria coinfection as 
well as composite STI/RTI and malaria coinfection according to HIV status. The 
prevalence of coinfection with malaria and individual STIs/RTIs was higher among 
HIV-infected than HIV-uninfected women but this was only statistically significant in 
the case of syphilis and BV regardless of the diagnostic tool used for malaria 
detection. In the case of malaria diagnosed by PCR, coinfection with syphilis among 
HIV-infected and HIV-uninfected women was 8.8% versus 3.3%, respectively (P = 
0.002). Coinfection with BV and malaria was 45.7% versus 26.8% among HIV-infected 
and HIV-uninfected women respectively (P < 0.001). Coinfection with malaria and BV 
was the most prevalent (29.2%; 95% CI 26.5-32.0) and coinfection with malaria and 
gonorrhoea was the least prevalent (2.1%; 95% CI 1.3-3.1). STI/RTI among the 621 
women who tested positive to malaria by PCR was as follows: 50.9% were infected 
with BV; 26.4% were infected with trichomoniasis; 6.0% were infected with 
Chlamydia; 3.5% were infected with gonorrhoea and 7.0% had syphilis. Composite 
STI/RTI and malaria coinfection was higher among HIV-infected than HIV-uninfected 
women, 50.0% versus 37%, P = 0.003 in case of Malaria diagnosed by PCR and 27.1% 
versus 20.5%, P = 0.073 in the case of malaria diagnosed by microscopy.  
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Table 3- 5: Prevalence of individual curable STI/RTI and malaria coinfection among first antenatal care attendees of Nchelenge       
District, Zambia 
 
Malaria diagnosed by PCR 
Coinfection N = 1084  
n (%) 
95% CI HIV-uninfected 
n = 941 n (%) 
HIV-infected 
n = 143 n (%) 
P-Value 
Malaria and Bacterial vaginosis 
   No 
   Yes 
   Missing* 
 
757 (70.8) 
313 (29.2) 
14 
 
68.0-73.5 
26.5-32.0 
 
682 (73.2) 
250 (26.8) 
9 
 
75 (54.4) 
63 (45.7) 
5 
 
< 0.001 
Malaria and Trichomonas vaginalis  
   No 
   Yes 
   Missing* 
 
909 (84.7) 
164 (15.3) 
11 
 
82.6-86.9 
13.3-17.6 
 
793 (84.8) 
142 (15.2) 
6 
 
116 (84.1) 
22 (15.9) 
5 
 
0.818 
Malaria and Chlamydia trachomatis 
   No 
   Yes 
   Missing* 
 
1036 (96.6) 
37 (3.4) 
11 
 
95.5-97.6 
2.4-4.5 
 
905 (96.8) 
30 (3.2) 
6 
 
131 (94.9) 
7 (5.1) 
5 
 
0.263 
Malaria and Neisseria gonorrhoeae 
   No 
   Yes 
   Missing* 
 
1051 (97.9) 
22 (2.1) 
11 
 
97.1-98.8 
1.2-2.9 
 
918 (98.2) 
17 (1.8) 
6 
 
133 (96.4) 
5 (3.6) 
5 
 
0.162 
Malaria and Treponema Pallidum 
   No 
   Yes 
   Missing* 
 
1029 (96.0) 
43 (4.0) 
12 
 
94.8-97.2 
2.8-5.2 
 
904 (96.7) 
31 (3.3) 
6 
 
125 (91.2) 
12 (8.8) 
5 
 
0.002 
Malaria and STI/RTI coinfection
$
 
  Coinfection 
    Malaria only 
    STI/RTI only 
    No infection  
    Missing* 
 
414 (38.7) 
202 (18.9) 
278 (26.0) 
177 (16.5) 
13 
 
35.8-41.6 
16.6-21.3 
23.4-28.7 
14.3-18.8 
 
 
345 (37.0) 
182 (19.5) 
237 (25.5) 
169 (18.1) 
8 
  
69 (50.0) 
20 (14.5) 
41 (29.7) 
8 (5.8) 
5 
 
0.003 
0.154 
0.286 
< 0.001 
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Table 3-5: Prevalence of individual curable STI/RTI and malaria coinfection among first antenatal care attendees of Nchelenge District, Zambia 
continued 
Malaria diagnosed by microscopy 
Coinfection N = 1084  
n (%) 
95% CI HIV-uninfected 
n = 941 n (%) 
HIV-infected 
n = 143 n (%) 
P-Value 
Malaria and Bacterial vaginosis 
   No 
   Yes 
   Missing* 
 
896 (83.1) 
182 (16.9) 
9 
 
80.8-85.3 
14.7-19.2 
 
789 (84.4) 
146 (15.6)  
6 
 
104 (74.3) 
36 (25.7) 
3 
 
0.003 
Malaria and Trichomonas vaginalis  
   No 
   Yes 
   Missing* 
 
983 (91.2) 
95 (8.8) 
6 
 
89.5-92.9 
7.1-10.5 
 
851 (90.7) 
87 (9.3) 
3 
 
132 (94.3) 
8 (5.7) 
3 
 
0.166 
Malaria and Chlamydia trachomatis 
   No 
   Yes 
   Missing* 
 
1055 (97.9) 
23 (2.1) 
6 
 
97.0-98.7 
1.2-3.0 
 
919 (98.0) 
19 (2.0) 
3 
 
136 (97.1) 
4 (2.9) 
3 
 
0.527 
Malaria and Neisseria gonorrhoeae 
   No 
   Yes 
   Missing* 
 
1069 (99.2) 
9 (0.83) 
6 
 
98.6-97.7 
034-1.4 
 
931 (99.2) 
7 (0.8) 
3 
 
138 (98.6) 
2 (1.42) 
3 
 
0.408 
Malaria and Treponema Pallidum 
   No 
   Yes 
   Missing* 
 
1051 (97.8) 
24 (2.2) 
9 
 
96.9-98.7 
1.3-3.1 
 
922 (98.4) 
15 (1.6) 
4 
 
129 (93.5) 
9 (6.5) 
5 
 
<  0.001 
Malaria and STI/RTI coinfection
$
 
  Coinfection 
  Malaria only 
  STI/RTI only 
  No infection 
    Missing* 
 
230 (21.4) 
93 (8.6) 
467 (43.4) 
286 (26.6) 
9 
 
18.9-23.8 
7.0-10.3 
40.4-46.4 
23.9-29.3 
 
192 (20.5) 
84 (9.0) 
395 (42.2) 
265 (28.3) 
 
38 (27.1) 
9 (6.5) 
72 (51.4) 
21 (15.0) 
 
 
0.073 
0.322 
0.039 
< 0.001 
 
*Missing values are only presented as numbers and were not included in the calculation of percentages 
$ Coinfection: infection with malaria and at least one STI/RTI  
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3.7 Quality control assessment results 
Results for quality control testing were highly concordant. There was a 96.4% (53/55) 
concordance in the Nugent score results obtained from the repeat reading of slides 
for detection of bacterial vaginosis. The two readings both conflicted between the 
normal and the intermediate class. Syphilis RPR results were 100% (55/55) 
concordant; TPHA testing was 100% (30/30) concordant. For C. trachomatis, 
agreement of test results between the in-house methods and the Seeplex® STI 
Master Panel 1 kit was 96.4% (54/55). In the case of N. gonorrhoeae and T. vaginalis, 
there was 100% concordance between the in house methods and the commercial 
kit. Repeat reading of slides for placental malarial diagnosis by histology was 95.7% 
(44/46) concordant. 
107 
 
4 Results (2): Risk factors for malaria, STI/RTI and their coinfection 
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4.1 Chapter introduction 
This chapter presents risk factors for (i) malaria (ii) STI, (iii) BV and (iv) malaria and 
STI/RTI coinfection as identified by logistic regression models. The variables included 
in the analyses were guided by risk factors for infection as identified from literature 
in section 1.5.1. The tables presented include both univariate and multivariate 
analyses of risk factors for infection. 
4.2 Risk factors for malaria infection  
Table 4-1 presents risk factors for malaria infection. In the univariate analyses the 
association between malaria infection and the following factors was statistically 
significant (P < 0.1); recruitment site, age group, marital status, gravidity, bed net 
ownership, bed net usage, wealth quintile and HIV status.  However, in the 
multivariate analysis, only three factors i.e. HIV status, site of recruitment and 
wealth quintile were independently associated with malaria infection (P < 0.05).   
Wealth quintile was not associated with malaria infection in a model with HIV 
infection and site of recruitment and was therefore excluded from the final model.  
In the final model, the risk of malaria infection was higher among women recruited 
at Nchelenge health centre (aOR = 1.81; 95% CI, 1.38-2.37, P < 0.001) and HIV-
infected women across both health centres (aOR = 1.46; 95% CI 1.00-2.13, P = 
0.045). There was no interaction between HIV status and site of recruitment (P = 
0.751). 
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Table 4- 1: Predictors of malaria infection in pregnant women of Nchelenge District 
Potential risk factor  
 
Number  % Unadjusted OR Adjusted OR  Adjusted OR for 
final model 
P-value 
 1074 100 - N = 1068 N = 1072 < 0.001¥ 
Recruitment site 
Kashikishi 
Nchelenge 
 
737 
337 
 
68.6 
31.4 
P < 0.001 
1.00 
1.80 (1.37-2.35) 
P < 0.001 
1.00 
1.89 (1.43-2.50) 
 
1.00 
1.81 (1.38-2.37) 
 
 
< 0.001 
Age group  
≤ 20 
21-25 
26-30 
≥ 30 
 
295 
304 
244 
231 
 
27.5 
28.3 
22.7 
21.5 
P < 0.001 
1.00 
0.51 (0.37-0.72) 
0.51 (0.36-0.73) 
0.45 (0.32-0.64) 
P = 0.153 
1.00 
0.63 (0.41-0.98) 
0.67 (0.41-1.09) 
0.58 (0.34 -0.96) 
- - 
Marital status 
Single 
Married 
Divorced/separated/ 
widowed 
 
201 
865 
8 
 
18.7 
80.5 
0.8 
P = 0.114 
1.00 
0.72 (0.53-0.99) 
0.56 (0.14-2.30) 
- - - 
Gravidity 
Primigravidae 
secundigravidae 
Multigravidae 
 
259 
165 
650 
 
24.1 
15.4 
60.5 
P < 0.001 
1.00 
0.74 (0.48-1.11) 
0.50 (0.37-0.68) 
P = 0.077 
1.00 
0.80 (0.48-1.33) 
0.58 (0.35-0.97) 
- - 
Bed net ownership  
No  
Yes 
 
547 
527 
 
50.9 
49.1 
P = 0.015 
1.00 
0.74 (0.58-0.94)  
P = 0.589 
1.00 
1.13 (0.73-1.75) 
- - 
Bed net use on previous night  
No  
Yes 
Missing* 
 
 
659 
412 
3 
 
61.5 
38.5 
P = 0.006 
1.00 
0.75 (0.48-0.91) 
 
P = 0.188 
1.00 
0.74 (0.48-1.16) 
 
- - 
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Table 4-1: Predictors of malaria infection in pregnant women of Nchelenge District continued 
Potential risk factor  
 
Number  % Unadjusted OR Adjusted OR for 
multivariate 
Analysis 
Adjusted OR for 
final model 
 
P-value 
1074 100 - N = 1068 N = 1072 < 0.001¥ 
IRS in past 12 months 
No  
Yes 
Unknown* 
 
799 
225 
46 
 
78.0 
22.0 
 
P = 0.386 
1.00 
1.19 (0.88-1.61) 
 
- 
 
 
 
 
- - 
Wealth quintile 
 Lowest 
Second 
Middle 
Fourth 
Highest 
Missing * 
 
216 
219 
209 
214 
214 
2 
 
20.1 
20.4 
19.5 
20.0 
20.0 
P = 0.072 
1.00 
0.80 (0.54-1.17) 
0.91 (0.61-1.34) 
1.08 (0.73-1.60) 
0.64 (0.44-0.95) 
 
P = 0.031 
1.00 
0.74 (0.50-1.09) 
0.77 (0.51-1.16) 
0.89 (0.58-1.36) 
0.53 (0.35-0.81) 
- - 
HIV status 
Negative 
Positive 
 
 
941 
143 
 
 
86.8 
13.2 
P = 0.057 
1.00 
1.30 (0.91-1.88) 
 
1.00 
1.56 (1.05-2.32) 
 
1.00 
1.46 (1.00-2.13)  
 
0.045 
-: Blank 
¥
P- value for overall final model 
P-values appearing with unadjusted odds ratios are for each univariate model indicating associations of the variable with the outcome at P < 0.1. 
P-values appearing with adjusted odds ratios indicate the independent association of each variable with the outcome at P < 0.05  
Bold type- statistically significant outcome for multivariate analysis and final model. 
Number of participants less than 1074 (available malaria test results by PCR) were due to missing values in individual variables.  
*Missing/unknown  values are only presented as numbers and were not included in the calculation of percentages and in the models 
When wealth quintile was put in the model with HIV and site of recruitment it was not significantly associated with malaria infection and was therefore 
excluded from the final model.  
There was no interaction between HIV infection and site of recruitment in the final model (P =0.751) 
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4.3 Risk factors for curable STIs/RTIs  
Risk factors for STIs and BV which is not sexually transmitted were analysed 
separately and are presented in Tables 4-2 and Table 4-3.  
4.3.1 Risk factors for STIs 
 Table 4-2 shows univariate and multivariate analyses of risk factors for composite 
STIs (Chlamydia, gonorrhoea, trichomoniasis and TPHA confirmed syphilis). In the 
univariate analysis infection with at least one STI was associated with age group, 
marital status, gravidity, number of life-time sexual partners, wealth quintile, HIV 
status and BV at P < 0.1. In multivariate analysis infection with at least one STI was 
associated with wealth quintile and infection with BV. Wealth quintile was not 
independently associated with infection with at least one STI in a model with BV and 
was therefore excluded from the final model. In the final model, infection with at 
least one STI was associated with BV. In comparison to uninfected women, women 
infected with BV were at a higher risk of being infected with at least one STI (aOR 
1.44; 95% CI, 1.08-1.92, P = 0.012). 
4.3.2 Risk factors for BV  
Table 4-3 shows univariate and multivariate analyses of risk factors for BV. In the 
univariate analysis bacterial vaginosis was associated with age group, marital status, 
gravidity, HIV and infection with at least one STI. In the multivariate analysis 
infection with HIV and infection with at least one STI were independently associated 
with BV. In the final model HIV-infected women had a higher risk of infection with BV 
than HIV-uninfected women (aOR 1.87; 95% CI, 1.24-2.83, P = 0.003) and women 
infected with at least one STI had a higher risk of BV (aOR 1.40; 95% CI (1.07 -1.84, P 
= 0.01).  
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  Table 4- 2: Univariate and multivariate analyses of risk factors for STIs  
Variable 
Category 
Number % Unadjusted OR Adjusted OR Final model  P-value 
1084 100 - N = 1067 N = 1078 0.007¥ 
Age group  
  ≤ 20 
  21-25 
  26-30 
  ≥ 30 
 
296 
309 
245 
234 
 
27.3 
28.5 
22.6 
21.6 
P < 0.001 
1.00 
0.79 (0.56-1.09) 
0.72 (0.51-1.02) 
0.45 (0.31-0.66) 
P = 0.101 
1.00 
0.89 (0.58 -1.35) 
0.82 (0.51-1.35) 
0.56 (0.33-0.95) 
- - 
Maternal education 
   0-6 years 
   ≥ 7 years 
 
426 
658 
 
 
39.3 
60.7 
P = 0.893 
1.00 
0.98 (0.76-1.27) 
 
- - - 
Marital status 
  Single 
  Married              
Separated/widowed/divorced  
 
203 
873 
8 
 
18.7 
80.4 
0.7 
P = 0.022 
1.00 
0.64 (0.47-0.87) 
0.80 (0.19-3.4) 
P = 0.768 
1.00 
0.87 (0.58-1.29) 
0.76 (0.13-4.40) 
- - 
Gravidity  
  Primigravidae 
  secundigravidae 
  Multigravidae 
 
261 
165 
658 
 
24.1 
15.2 
60.7 
P < 0.001 
1.00 
1.03 (0.69-1.52) 
0.59 (0.43-0.79) 
P = 0.151 
1.00 
1.12 (0.69-1.81) 
0.76 (0.46-1.24) 
- - 
No. of life time sexual 
partners 
  1 or 2 
  3 or more 
 Unknown 
 
797 
277 
10 
 
74.2 
25.8 
P = 0.037 
1.35 (1.02-1.79) 
0.49 (0.42-0.56) 
 
P = 0.05 
1.00 
1.34 (1.00-1.80) 
- - 
Age at sexual debut 
≤15 
16-17 
≥ 18 
Unknown* 
 
 
245 
282 
404 
153 
 
26.3 
30.3 
43.4 
P = 0.771 
1.00 
0.88 (0.61-1.26) 
0.93 (0.67 -1.31) 
 
- - - 
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Table 4-2: Univariate and multivariate analyses of risk factors for STIs 
Variable 
Category 
Number % Unadjusted OR Adjusted OR Final model  P-value 
1084 100 - N = 1067 N = 1078 0.007¥ 
Wealth quintile 
   Lowest 
   Second 
   Middle 
   Fourth 
   Highest 
   Missing* 
 
217 
221 
213 
215 
216 
2 
 
20.0 
20.4 
19.7 
19.9 
20.0 
P = 0.018 
1.00 
1.13 (0.76-1.68) 
1.03 (0.69-1.54) 
1.44 (0.97-2.13) 
0.71 (0.47-1.08) 
 
P = 0.008 
1.00 
1.00 (0.67-1.51) 
0.79 (0.51-1.20) 
1.02 (0.67-1.55) 
0.52 (0.33-0.82) 
- - 
HIV status 
   Negative 
   Positive 
   Missing* 
 
940 
143 
1 
 
86.8 
13.2 
P = 0.072 
1.00 
1.39 (0.97-1.99) 
P =  0.064 
1.00 
1.44 (0.98-2.10) 
- - 
Bacterial vaginosis 
  Negative 
  Intermediate 
  Positive   
 
375 
184 
521 
4 
 
34.7 
17.0 
48.3 
 
P = 0.034 
1.00 
1.37 (0.95-2.00) 
1.44 (1.08-1.91) 
P = 0.037 
1.00 
1.52 (1.04-2.23) 
1.40 (1.04-1.87) 
 
 
1.00 
1.38 (0.95-2.00) 
1.44 (1.08-1.92) 
 
 
0.091 
0.012 
-: Blank 
¥P-value for overall final model 
P-values appearing with unadjusted odds ratios are for each univariate model indicating associations of the variable with the outcome at P < 
0.1. 
P-values appearing with adjusted odds ratios indicate the independent association of each variable with the outcome at P < 0.05  
Bold type- statistically significant outcome for multivariate analysis and final model. 
When wealth quintile was put in the model with BV, it was not independently associated with infection with at least one STI and was therefore 
excluded from the final model. 
*Missing/unknown  values are only presented as numbers and were not included in the calculation of percentages and in the models 
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Table 4- 3: Univariate and multivariate analyses of risk factors for BV 
 
Potential risk factor Number % Unadjusted OR Adjusted OR Final model  P-value 
1081 100 - N= 1079 N = 1079 0.001¥ 
Age group  
  ≤ 20 
  21-25 
  26-30 
  ≥ 30 
 
294 
307 
246 
234 
 
27.3 
28.4 
22.8 
21.6 
 
P = 0.050 
1.00 
1.46 (1.04-2.03) 
1.43 (1.00-2.06) 
1.02 (0.72-1.46) 
P = 0.120 
1.00 
1.43 (0.93-2.20) 
1.45 (0.89-2.39) 
1.04 (0.63-1.72) 
- - 
Maternal education 
   0-6 years 
   ≥ 7 years 
 
425 
656 
 
39.3 
60.7 
P =   0.550 
1.00 
1.08 (0.84-1.39) 
- - - 
Marital status 
  Single 
  Married             
Separated/widowed/divorced  
 
201 
872 
8 
 
18.6 
80.7 
0.7 
P = 0.066 
1.00 
1.46 (1.06-1.99) 
1.20 (0.27-5.14) 
P = 0.127 
1.00 
1.50 (1.01-2.24) 
1.19 (0.26-5.39) 
- - 
Gravidity  
  Primigravidae 
  secundigravidae 
  Multigravidae 
 
259 
164 
658 
 
23.9 
15.2 
60.9 
P = 0.191 
1.00 
1.47 (0.97-2.24) 
1.14 (0.84-1.54) 
P = 0.261 
1.00 
0.99 (0.60-1.64) 
0.73 (0.44-1.20) 
- - 
No. of life time sexual partners 
  1 or 2 
  3 or more 
  Unknown* 
 
795 
276 
10 
 
74.2 
25.8 
P = 0.570 
1.00 
1.08  (0.81-1.45) 
- - - 
Age at sexual debut 
   ≤15 
   16-17 
   ≥ 18 
   Unknown* 
 
 
244 
282 
402 
153 
 
26.3 
30.4 
43.3 
P = 0.977 
1.00 
1.04 (0.72-1.49) 
1.03 (0.74-1.44) 
- - - 
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            Table 4-3: Univariate and multivariate analyses of risk factors for BV continued 
 
Potential risk factor Number % Unadjusted OR Adjusted OR Final model   P-value 
1081 100 -  N = 1079 N = 1079 0.001
¥
 
Wealth quintile 
   Lowest 
   Second 
   Middle 
   Fourth 
   Highest 
   Missing* 
 
217 
221 
214 
213 
215 
2 
 
20.0 
20.5 
19.8 
19.7 
19.9 
P = 0.484  
1.00 
1.10 (0.75-1.62) 
1.39 (0.93-2.03) 
1.36 (0.91-2.02) 
1.13 (0.76-1.67) 
 
- - - 
HIV status 
   Negative 
   Positive 
   Missing* 
 
937 
143 
1 
 
86.8 
13.2 
P = 0.001 
1.00 
1.91 (1.27-2.89) 
P = 0.002 
1.00 
1.88 (1.24-2.86) 
 
1.00 
1.87 (1.24-2.83) 
 
 
0.003 
STI 
   Negative 
   Positive 
   Missing 
 
708 
372 
1 
 
65.6 
34.4 
 
P = 0.010 
1.00 
1.42 (1.09-1.87) 
P = 0.016 
1.00 
1.40 (1.06-1.85) 
 
1.00 
1.40 (1.07-1.84) 
 
 
0.015 
-: Blank 
¥P-value for overall final model 
P-values appearing with unadjusted odds ratios are for each univariate model indicating associations of the variable with the outcome at P < 0.1. 
P-values appearing with adjusted odds ratios indicate the independent association of each variable with the outcome at P < 0.05  
Bold type- statistically significant outcome for multivariate analysis and final model. 
*Missing/unknown  values are only presented as numbers and were not included in the calculation of percentages and in the models 
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4.4 Risk factors for malaria and curable STI/RTI coinfection 
In the univariate analysis the following factors were associated with malaria and 
STI/RTI coinfection (P < 0.1); age group, gravidity, bed net ownership, bed net usage 
and HIV status (Table 4-3).  None of the factors tested using the likelihood ratio test 
were independently associated with coinfection except HIV infection. HIV-infected 
women were at a higher risk of being coinfected with malaria and at least one 
curable STI/RTI than HIV-uninfected women [OR; 3.59 (95% CI, 1.73-7.48), P < 0.001].  
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            Table 4- 4: Risk factors for malaria and curable STI/RTI coinfection in pregnant women of Nchelenge District 
Potential risk factor  Number % Unadjusted OR Adjusted OR  Final model P-value 
1071 100 - N = 931 N = 1071 < 0.001¥ 
Recruitment site 
   Kashikishi 
   Nchelenge 
 
734 
337 
 
68.5 
31.5 
P = 0.273 
1.00 
1.22(0.85-1.74) 
- - - 
Age group  
   ≤ 20 
   21-25 
   26-30 
   ≥ 30 
 
295 
304 
244 
231 
 
27.5 
28.3 
22.7 
21.5 
P = 0.026 
1.00 
0.84 (0.53-1.34) 
0.71 (0.44-1.13) 
0.51 (0.32-0.81) 
P = 0.149 
1.00 
0.95 (0.52-1.72) 
0.83 (0.43-1.61) 
0.58 (0.30-1.14) 
- - 
Marital status 
   Single 
   Married 
   Divorced/separated/widowed  
 
201 
862 
8 
 
18.8 
80.5 
0.7 
P = 0.751 
1.00 
0.91 (0.60-1.39) 
0.55 (0.11-2.84) 
- - - 
Gravidity 
   Primigravidae 
   Secundigravidae 
   Multigravidae  
 
258 
165 
648 
 
24.1 
15.4 
60.5 
P = 0.039 
1.00 
1.95 (0.53-1.70) 
0.63 (0.42-0.95) 
P = 0.681 
1.00 
0.96 (0.52-1.88) 
0.77 (0.41-1.46) 
- - 
Bed net ownership  
   No  
   Yes 
 
734 
337 
 
68.5 
31.5 
P = 0.064 
1.00 
0.74 (0.53-1.02) 
P = 0.937 
1.00 
0.83 (0.47-1.47) 
 
- - 
Bed net use on previous night 
   No  
   Yes 
   Missing* 
 
658 
410 
3 
 
61.6 
38.4 
P = 0.097 
1.00 
0.76 (0.55-1.05) 
P = 0.386 
1.00 
0.98 (0.56-1.74) 
 
 
 
 
- - 
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             Table 4-4: Risk factors for malaria and curable STI/RTI coinfection in pregnant women of Nchelenge District continued 
Potential risk factor  Number % Unadjusted OR Adjusted OR  Final model P-value 
1071 100 - N = 931 N = 1071 < 0.001¥ 
IRS in past 12 months  
   No  
   Yes 
   Unknown* 
   Missing* 
 
798 
224 
46 
3 
 
74.7 
21.0 
 
P = 0.193 
1.00 
0.78 (0.53-1.15) 
 
- - - 
No. of life time sexual partners 
  1 or 2 
  3 or more 
  Unknown* 
 
788 
274 
9 
 
74.2 
25.8 
P = 0.793 
1.00 
1.47(1.06-2.04) 
 
- - - 
Age at sex debut 
  >14 years 
  14 years & above 
   Unknown* 
 
97 
821 
153 
 
10.4 
89.6 
 
P = 0.593 
1.00  
1.88 (0.49-1.60) 
 
- - - 
Wealth quintile 
   Lowest 
   Second 
   Middle 
   Fourth 
   Highest 
   Missing* 
 
215 
219 
208 
214 
214 
2 
 
20.1 
20.5 
19.5 
19.9 
20.0 
P = 0.166 
1.00 
0.77 (0.46-1.26) 
1.07 (0.63-1.82) 
1.35 (0.77-2.34) 
0.76 (0.46-1.26) 
- - - 
HIV status 
   Negative 
   Positive 
   Missing* 
 
933 
138 
1 
 
87.1 
12.9 
P < 0.001 
1.00 
3.59 (1.73-7.48) 
P < 0.001 
1.00 
3.93 (1.87-8.27) 
 
1.00 
3.59 (1.73-7.48) 
 
 
< 0.001 
-: Blank; 
¥
P- value for overall final model 
P-values appearing with unadjusted odds ratios are for each univariate model indicating associations of the variable with the outcome at P < 0.1. 
P-values appearing with adjusted odds ratios indicate the independent association of each variable with the outcome at P < 0.05. 
Bold type- statistically significant outcome for multivariate analysis and final model.  
*Missing/unknown values are only presented as numbers and were not included in the calculation of percentages and in the models 
Only HIV infection was found to be associated with malaria and STI/RTI coinfection therefore was not adjusted for any other variable in the final model. 
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5 Results (3): The prevalence of DHFR and DHPS mutations 
associated with SP resistance and in vivo efficacy, parasitological 
failure and prophylactic failure of SP in pregnant Zambian women 
120 
 
5.1 Chapter introduction 
The work in this chapter was included in the thesis in order to present information 
on the status of parasite resistance in the study population. The chapter gives results 
of the prevalence of SP resistance markers in a random sample of 96 women who 
tested positive at first ANC visit. The chapter also presents results from the 
determination of in vivo efficacy of SP and its treatment and prophylactic failure over 
a period of 28 days in pregnant women who were tested for peripheral parasitaemia 
at both day 0 and day 28.  
5.2 The prevalence of DHFR and DHPS mutations associated with SP resistance  
Only 96 samples were processed based on the required sample size for the 
characterisation of SP resistance markers in this study population. The 
pyrimethamine resistant DHFR Asn-108 was high among the 96 P. falciparum 
infections that were assayed (94.8%, n = 91). Mixed infections of Asn-108 occurring 
with the wild type Ser-108 were observed in 3.1% (n = 3) of the samples. High levels 
of the DHFR Ile-51 and Arg-59 mutants (Figure 5.1) as well as the DHPS Gly-437 and 
Glu-540 were found (Figure 5.2).  
Figure 5. 1: Prevalence of P. falciparum DHFR mutations in pregnant women of 
Nchelenge district 
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Figure 5. 2: Prevalence of P. falciparum DHPS point mutations in pregnant women 
of Nchelenge district 
  
 
 
Table 5-1 presents the prevalence of the double, triple, quintuple and sextuple 
mutants. The DHPS double (Gly-437 + Glu-540) mutant was found in 70.8% (n = 68) 
and the DHFR triple (Asn-108 + Ile-51 + Arg-59) mutant in 92.7% (n = 89) of the 
samples that were assayed. The quintuple mutant (DHFR triple + DHPS double) was 
detected in 68.8% (n = 66). The sextuple mutant (DHFR triple + DHPS double + Arg-
581) was observed in 9.4% (n = 9) of the overall total with 2 of these occurring as 
mixed infections with the wild type.  
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     Table 5- 1: Antifolate multiple mutants among first ANC attendees of Nchelenge District, Zambia 
Number of P. 
falciparum 
infections 
Mutant 
DHFR Triple DHPS Double DHFR/DHPS Quintuple DHFR/DHPS Sextuple 
 
96 
n % (95% CI) n % (95% CI) n % (95% CI) n % (95% CI) 
89 92.7 (85.3- 96.5) 68 70.8 (60.8 -79.2) 66 68.8 (58.6 -77.34) 9 9.4 (4.2-16.0) 
 
95% CI: 95% confidence interval 
DHFR: Dihydrofolate reductase 
DHPS: Dihydropteroate synthase  
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Table 5-2 presents results of DHFR and DHPS genotyping of 96 samples. It highlights 
the number of samples that carried a particular combination of point mutations 
associated with SP resistance.   
Table 5- 2: Results of DHFR and DHPS genotyping of samples from 96 first antenatal 
care attendees of Nchelenge District 
n dhfr51 dhfr59 dhfr108 dhps437 dhps540 dhps581 
1 - - - - - - 
2 + - + - - - 
2 + + + - + - 
1 + - + + + - 
1 + + - + + - 
7 + + + - - - 
16 + + + + - - 
57 + + + + + - 
9 + + + + + + 
- = wild type 
+ = Mutant or mixed genotype 
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 5.3 Therapeutic efficacy of IPTp-SP over a 28-day period  
Therapeutic efficacy of IPTp-SP was assessed based on malaria diagnosed by 
microscopy only. Of the 343 women who tested positive for malaria by microscopy 
at day 0, 60.3% (n = 207) were screened for malaria at day 28 post IPTp-SP to assess 
the therapeutic efficacy and prophylactic effect of SP. The number of women was 
higher than the 138 asymptomatic malaria positive pregnant women required for 
determination of therapeutic efficacy as earlier mentioned in the methods section. 
Of these women 14.3% (n = 49) were HIV-infected and 85.7% (n = 294) were HIV 
uninfected. 
Sulphadoxine-pyrimethamine cleared parasitaemia in 70.0% (n = 145) of the 207 
pregnant women who tested positive for malaria at enrolment and were tested at 
day 28.  Slightly below a third of these women, 30.0% (n = 62) were positive at day 0 
and at day 28 and were classified as cases of therapeutic failure before PCR 
correction.  
Among those with a negative malaria smear test result at day 0, 52.0% (383/736) 
were also screened at day 28. Of the 383 women who tested negative at day 0, 
12.3% (n = 47) tested positive for malaria at day 28 and 87.7% (n = 336) of those who 
were negative at day 0 maintained the malaria negative status by day 28. The 47 
women who tested negative at day 0 and positive at day 28 were classified as cases 
of prophylactic failure before PCR correction. 
 
5.4 Classification of parasitological failure cases based on MSP-2 genotyping 
Sixty out of the 62 pairs of samples from the participants, who tested positive by 
microscopy at day 0 and day 28, were successfully processed. One dried blood spot 
sample among those collected at day 28 was missing and amplification of another 
sample from another pair was unsuccessful. Of the 60 pairs that were processed 
46.7% (95% CI, 33.7-59.7, n = 28) were classified as recrudescence and the rest, 
53.3% (95% CI, 40.3-66.3, n = 32) as reinfection (Figure 5.3).    
After PCR correction, therapeutic efficacy without recrudescence occurred in 84.4% 
(173/205) of the women who were infected at day 0. Failure of SP to prevent 
reinfection occurred in 15.6% (32/205) of participants.  
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The proportion of therapeutic failure observed among primigravidae, 24.1% (21/87), 
and secundigravidae, 24.1% (7/29) was similar, however what was observed among 
multigravidae was much lower (7.9% (7/89), P = 0.009). Younger women were more 
likely to experience failure. Median ages of women who experienced therapeutic 
failure and those whose parasitaemia cleared were 20 (IQR, 18-22) and 22 (IQR, 19-
28) years respectively and the difference in the distribution of age in the two groups 
was statistically significant (P = 0.001).  
The median age of women who experienced prophylactic failure was 24 (IQR, 20-29) 
years and that of women who did not experience prophylactic failure was 26 (IQR, 
22-32) years with the distribution of age in the two groups being statistically 
significant, (P = 0.03).  
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Table 5- 3: Frequency of prophylactic and treatment failure of sulphadoxine-
pyrimethamine among HIV negative first ANC attendees of Nchelenge District, 
Zambia  
Category Total Number (%) 95% Confidence interval 
PCR-uncorrected 
Therapeutic efficacy 207 145 (70.0) 63.8 - 76.3 
Therapeutic failure 207  62 (30.0) 23.7 - 36.2 
Prophylactic failure 338 47 (12.3)  9.0 -15.6 
PCR-corrected 
Therapeutic efficacy 205 173 (84.4) 79.4-89.4 
Therapeutic failure 205 32 (15.6) 10.6-20.6 
PCR: Polymerase chain reaction 
Two samples could not be differentiated into recrudescence or reinfection because one dried 
blood sample among those collected at day 28 was missing and amplification of another sample 
from another pair was unsuccessful, thus the reduction in the denominator after PCR 
correction in the case of therapeutic efficacy and failure 
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Figure 5. 3: Classification of recurrent parasitaemia among participating women at 
day 28 post-IPTp-SP in reference to day 0. 
  
 
 
53.3% 
46.7% Re-infection
Recrudescence
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6 Results (4) The prevalence of adverse birth outcomes among 
delivering participants and predictors of adverse birth 
outcomes 
129 
 
6.1 Chapter introduction 
This chapter presents infant and maternal characteristics. Characteristics of 
delivering women are presented overall and according to recruitment site and 
follow-up with comparisons of proportions in the groups. The chapter also presents 
the prevalence of ABO among participating women according to parity and infection 
status. Proportions of ABO are also presented for each placental malaria 
histopathology class. The chapter also presents risk factors for composite ABO and 
for individual ABO (PD, LBW and IUGR). Analysis of risk factors for stillbirth was not 
conducted because the number of women who delivered still born babies was small. 
6.2 Maternal and infant characteristics 
6.2.1 Baseline characteristics of delivering participants 
Table 6-1 shows baseline characteristics of women who were successfully followed-
up to delivery and those who were not. There were no differences in proportions of 
characteristics among women who were followed up to delivery and those who were 
lost to follow-up except in the case of gravidity. The proportion of primigravidae 
among women who were followed up to delivery was higher than that among 
women who were lost to follow-up (26.6 versus 18.6%, P = 0.004). A lower 
proportion of secundigravidae was observed among those followed up to delivery 
than among women lost to follow-up (13.4 versus 18.6%, P = 0.025). In the case of 
multigravidae, a higher proportion was observed among women lost to follow-up 
than among those followed to delivery but this was not statistically significant (62.8 
versus 60.0%, P = 0.375).  
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Table 6- 1: Baseline characteristics of study participants according to follow-up to 
delivery 
variable All (n = 1085) 
n (%) or Median  
(IQR) 
Followed-up  
(n = 729) 
n (%) or Median  
(IQR) 
Lost to follow-up 
 (n = 356) 
n (%) or Median  
(IQR) 
P-value 
Age (median) 25 (20-30) 24 (20-30) 25 (20-31) 0.510 
Recruitment site 
  Kashikishi 
  Nchelenge 
 
747 (68.9) 
338 (31.2) 
 
508 (69.7) 
221 (30.3) 
 
239 (67.1) 
117 (32.9) 
 
0.395 
Marital status 
  Single  
  Married 
  Divorced/separated/ 
  widowed 
 
203 (18.7) 
874 (80.6) 
8 (0.7) 
 
143 (19.9) 
569 (79.3) 
6 (0.8) 
 
60 (16.4) 
305 (83.1) 
2 (0.5) 
 
0.304 
Years of schooling 
   None to 6 
   7 and above 
 
426 (39.3) 
659 (60.7) 
 
273 (37.4) 
456 (62.6) 
 
153 (43.0) 
203 (57.0) 
 
0.080 
Gravidity 
   Primigravidae 
   Secundigravidae 
   Multigravidae 
 
261 (24.1) 
165 (15.2) 
659 (60.7) 
 
194 (26.6) 
98 (13.4) 
437 (60.0) 
 
67 (18.6) 
67 (18.6) 
222 (62.8) 
 
0.004 
0.025 
0.375 
Bed net ownership  
   No 
   Yes    
 
551 (50.8) 
534 (49.2) 
 
373 (51.2) 
358 (48.8) 
 
178 (50.0) 
178 (50.0) 
 
0.718 
Bed net use 
   No 
   Yes  
   Missing*  
 
666 (61.6) 
416 (38.5) 
3 
 
452 (62.3) 
274 (37.7) 
0 
 
214 (60.1) 
274 (37.7) 
3 
 
 
0.718 
IRS in previous 12 
months  
   No 
   Yes 
   Unknown*   
 
808 (78.1) 
226 (21.9) 
51 
 
553 (78.8) 
149 (21.2) 
27 
 
255 (76.8) 
77 (23.2) 
24 
 
0.475 
Wealth quintile 
   Lowest 
   Second 
   Middle 
   Fourth 
   Highest 
 
217 (20.0) 
221 (20.4) 
214 (19.8) 
215 (19.9) 
216 (19.9) 
 
137 (18.8) 
148 (20.3) 
148 (20.3) 
138 (18.9) 
158 (21.7) 
 
80 (22.6) 
73 (20.6) 
66 (18.6) 
77 (21.8) 
58 (16.4) 
 
0.174 
HIV status  
   Negative 
   Positive 
   Missing*   
 
941 (86.8) 
143 (13.2) 
1 
 
635 (87.1) 
94 (12.9) 
0 
 
306 (86.2) 
49 (13.8) 
1 
 
0.678 
Past experience of 
 miscarriage 
    No  
    Yes 
    NA (primigravidae)* 
 
 
708 (85.1) 
116 (14.1)  
261 
 
 
463 (86.5) 
72 (13.5) 
194 
 
 
245 (84.8) 
44 (15.2) 
67 
 
 
 
0.486 
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Table 6-1: Baseline characteristics of study participants according to follow-up to 
delivery continued 
variable All (n = 1085) 
n (%) or Median 
(IQR) 
Followed-up  
(n = 729) 
n (%) or Median 
(IQR) 
Lost to follow-up 
 (n = 356) 
n (%) or Median 
(IQR) 
P-value 
Prior delivery of  
stillborn   
   No 
   Yes 
   NA (primigravidae)*  
 
 
755 (91.6) 
69 (8.4) 
261 
 
 
 
489 (91.4) 
46 (8.6) 
194 
 
 
 
266 (92.0) 
23 (8.0) 
67 
 
 
0.752 
Prior delivery of 
 a Preterm baby  
    No  
   Yes 
   Missing* 
   NA (primigravidae) 
 
 
784 (95.3) 
39 (4.7) 
1 
261 
 
 
505 (94.4) 
30 (5.6) 
0 
194 
 
 
279 (96.9) 
9 (3.1) 
1 
67 
 
0.110 
Malaria infection PCR  
   Negative 
   Positive 
   Missing* 
 
453 (42.2) 
621 (57.8) 
11 
 
304 (42.1) 
418 (57.9) 
4 
 
149 (42.3) 
203 (57.7) 
7 
 
0.944 
Microscopy  
   Negative 
   Positive 
   Missing* 
 
736 (68.2) 
343 (31.8) 
6 
 
491 (67.6) 
235 (32.4) 
3 
 
245 (69.4) 
108 (30.6) 
3 
 
0.557 
STI/RTI 
   Negative 
   Positive 
   Missing* 
 
384 (35.4) 
700 (64.6) 
1 
 
262 (35.9) 
467 (64.1) 
0 
 
122 (34.4) 
233 (65.6) 
1 
 
0.611 
Malaria & STI/RTI  
Coinfection 
   No infection 
   Malaria 
   STI/RTI 
   Coinfection 
   Missing* 
 
 
177 (16.5) 
202 (18.8) 
278 (26.0) 
414 (38.7) 
14 
 
 
119 (16.5) 
142 (19.7) 
186 (25.8) 
274 (38.0) 
8 
 
 
58 (16.6) 
60 (17.1) 
92 (26.3) 
140 (414) 
6 
 
 
0.782 
IRS: Indoor residual spraying 
*Missing values/NA primigravidae are only presented as numbers and were not included in the 
calculation of percentages and in the Chi-squared test for association 
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6.2.2 Characteristics of delivering women and infants 
There were no known maternal deaths among participants. Table 6-2 presents 
characteristics of the 729 participants followed up to delivery by recruitment site. 
There was no statistically significant difference in the place of delivery or type of 
delivery between the two sites. Slightly more deliveries were conducted by TBAs 
among women recruited at Nchelenge than those recruited at Kashikishi.  
The clinical factors (level of Hb, treatment of RPR positives women, IPTp-SP doses 
taken, and use of cotrimoxazole and ART, and antimalarial treatment) did not differ 
between the two sites.  
The median gestational age at delivery was 38 (IQR, 37-39) weeks and the mean 
birth weight was 2784g (95% CI, 2752-2816).  Among the 729 participants who were 
followed-up to delivery, 98.4% (n = 717) had a singleton delivery and the rest 
delivered twins. Of the 717 singleton deliveries 50.9% (n = 365) were female and 
49.1% (n = 352) were male babies.  The mean birth weight of female babies was 
lower than that of male babies (2738g versus 2831g) and this difference was 
statistically significant (P = 0.004).  
With the exclusion of BV, 18.8% (n = 46) of the 248 STI-infected women received 
antibacterial treatment during the pregnancy duration. Of the 467 women who were 
infected with at least one STI/RTI only 12.8% (n = 60) received antibacterial 
treatment during the pregnancy duration. Of the 60 women who received 
antibacterial treatment only eight received drugs other than benzathine penicillin G 
and 10 of the remaining 52 received both benzathine penicillin G and a different 
antibiotic during the pregnancy duration based on syndromic management 
assessment. Antibacterial agents that were used were metronidazole, erythromycin 
and spectinomycin. Some of the STI/RTI-infected women (n = 40) had been treated 
with antifungal agents by the time of delivery and only two of these also received an 
antibiotic. Antifungal agents that were recorded were nystatin and fluconazole.  
Coverage of IPTp-SP among participants was high with 99.2% of delivering women 
receiving at least one dose of IPTp-SP during the pregnancy duration; 0.8% (n = 6), 
17.0% (n = 124), 43.0% (n = 314), 38.3% (n = 279) and 0.7% (n = 5) of participants 
received, none, one, two, three and four doses respectively.  
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Among the 92 HIV-infected delivering women, 37.0% (n = 34) were on cotrimoxazole 
prophylaxis. Of the 88 HIV-infected women who took at least one dose of IPTp-SP, 
36.4% (n = 32) also took cotrimoxazole during the pregnancy duration.   
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    Table 6- 2: Characteristics of delivering participants according to recruitment site 
Variable All (N = 729) 
n (%) 
Kashikishi (n = 508) 
n (%) 
Nchelenge (n =221) 
n (%)  
P-value 
Number of babies  
  One 
  Two 
 
717 (98.4) 
12 (1.6) 
 
501 (98.6) 
7 (1.4) 
 
216 (97.7) 
5 (2.3) 
 
0.388 
Sex of baby  
  Female 
  Male 
  Twins 
 
365 (50.9) 
352 (49.1) 
12 
 
248 (49.5) 
253 (50.5) 
7 
 
117 (54.2) 
99 (45.8) 
5 
 
0.252 
Place of delivery 
 Hospital 
 Health Centre 
 Home 
 
683 (93.8) 
20 (2.8) 
25 (3.4) 
 
479 (94.4) 
14 (2.8) 
14 (2.8) 
 
204 (92.3) 
6 (2.7) 
11 (5.0) 
 
0.320 
Delivered by 
  Family member 
  TBA 
   Midwife 
   Doctor 
 
22 (3.0) 
14 (1.9) 
651 (89.3) 
42 (5.7) 
 
13 (2.5) 
5 (1.0) 
457 (90.0) 
33 (6.5) 
 
9 (4.1) 
9 (4.1) 
194 (87.7) 
9 (4.1) 
 
0.015 
Type of delivery 
  Vaginal 
  C-section    
 
687 (94.2) 
42 (5.8)  
 
475 (93.5) 
33 (6.5) 
 
212 (95.9) 
9 (4.1) 
 
0.197 
Haemoglobin level 
  Normal 
  Anaemia 
  Missing* 
 
585 (84.0) 
111 (16.0) 
33 
 
406 (83.9) 
78 (16.1) 
24 
 
179 (84.4) 
33 (15.6) 
9 
 
0.855 
Antimalarial treatment 
besides IPTp-SP 
  No 
  Yes 
  Missing* 
 
 
635 (87.5) 
91 (12.5) 
3 
 
 
440 (87.1) 
65 (12.9) 
3 
 
 
195 (88.2) 
26 (11.8) 
0 
 
0.649 
Iron supplementation 
  No 
  Yes 
 
15 (2.1) 
714 (97.9) 
 
13 (2.6) 
495 (97.4) 
 
2 (0.9) 
219 (99.1) 
 
0.254 
IPTp-SP doses taken  
  0 to 1 
  2 or more 
Missing* 
 
130 (17.9) 
598 (82.1) 
1 
 
97 (19.1) 
410 (80.9) 
1 
 
33 (14.9) 
188 (85.1) 
0 
 
0.174 
Cotrimoxazole use 
among      HIV+ 
  No 
  Yes 
  Missing* 
  NA (HIV negative)* 
 
 
58 (63.0) 
34 (37.0) 
2 
635 
 
 
41 (61.2) 
26 (38.8) 
1 
440 
 
 
17 (68.0) 
18 (32.0) 
1 
195 
 
0.547 
ART among HIV positive 
women  
  No 
  Yes 
  NA (HIV negative)* 
 
 
36 (37.2) 
58  (61.7) 
635 
 
 
24 (35.3) 
44 (64.7) 
440 
 
 
12 (46.2) 
14 (53.8) 
195 
 
0.333 
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Table 6-2: Characteristics of delivering participants according to recruitment site    
continued 
Variable All (N = 729) 
n (%) 
Kashikishi (n = 508) 
n (%) 
Nchelenge (n = 
221) 
n (%) 
P-value 
Treatment among RPR 
Reactive 
  No  
  Yes 
  Non-reactive 
 
 
29 (35.8) 
52 (64.2) 
648 
 
 
21 (38.9) 
33 (61.1) 
454 
 
 
8 (29.6) 
21 (70.4) 
194 
 
0.413 
Anti-bacterial‡ 
treatment among  all 
STI/RTI positives 
  No 
  Yes 
  NA (Negative)*   
 
 
 
407 (87.2) 
60 (12.8) 
262 
 
 
 
284 (87.1) 
42 (12.9) 
182 
 
 
 
123 (87.2) 
18 (12.8) 
80 
 
 
0.972 
 
* Missing and NA (not applicable) values are only presented as numbers and were not included in the 
calculation of percentages and in the Chi-squared test for association 
IPTp-SP:  Intermittent preventive treatment in pregnancy with sulphadoxine-pyrimethamine 
ART: Antiretroviral therapy. Anaemia was defined as haemoglobin level  <  11grams/decilitre 
‡Antibacterial treatment included benzathine penicillin G, metronidazole, erythromycin and 
spectinomycin. 
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6.3 Prevalence of adverse birth outcomes 
Overall the prevalence of ABO among the 717 women with singleton deliveries was 
35.0%.  Women who experienced at least one ABO were younger than women who 
had normal birth outcome, median age 22 (IQR, 19-28) verses 25 (IQR, 21-31) years, 
with the age distribution being significantly different in the two groups, P < 0.001, 
Mann-Whitney U test. Preterm delivery and LBW were the most common ABOs, 
22.1% and 21.9% respectively.  
6.3.1 Prevalence of adverse birth outcome according to parity 
The prevalence of composite ABO was 53.4% among primiparae, 31.2% among para 
II and 27.8% among multiparous women, P < 0.001.  The prevalence of LBW, PD and 
IUGR were highest among primiparae followed by para II and lowest among 
multiparae as follows; PD 29.5%, 20.8% and 18.9%, P = 0.013; LBW 41.1%, 19.8% and 
13.8%, P < 0.001; IUGR 31.6%, 13.2% and 9.3%, P < 0.001. None of the para II women 
experienced stillbirth. The prevalence of stillbirth was higher among primiparae than 
multiparae but the difference was not statistically significant, 2.6% versus 1.6%, P = 
0.309 (Table 6-3).  
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  Table 6- 3: Frequency of adverse birth outcomes among participants with singleton deliveries according to parity 
Adverse 
outcome 
All  
N = 717 
n (%) 
 
95% Confidence 
interval‡ 
Primiparae 
n = 193 
n (%) 
Para II  
n = 96 
n (%) 
 
Multiparae 
n = 428 
n (%) 
 
P-value  
PD 
No  
Yes 
Missing* 
 
558 (77.9) 
158 (22.1) 
1 
 
74.9-81.0 
19.2-25.3 
 
136 (70.5) 
57 (29.5) 
 
76 (79.2) 
20 (20.8) 
 
346 (81.0) 
81 (18.9) 
 
0.013 
LBW 
No  
Yes 
 
559 (78.1) 
157 (21.9) 
 
75.0-81.1 
19.0-25.0 
 
113 (58.9) 
79 (41.1) 
 
77 (80.2) 
19 (19.8) 
 
369 (86.2) 
59 (13.8) 
 
< 0.001 
IUGR 
No 
Yes 
Na (preterm)* 
Missing* 
 
473 (84.8) 
85 (15.2) 
158 
1 
 
81.8-87.8 
12.5-18.5 
 
93 (68.4) 
43 (31.6) 
 
66 (86.8) 
10 (13.2) 
 
314 (90.8) 
32 (9.3) 
 
< 0.001 
Stillbirth 
No 
Yes 
 
705 (98.3) 
12 (1.7) † 
 
97.4-99.3 
1.0-2.9 
 
188 (97.4) 
5 (2.6) 
 
96 (100) 
0 (0.0) 
 
421 (98.4) 
7 (1.64) 
 
0.309 
Composite ABO 
No  
Yes 
 
466 (65.0) 
251 (35.0) 
 
61.5-68.5 
31.6-38.6 
 
90 (46.6) 
103 (53.4) 
 
 
66 (68.8) 
30 (31.2) 
 
310 (71.4) 
118 (27.6) 
 
< 0.001 
 
†The percentage of stillbirths (1.7%) consisted of 1.0% macerated and 0.7% fresh stillbirths. One woman among those with twin deliveries had 
spontaneous abortion at 26 weeks.  
*Missing values are only presented as numbers and were not included in the calculation of percentages and in the Chi-squared test for association 
LBW: low birth weight 
PD: preterm delivery 
IUGR: Intrauterine growth retardation 
ABO: Adverse birth outcome 
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6.3.2 Prevalence of adverse birth outcome among infected and uninfected women 
Table 6-4 presents the prevalence of PD, LBW, IUGR and stillbirth) among women 
classified as infected (infected with at least one STI/RTI or malaria) or uninfected at 
first ANC attendance. Although not statistically significant, the prevalence of PD, 
LBW and IUGR was slightly higher among infected women than among uninfected 
women. The frequency of stillbirth was slightly higher among uninfected than 
infected women, 1.7% versus 1.5% but this could be due to chance (P = 0.880). The 
mean birth weight of babies born to uninfected women was higher than those born 
to infected women but this difference was not statistically significant (2821g versus 
2774g, P = 0.285). 
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Table 6- 4: Prevalence of preterm delivery, low birth weight, intra-uterine growth 
retardation and stillbirth among women classified as infected and uninfected at first ANC 
visit 
Adverse birth 
outcome 
All 
N = 709 
n (%) 
Infected 
N = 117  
n (%) 
Uninfected 
N = 592 
n (%) 
P-Value 
PD 
  No 
  Yes 
  Missing* 
 
550 (77.7) 
158 (22.3) 
1 
 
93 (79.5) 
24 (20.5) 
0 
 
457 (77.3) 
134 (22.7) 
1 
 
0.608 
LBW 
  No 
  Yes 
  Missing* 
 
551 (77.8) 
157 (22.2) 
1 
 
95 (81.2) 
22 (18.8) 
0 
 
456 (77.2) 
135 (22.8) 
1 
 
0.337 
Stillbirth 
  No 
  Yes 
 
698 (98.5) 
11(1.5) 
 
15 (98.3) 
2 (1.7) 
 
583 (98.5) 
9 (1.5) 
 
0.880 
 
IUGR 
  No 
  Yes 
  NA (Pre-term)* 
  Missing*           
 
465 (84.5) 
85 (15.5) 
158 
1 
 
82 (88.2) 
11 (11.8) 
 
383 (83.8) 
74 (16.2) 
 
0.288 
All  
  No 
  Yes 
 
 
459 (64.7) 
250 (35.3) 
 
81 (69.2) 
36 (30.8) 
 
378 (63.9) 
214 (36.1) 
 
0.266 
N: Number, was equal to 709, 8 of the 717 participants with singleton deliveries could not be 
classified as infected or uninfected at recruitment due to missing results and negative outcomes in 
those available  
LBW: low birth weight 
PD: preterm delivery 
IUGR: Intrauterine growth retardation 
NA: Not applicable 
* Missing values and NA(pre-term) are only presented as numbers and were not included in the 
calculation of percentages and in the Chi-squared test for association 
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6.4 Placental malaria burden 
Of the 702 placental tissue samples, placental malaria was identified in 40.9% (n = 
287) by histopathology, the majority of these, 30.3% (n = 213) were classified as past 
infections (class 4). Placental histopathology identified 8.1% (n = 57) chronic 
infections (class 2) and 2.4% (n = 17) active infections. 
The median gestational age of women with placental malaria infection regardless of 
the pathology class was 38 weeks (IQR, 36-39) and that of uninfected women was 38 
weeks (IQR, 37-39) with a statistically significant difference in the distribution of 
gestational age in the two groups, P = 0.017.  
The mean birthweight, mean Hb, and median gestational age in the different 
placental pathology classes and comparison of each class with class 5 (the 
uninfected) are presented in Table 6-5.  
The median gestational age of women with chronic placental malaria infection was 
lower than that of uninfected women and the distribution of gestational age was 
significantly different in the two groups 37 (IQR, 35-39) weeks and 38 (IQR, 37-39) 
weeks, P = 0.001. The mean birth weight of babies born to mothers with chronic 
placental malaria infection was significantly lower than the mean birthweight of 
babies born to uninfected mothers, 2537 grams versus 2834 grams, P = 0.001. 
Furthermore, the mean Hb of women with chronic placental malaria infection was 
significantly lower than that of uninfected women, 12.2g/dl versus 13.0g/dl, P = 
0.024. 
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 Table 6- 5: Association between placental pathology class and birthweight, maternal haemoglobin and gestational age among study 
participants with singleton deliveries 
Pathology 
class 
(Number) 
Description Mean Birth 
weight in grams 
(95% CI) 
Probability 
compared with 
uninfected 
(class 5) 
Maternal 
Haemoglobin 
Geometric Mean  
(95% CI) 
Probability 
compared with 
uninfected 
(class 5) 
Median 
gestational age 
(IQR) 
Probability 
compared with 
uninfected 
(class 5) 
1 (17) 
Active 
infection 
Parasites, No 
pigment in 
monocytes or 
fibrin 
 
2765 (2561-2969) 
 
0.5022 
 
13.2 (12.2-14.4) 
 
0.731 
 
38 (37-38) 
 
0.284 
2 (57) 
Chronic 
infection 
Parasites, 
pigment in 
monocytes +/- 
fibrin 
 
2537 (2408-2665) 
 
< 0.001 
 
12.2 (11.2-13.2) 
 
0.026 
 
37 (35-39) 
 
0.001 
3 (0)* 
Chronic 
infection 
Parasites, 
pigment in 
Fibrin 
- - - - - - 
4 (213) 
Past 
infection 
No parasites, 
pigment only 
2767 (2706-2828) 0.066 12.8 (12.5-13.3) 0.521 38 (37-39) 0.212 
5 (415) 
No infection 
No parasite or 
pigment 
(No infection) 
 
2834 (2793-2874) 
 
Reference 
group 
 
13.0 (12.8-13.3) 
 
Reference group 
 
38 (37-39) 
 
Reference group 
-: Blank, no specimen was classified under class 3 
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6.4.1 Frequency of adverse birth outcome in placental malaria histopathology 
classes 
Table 6-6 presents the prevalence of LBW, PD, IUGR and stillbirth among 691 women 
with singleton deliveries and placental histology results. The highest proportion of 
each of these four ABO was observed among babies born to mothers with placental 
infection classified under pathology class 2 as follows: PD among women with 
chronic infection was 37.5% versus 23.5%, 24.0% and 18.1%, in women with active 
infection, past infection and no infection respectively, P = 0.007; LBW in women with 
chronic infection was 38.5% versus 17.7%, 24.0% and 18.1% in women with active 
infection, past infection and no infection respectively, P = 0.004; IUGR was 17.7% 
among women with chronic infection against 7.7% 16.3% and 14.9% in women with 
active infection, past infection and no infection respectively, P = 0.827 and the 
prevalence of stillbirth in women with chronic infection was 5.3% versus 0%, 1.9% 
and 1.6% in women with active infection, past infection and no infection 
respectively, P = 0.093.  The overall prevalence of ABO was also highest among 
women with chronic placental malaria infection, 50.9%; and in the other classes the 
prevalence was 29.4% among women with active infection; 38.0% among women 
with past infection and 31.0% among uninfected women, P = 0.017.  
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Table 6- 6: Prevalence of low birth weight, preterm delivery, intrauterine growth retardation and stillbirth according to pathology class   
among     participants with singleton deliveries 
Pathology class All 1 2 3 4 5  
P-Value Adverse birth 
outcome 
 
All 
N = 691 
n (%) 
Parasites, No 
pigment in 
monocytes or fibrin 
(active infection) 
n (%) 
Parasites, pigment 
in monocytes +/- 
fibrin 
(Chronic infection) 
n (%) 
Parasites, 
pigment in Fibrin 
(Chronic 
infection) 
n (%) 
No parasites, 
pigment only 
(past infection) 
n (%) 
No parasites, 
no pigment 
(No infection) 
n (%) 
PD  
  No 
  Yes 
  Missing* 
 
542 (78.4) 
149 (21.6) 
1 
 
13 (76.5) 
4 (23.5) 
0 
 
35 (62.5) 
21 (37.5) 
1 
 
- 
 
158 (76.0) 
50 (24.0) 
0 
 
335 (81.9) 
74 (18.1) 
0 
 
0.007 
LBW  
  No 
  Yes 
 
542 (78.4) 
149 (21.6) 
 
14 (82.3) 
3 (17.7) 
 
35 (61.4) 
22 (38.6) 
 
- 
 
158 (76.0) 
50 (24.0) 
 
81.9 (335) 
74 (18.1) 
 
0.004 
IUGR  
  No 
  Yes 
  NA (preterm)* 
 
458 (84.7) 
83 (15.4) 
150 
 
12 (92.3) 
1 (7.7) 
 
28 (82.3) 
6 (17.7) 
 
- 
 
133 (83.7) 
26 (16.3) 
 
285 (85.1) 
50 (14.9) 
 
0.827 
Stillbirth  
  No 
  Yes 
 
680 (98.4) 
11 (1.6) 
 
17 (100) 
0 (0) 
 
54 (94.7) 
3 (5.3) 
 
- 
 
204 (98.1) 
4 (1.9) 
 
405 (99.4) 
4 (1.6) 
 
0.098 
Composite ABO  
  No 
  Yes 
 
51 (65.3) 
240 (34.7) 
 
12 (70.6) 
5 (29.4) 
 
28 (49.1) 
29 (50.9) 
  
129 (62.0) 
79 (38.0) 
 
282 (69.0) 
127 (31.0) 
 
0.017 
LBW: low birth weight, PD: preterm delivery, IUGR: Intrauterine growth retardation, NA: Not applicable 
-: Blank, no specimen was classified under pathology class 3 
*Missing and NA (preterm) values are only presented as numbers and were not included in the calculation of percentages and in the Chi-
squared test for association 
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6.5 Prevalence of adverse birth outcome according to antimalarial and 
antibiotic treatment 
Table 6-7 shows proportions of ABO in different categories of STIs/RTIs and malaria 
treatment taken during the pregnancy duration. The proportion of LBW babies 
delivered among those who were uninfected, infected and treated and infected and 
untreated women was 20.9%, 10.0% and 24.4%  (P  = 0.039) respectively. The 
proportion of LBW babies delivered among women who received antimalarial 
treatment was higher than that observed among women who were not treated for 
malaria during pregnancy (34.4 versus 20.2, P = 0.002).  
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Table 6- 7: Proportions of adverse birth outcome in antimalarial and antibacterial treatment categories 
Factor Number 
in 
category 
Composite Adverse 
birth outcome  
Preterm delivery Low birth weight Intra-uterine birth 
retardation 
Number (%) Number (%) Number (%) Number (%) 
Syphilis  
No 
Yes-treated 
No-untreated 
 
637 
52 
28 
 
P = 0.840 
223 (35.0) 
17 (32.7) 
11 (39.3) 
P = 0.352 
136 (21.4) 
13 (25.0) 
9 (32.1) 
P = 0.449 
142 (22.3) 
8 (15.4) 
7 (25.9) 
P = 0.423 
80 (16.0) 
3 (7.7) 
2 (10.5) 
STI/RTI including syphilis 
No 
Yes-treated 
Yes- untreated 
 
 
259 
60 
398 
P = 0.566 
88 (34.0) 
18 (30.0) 
145 (36.4) 
P = 0.912 
50 (19.3) 
15 (25.0) 
93 (23.4) 
 
P = 0.037 
54 (20.9) 
6 (10.0) 
94 (24.4) 
P = 0.261 
33 (15.8) 
3 (6.7) 
49 (16.2) 
Antimalarial treatment* 
No  
Yes 
 
 
464 
250 
P = 0.195 
213 (34.1) 
37 (41.1) 
 
P = 0.912 
137 (22.0) 
20 (22.5) 
P = 0.002 
126 (20.2) 
31 (34.4) 
 
P = 0.217 
71 (14.6) 
14 (20.3) 
*Antimalarial treatment (not prophylaxis) during the pregnancy duration 
Bold type: Significant outcome (Chi-square test)  
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  6.6 Protective and risk factors for composite adverse birth outcomes  
In the univariate analyses the following factors were associated with ABO; height, 
age, parity, sex of the baby, placental malaria, hypertension and the number of 
doses of IPTp-SP taken during pregnancy. In the univariate analysis women who 
were mono-infected (malaria or at least one STI/RTI) or coinfection had 24% and 
31% increased risk of experiencing an ABO, respectively compared to uninfected 
women but this was not statistically significant. None of the STIs/RTIs or malaria 
diagnosed at first ANC were associated with composite ABO.  Women infected with 
STI/RTI and treated had 17% reduced risk and STI/RTI-infected and untreated 
women had 11% increased risk of experiencing an ABO than uninfected but this was 
not statistically significant in univariate analysis.  
In the multivariate analysis short stature (< 1.5 metres), parity and the number of 
doses of IPTp-SP were associated with ABO (Table 6-8).  Women with a height < 1.5 
metres had a higher risk of experiencing at least one ABO after adjusting for the 
number of doses of IPTp-SP taken during the pregnancy duration and parity (aOR 
1.55; 95% CI, 1.10-2.18, P = 0.013). The risk of having an ABO among para II was less 
than half of the risk observed in primiparous (aOR 0.42; 95% CI, 0.28-0.63, P < 0.001) 
women and this was even much lower among multiparous women (aOR 0.32; 95% 
CI, 0.22-0.48, P < 0.001). After taking account of parity and height, women who had 
taken 2 or more doses of SP during their pregnancy had a lower risk of experiencing 
an adverse delivery outcome than women who had taken one dose or none (aOR 
0.51; 95% CI, 0.34-0.76, P = 0.001). There was no interaction between parity and 
height (P = 0.036), parity and doses of IPTp-SP (P = 0.067), height and doses of IPTp-
SP (P = 0.096). 
To check if the effects of malaria, STI/RTIs and their coinfection on birth outcome 
were modified by the site of recruitment, these variables were individually included 
in the final model with the variable for recruitment site. There was no interaction 
between malaria and site of recruitment (P = 0.672), STI/RTI and recruitment site (P 
= 0.864) and coinfection and the site of recruitment (P = 0.809).  
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         Table 6- 8: Risk factors for composite adverse birth outcomes among study participants with singleton deliveries 
Potential risk factor  Number  % Unadjusted OR Adjusted OR 
 
Adjusted OR 
(Final model) 
P-value 
 717 100 - N = 595 N = 715 < 0.001¥ 
Recruitment site 
   Kashikishi 
   Nchelenge 
 
501 
216 
 
69.9 
30.1 
P = 0.329 
1.00 
0.84 (0.59-1.19) 
- - - 
Age group  
   ≤ 20 
   21-25 
   26-30 
   ≥ 30 
 
204 
205 
148 
160 
 
28.5 
28.6 
20.6 
22.3 
P < 0.001 
1.00 
0.52 (0.35-0.77) 
0.43 (0.27-0.66) 
0.34 (0.22-0.54) 
P = 0.716 
1.00 
1.26 (0.69-2.29) 
1.14 (0.56-2.35) 
1.01(0.48-2.10) 
- - 
Years of schooling 
   0-6 years 
   7 years and above 
 
266 
451 
 
37.1 
62.9 
P = 0.247 
1.00 
1.21 (0.88-1.66) 
- - - 
Maternal height 
   ≥  1.5m 
   <  1.5m 
   Missing* 
 
503 
213 
1 
 
70.2 
29.8 
 
P = 0.002 
1.00 
1.69 (1.21-2.35) 
P = 0.013 
1.00 
1.57 (1.06-2.32) 
 
1.00 
1.55 (1.10-2.18 )  
 
 
0.013 
Marital status 
   Single 
   Married  
   Separated/widowed/divorced  
 
142 
569 
6 
 
19.8 
79.4 
0.8 
P = 0.03 
1.00 
0.57 (0.39- 0.82) 
0.24 (0.03-2.03) 
P = 0.512 
1.00 
1.14 (0.66-1.97) 
- 
- - 
Parity 
   Primiparae 
   Para II 
   Multigravidae  
 
193 
96 
428 
 
27.0 
13.4 
59.6 
P < 0.001 
1.00 
0.39 (0.24-0.67) 
0.33 (0.23-0.47) 
P < 0.001 
1.00 
0.27 (0.13-0.57) 
0.31 (0.15-0.61) 
 
1.00 
0.41 (0.28-0.63) 
0.32 (0.20-0.43)  
 
  
< 0.001 
< 0.001 
Past experience of miscarriage 
   No 
   Yes 
   Primigravidae* 
 
457 
67 
193 
 
87.2 
12.8 
P = 0.023 
1.00 
1.87 (1.10-3.19) 
 
- - - 
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          Table 6-8: Risk factors for composite adverse birth outcomes among study participants with singleton deliveries continued 
Potential risk factor  Number  % Unadjusted OR Adjusted OR 
 
Adjusted OR 
(Final model) 
P-value 
717 100 - N = 595 N = 715 < 0.001¥ 
Prior delivery of  still born  
   No 
   Yes 
   Primigravidae* 
 
481 
43 
193 
 
91.8 
8.2 
P = 0.184 
1.00 
1.57 (0.82-3.00) 
 
- - - 
Prior delivery of a Preterm baby  
   No  
   Yes 
   Primigravidae* 
 
495 
29 
193 
 
94.5 
5.5 
P = 0.733 
1.00 
1.15 (0.51-2.59) 
- - - 
Peripheral malaria infectiona  
   Negative 
   Positive 
   Missing* 
 
301 
409 
7 
 
42.4 
57.6 
P = 0.181 
1.00 
1.24 (0.90-1.69) 
 
- - - 
Placental malaria infection  
   Negative 
   Positive 
   Missing* 
 
409 
282 
26 
 
59.3 
40.7 
P = 0.015 
1.00 
1.48 (1.08-2.03) 
P = 0.149 
1.00 
1.28 (0.89-1.84) 
- - 
Syphilis 
   Negative 
   Positive-Treated 
   Positive-Untreated 
 
637 
52 
28 
 
88.8 
7.3 
3.9 
P = 0.842 
1.00  
0.90 (0.49-1.65) 
1.20 (0.55-2.61) 
- - - 
Chlamydia trachomatis 
   Negative 
   Positive 
 
683 
34 
 
95.3 
4.7 
P = 0.971 
1.00 
1.01 (0.49-2.08) 
- - - 
Neisseria gonorrhoeae 
   Negative 
   Positive 
 
695 
22 
 
36.9 
3.1 
P = 0.893 
1.00 
1.06 (0.44-2.57) 
 
 
- - - 
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           Table 6-8: Risk factors for composite adverse birth outcomes among study participants with singleton deliveries continued 
Potential risk factor  Number  % Unadjusted OR Adjusted OR 
 
Adjusted OR 
(Final model) 
P-value 
 717 100 - N = 595 N = 715 < 0.001¥ 
Trichomonas vaginalis 
   Negative 
   Positive 
 
547 
170 
 
76.3 
23.7 
P = 0. 121 
1.00 
1.33 (0.93-1.89) 
- - - 
Bacterial vaginosis 
   Normal 
   Intermediate 
   Positive 
   Missing* 
 
246 
130 
339 
2 
 
34.4 
18.2 
47.4 
P = 0.539 
1.00 
1.01 (0.65-1.58) 
0.84 (0.60-1.19) 
 
- - - 
STI/RTI 
   Uninfected‡ 
   Infected & treated 
   Infected & untreated 
  
259 
60  
398 
 
36.1 
8.4 
55.5 
P = 0.562 
1.00 
0.83 (0.45-1.53) 
1.11 (0.80-1.55) 
- - - 
Malaria and STI/ RTI coinfectionb 
   No infection 
   Single infectionc 
   Coinfectionb 
   Missing* 
 
117 
326 
266 
8 
 
16.5 
46.1 
37.5 
P = 0.507 
1.00 
1.24 (0.79-1.96) 
1.31 (0.82-2.09) 
- - - 
Anaemia$ 
   Normal  
   Anaemic 
   Missing* 
 
574 
111 
32 
 
83.8 
16.2 
P = 0.255 
1.00 
1.28 (0.83-1.96) 
- - - 
Hypertension 
   Normal 
   Hypertensive 
   Missing*  
 
608 
14  
95 
 
97.8 
2.2 
P = 0.027 
1.00 
3.36 (1.11-10.2) 
 
1.00 
0.73 (0.50-1.05) 
 
- - 
Sex of baby 
   Female 
   Male 
 
365 
352  
 
50.9 
49.1 
P = 0.055 
1.00 
0.74 (0.54-1.00) 
P = 0.103 
1.00 
0.73 (0.50-1.05) 
- - 
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           Table 6-8: Risk factors for composite adverse birth outcomes among study participants with singleton deliveries continued 
Potential risk factor  Number  % Unadjusted OR Adjusted OR 
 
Final model P-value 
717 100 - N = 595 N = 715 < 0.001¥ 
Antimalarial treatment 
   No  
   Yes 
   Missing* 
 
464 
250 
3 
 
65.0 
35.0 
P = 0.199 
1.00 
1.35 (0.86-2.11) 
- - - 
Number of doses of IPTp-SP  
   0 or 1 
   2 or more 
   Missing* 
 
126 
590 
1 
 
17.6 
82.4 
P < 0.001 
1.00 
0.57 (0.38-0.84 ) 
P = 0.015 
1.00 
0.56 (0.36-0.89) 
 
 
1.00 
0.51 (0.34-0.76)  
  
 
0.001 
aMalaria infection at first ANC attendance; bInfection with at least one STI/RTI and malaria; cInfection with at least one STI/RTI or malaria 
IPTp-SP – Intermittent preventive treatment in pregnancy with sulphadoxine-pyrimethamine 
¥P-value for overall final model 
P-values appearing with unadjusted odds ratios are for each univariate model indicating associations of the variable with the outcome at P < 0.1. 
P-values appearing with adjusted odds ratios indicate the independent association of each variable with the outcome at P < 0.05. 
Bold print: statistically significant outcome for multivariate analysis and final model 
$ Normal haemoglobin level (Hb) was defined as Hb ≥ 11grams per decilitre and anaemia as Hb < 11 grams per decilitre. 
Number of participants less than 715) (Number of singleton deliveries) are indicated in the first column. These were due to missing values in 
individual variables 
*Missing/primigravidae values are only presented as numbers and were not included in the calculation of percentages and in the models 
When placental malaria was put in a model with maternal height, parity and number of doses of IPTP-SP, it was not independently associated 
with adverse birth outcomes. 
†Antibacterial treatment included benzathine penicillin, metronidazole, erythromycin and spectinomycin.    
‡ Uninfected in relation to STI/RTI among those who were followed-up  to delivery (malaria was not considered) 
Past experience of a miscarriage was associated with adverse birth outcome in the univariate analysis but was not included in the multivariable 
model because that would have excluded all primiparous women from the model. 
 
 
151 
 
6.7 Risk factors for PD, LBW and IUGR 
Univariate and multivariate analyses of factors associated with individual ABO (PD, 
LBW and IUGR) are reported in Table 6-9.  The number of women who experienced 
stillbirth was small (12) and was not amenable to statistical analyses. None of the 
individual STIs/RTIs or malaria diagnosed at first ANC or placental malaria diagnosed 
at delivery were associated with any one of the individual ABO.  
Potential risk factors for ABO that were associated with individual ABO at P < 0.1 and 
were included in the multivariate models for each outcome were as follows: PD was 
associated with maternal age group, maternal height, parity, placental malaria, 
anaemia, and the number of doses of IPTp-SP taken during pregnancy; LBW was 
associated with maternal age group, maternal height, parity, infection with 
trichomoniasis, HIV status, placental malaria and antimalarial treatment during 
pregnancy; IUGR was associated with maternal age group, maternal height, parity, 
and peripheral malaria diagnosed at first ANC attendance.  
In the multivariate analysis only the number of doses of SP taken during the 
pregnancy duration was independently associated with PD; LBW was associated with 
marital status, maternal height, parity, HIV and antimalarial treatment during the 
pregnancy duration; and IUGR was associated with parity and height.  
The final models for factors associated with PD, LBW and IUGR are shown in Table 6-
10. In the final model women who took 2 or more doses of SP had a reduced risk of 
experiencing PD (OR 0.34; 95% CI, 0.23-0.52) than women who took one dose or 
none.  
Marital status was not independently associated with LBW in a model with height, 
parity, HIV and antimalarial treatment during the pregnancy duration hence it was 
excluded from the final model.  Compared to primiparae, Para II women had a 
reduced risk of delivering LBW babies (aOR 0.32; 95% CI; 0.18-0.58) and the risk was 
slightly lower among multiparous women (aOR 0.22; 95% CI, 0.15-0.34).  Women 
with height < 1.5 metres had increased risk of delivering a LBW baby than women 
whose height was   ≥ 1.5 metres (aOR 2.10, 95% CI, 1.43-3.08). Women who had 
been treated for malaria were at increased risk of experiencing LBW than women 
who had not been treated for malaria during the pregnancy duration (aOR 2.01; 95% 
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CI, 1.20-3.5). Women infected with HIV had twice the risk of delivering LBW babies 
than HIV-uninfected (aOR 2.10; 95% CI, 1.23-3.55).  
A reduced risk of IUGR was observed among para II (aOR 0.33; 95% CI, 0.16-0.71) and 
multiparae (aOR 0.23; 95% CI, 0.13-0.37) in comparison to primiparae and babies 
born to shorter women were at increased risk of experiencing IUGR (aOR 1.71; 95% 
CI, 1.04-2.83) than those born to women whose height was ≥ 1.5 metres. 
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       Table 6- 9: Univariate and multivariate analyses of factors associated with PD, LBW and IUGR 
Potential risk factor Preterm delivery Low birth weight Intra-uterine growth retardation 
Unadjusted OR Adjusted OR Unadjusted OR Adjusted OR Unadjusted OR Adjusted OR 
- N = 659 - N = 659 - N = 540 
Recruitment site 
  Kashikishi 
  Nchelenge 
 
P = 0.648 
1.00 
1.09 (0.74-1.60) 
- P = 0.900 
1.00 
1.02 (0.69-1.51) 
- P = 0.910 
1.00 
0.97(0.58-1.16) 
- 
Age group  
  ≤ 20 
  21-25 
  26-30 
  ≥ 30 
P = 0.045 
1.00 
0.61 (0.38-0.97) 
0.63 (0.38-1.04) 
0.54 (0.31- 0.87) 
P = 0.812 
1.00 
0.85 (0.44-1.65) 
0.88 (0.39-1.96) 
0.69 (0.31-1.56) 
P < 0.001 
1.00 
0.48 (0.31-0.74) 
0.31 (0.18-0.53) 
0.24 (0.13-0.42) 
 
P = 0.677 
1.00 
1.42 (0.74-2.71) 
1.20 (0.51-2.78) 
1.02 (0.41-2.55) 
P < 0.001 
1.00 
0.48 (0.27-0.85) 
0.28 (0.13-0.58) 
0.22 (0.11-0.47) 
P = 0.918 
1.00 
1.34 (0.60-2.88) 
0.95 (0.33-2.72) 
0.86 (0.29-2.52) 
Height 
  ≥ 1.5m 
  < 1.5m 
   
P = 0.053 
1.00 
1.45 (0.99-2.11) 
P = 0.262 
1.00 
1.28 (0.83-1.98) 
P < 0.001 
1.00 
2.25 (1.56-3.26) 
P = 0.002 
1.00 
1.90 (1.24-2.91) 
P = 0.019 
1.00 
1.80 (1.11-2.91) 
P = 0.026 
1.00 
1.81 (1.07-3.06) 
 
Parity 
  Primiparae 
  Para II 
  Multiparae 
 
P = 0.015 
1.00 
0.63 (0.35-1.12) 
0.56 (0.38-0.83) 
P = 0.150 
1.00 
0.47 (0.21-1.02) 
0.69 (0.34-1.39) 
P < 0.001 
1.00 
0.35 (0.20-0.63) 
0.22 (0.15-0.34) 
P < 0.001 
1.00 
0.18 (0.09-0.37) 
0.15 (0.06-0.34) 
P < 0.001 
1.00 
0.33 (0.15-0.70) 
0.22 (0.13-0.37) 
 
P = 0.005 
1.00 
0.33 (0.13-0.86) 
0.27 (0.11-0.66) 
Bacterial vaginosis 
  Negative 
  Intermediate 
  Positive   
P =0.783 
1.00 
0.92 (0.54-1.55) 
1.08 (0.73-1.62) 
- P = 0.404 
1.00 
1.05 (0.64-1.73) 
0.80 (0.53-1.19) 
- P = 0.175 
1.00 
1.05 (0.57-1.96) 
0.65 (0.39-1.10) 
- 
Trichomoniasis 
  Negative 
  Positive 
   
P =  0.435 
1.00 
1.18 (0.78-1.77) 
- P = 0.069 
1.00 
1.45 (0.97-2.16) 
P = 0.722 
1.00 
0.50 (0.10-2.49) 
P = 0.132 
1.00 
1.49 (0.89-2.5) 
-    
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       Table 6-9: Univariate and multivariate analyses of factors associated with PD, LBW and IUGR continued 
Potential risk factor Preterm delivery Low birth weight Intra-uterine growth retardation 
Unadjusted OR Adjusted OR Unadjusted OR Adjusted OR Unadjusted OR Adjusted OR 
- N = 659 - N = 659 - N = 540 
Chlamydia 
  Negative 
  Positive  
 
P = 0.834 
1.00 
1.09 (0.48-2.46) 
 
- P = 0.818 
1.00 
1.08 (048-2.48) 
 
- P = 0.982 
1.00 
1.01 (0.34-3.01) 
- 
 Gonorrhoea 
  Negative 
  Positive     
 
P = 0.559 
1.00 
1.34 (0.51-3.47) 
- P = 0.659 
1.00 
0.78 (0.26-2.35) 
-  P = 0.752 
1.00 
0.79 (0.18-3.54) 
- 
Confirmed Syphilis 
   Negative 
   Positive-treated 
   Positive-untreated 
P = 0.380 
1.00 
1.02 (0.46-2.29) 
1.53 (0.58-4.07) 
- P = 0.292 
1.00 
0.57 (0.22-1.49) 
1.63 (0.61-4.36) 
- P = 0.270 
1.00 
0.41 (0.09-1.74) 
0.62 (0.05-3.15) 
- 
STIs/RTIs 
    No 
    Yes-treated 
   Yes- untreated 
P = 0.387 
1.00 
1.39 (0.72-2.70) 
1.28 (0.87-1.88) 
- P = 0.023 
1.00 
0.42 (0.17-1.03) 
1.23 (0.84-1.79) 
P = 0.127 
1.00 
0.39 (0.15-1.04) 
0.91 (0.56-1.47) 
P = 0.186 
1.00 
0.38 (0.11-1.30) 
1.02 (0.63-1.66) 
- 
HIV status 
   Negative 
   Positive 
P = 0.193 
1.00 
1.40 (0.85-2.31) 
- P = 0.035 
1.00 
1.71 (1.05-2.77) 
P = 0.029 
1.00 
1.91 (1.04-3.49) 
P = 0.48 
1.00 
1.27 (0.65-2.50) 
- 
Peripheral Malaria at 
first ANC visit  
   Negative 
   Positive 
 
P = 0.989 
 
1.00 
1.00 (0.70-1.43) 
- P = 0.160 
 
1.00 
1.30 (0.90-1.87) 
 
- P = 0.081 
 
1.00 
1.53 (0.94-2.48) 
P = 0.208 
 
1.00 
1.38 (0.82-2.34) 
Placental malaria   
   Negative 
   Positive 
P = 0.007 
1.00 
1.64 (1.14-2.37) 
 
P = 0.069 
1.00 
1.46 (0.97-2.20) 
P = 0.008 
1.00 
1.64 (1.14-2.36) 
P = 0.157 
1.00 
1.37 (0.90-2.07) 
P = 0.732 
1.00 
1.08 (0.67-1.75) 
- 
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        Table 6-9: Univariate and multivariate analyses of factors associated with PD, LBW and IUGR continued 
Potential risk factor  Preterm delivery Low birth weight Intra-uterine growth retardation 
Unadjusted OR Adjusted OR Unadjusted OR Adjusted OR Unadjusted OR Adjusted OR 
 - N = 659 - N = 659 - N = 540 
Anaemia¥ 
   Normal  
   Anaemic 
 
P = 0.051 
1.00 
1.60 (1.01-2.52) 
P = 0.177 
1.00 
1.44 (0.85-2.46) 
P = 0.610 
1.00 
1.13 (0.70-1.84) 
- P = 0.413 
1.00 
1.75 (0.37-1.52) 
- 
Hypertension 
   Normal 
   Hypertensive 
 
 P =  0.097 
1.00 
2.57 (0.87-7.54) 
P = 0.245 
1.00 
1.99 (0.63-6.20) 
P = 0.573 
1.00 
1.41 (0.44-4.58) 
- P = 0.112 
1.00 
3.55 (0.83-15.2) 
- 
Sex of baby 
   Female 
   Male  
P = 0.035 
1.00 
0.68 (0.48-0.98) 
P = 0.083 
1.00 
0.69 (0.46-1.05) 
P = 0.349 
1.00 
0.84 (0.59-1.20) 
- P = 0.739 
1.00 
0.92 (0.58-1.47) 
- 
Antimalarial  
treatment 
    No  
    Yes 
P = 0.912 
 
1.00 
1.03 (0.60-1.76) 
- P = 0.004 
 
1.00 
2.08 (1.29-3.34) 
 
P = 0.016 
 
1.00 
2.00 (1.15-3.47) 
P = 0.233 
 
1.00 
1.49 (0.79-2.82) 
- 
Number of doses of 
IPTp-SP  
   0 or 1 
   2 or more 
P < 0.001 
 
1.00 
0.34 (0.23-0.52) 
P < 0.001 
 
1.00 
0.35 (0.22-0.56) 
P = 0.260 
 
1.00 
0.77 (0.49-1.21) 
- P = 0.104 
 
1.00 
1.87 (0.83-4.24) 
- 
Bold type indicates statistically significant outcome 
¥ Normal haemoglobin level (Hb) was defined as Hb ≥ 11grams per decilitre and anaemia as Hb < 11 grams per decilitre. 
Only 12 women experienced stillbirth and were not amenable to statistical analysis because of the small number. 
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         Table 6- 10: Final logistic regression models of factors associated with PD, LBW and IUGR 
Risk factor Preterm delivery P-value Low birth weight P-value Intra-uterine growth 
retardation 
P-value 
N = 715 < 0.001¥ N = 713 < 0.001¥ N = 557 < 0.001¥ 
Parity 
  Primiparae 
  Para II 
  Multigravidae 
- -  
1.00 
0.32 (0.18-0.58) 
0.22 (0.15-0.34) 
 
 
< 0.001 
< 0.001 
 
1.00 
0.33 (0.16-0.71) 
0.23 (0.13-0.37) 
 
 
   0.005 
< 0.001 
Maternal Height 
  ≥ 1.5m 
  < 1.5m   
- -  
1.00 
2.10 (1.42-3.10) 
 
 
< 0.001 
 
1.00 
1.71 (1.04-2.83 ) 
 
 
0.035 
HIV status 
   Negative 
   Positive 
- -  
1.00 
2.10 (1.23-3.55) 
 
 
0.006 
- - 
Antimalarial  
Other than  IPTp-SP 
No  
Yes 
- -  
 
1.00 
2.01 (1.20-3.35) 
 
 
 
0.008 
- - 
Number of doses of 
IPTp-SP  
0 or 1 
2 or more 
 
1.00 
0.34 (0.23-0.52) 
 
 
 
< 0.001 
- - - - 
¥P value for overall final model 
-: Blank-only variables independent associated with each adverse outcome in multivariate analysis are shown 
Bold type indicates statistically significant outcome 
When marital and HIV status were put in a model with parity and height in the analysis of risk factors for LBW, there were not independently 
associated with LBW therefore they were excluded from the final model.  
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7 Discussion 
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7.1 Losses to follow-up 
The loss to follow in this study was much higher (33%) than was expected (10%) and 
provided for in the sample size mainly due to interruptions in the provision of 
transport that were experienced as a result of delays in the disbursement of project 
funds during the follow-up to delivery period. Monthly efforts to supplement the 
budget during the waiting period were not sufficient because provision of transport 
was only possible for about a week in each month. The extended periods of lack of 
funds for fuel resulted in high losses to follow-up as it was impossible to provide 
transport to some delivering women who called members of the team during the 
period when funds were unavailable. Long distances to the health facilities and lack 
of transport have been cited as some of the reasons why women deliver at home in 
Zambia [174, 210]. During this period, team members who were still involved in the 
study went without pay and this may have negatively influenced their attitude 
towards work although they were assured of backdated payment when funds 
became available. 
Furthermore, before the unavailability of funds became a problem, the main field 
vehicle that was used to transport participants to and from the hospital was involved 
in an accident and was destroyed by an act of arson which resulted in a period of 
transport shortage before alternative transport arrangements could be made.  
In the current study refusals were low (< 1%) and only one participant withdrew 
from the study, however a high proportion of participants (30%) were lost to follow-
up. A higher proportion of loss to follow-up than that observed in the current study 
was noted in another study conducted in 2010-2011 in Mansa District by Tan et al., 
in the same province where the current study was carried out.  The study was 
designed to examine the efficacy of IPTp-SP and presence of quintuple mutant in 
pregnant women [114]. Participants were followed up weekly over a period of 5 
weeks. Among 109 pregnant women who were recruited, 53 (58%) completed the 
study, 34 (31%) had incomplete follow-up and 17 (16%) were lost after day 0 despite 
the fact that there were no refusals and withdrawals [114]. The study by Tan et al., 
differs from the current study in that the number of follow-up points was higher 
(weekly) over a shorter period of time (5 weeks) while in the current study follow-up 
was scheduled at day 28 (for some participants) and at delivery for all participants. 
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Weekly follow-up over a period of 5 weeks may be difficult to endure in comparison 
to follow-up at day 28 and at delivery although follow-up after longer periods of time 
may be difficult to remember. However in the current study global positioning 
system mapping of homes locations and checking on some participants via phone 
calls helped to reduce incidence of loss to follow-up although contact via phone was 
only possible in the case of participants with active phone lines over the study 
period. Factors associated with high losses to follow-up in this region are not clear 
but understanding these factors might be helpful to future studies. It is highly likely 
that the proportion of women lost to follow-up to delivery was increased by myths 
and traditional beliefs discussed in Section 1.8 that influence birthing practices in 
Zambia and cause women to prefer delivery at home in seclusion or away from 
hospital and their home villages.  
 
7.2 Prevalence of malaria, STI/RTI and their coinfection 
7.2.1 The malaria burden 
This study provides a robust estimate of the prevalence of peripheral malaria 
infection among pregnant women of Nchelenge District.  A high burden of P. 
falciparum malaria diagnosed by PCR was observed in this population. The 
prevalence of malaria detected by microscopy was much lower than that detected 
by PCR suggesting that a good proportion of this study population had sub-
microscopic infections (smear negative but PCR positive).  Sub-microscopic infections 
have been associated with placental malaria and decreased maternal Hb [211].  
Although no association was found between sub-microscopic infections and adverse 
maternal and foetal outcomes, the importance of these infections in pregnancy 
cannot be ignored in malaria policy formulation because of their role in maternal 
morbidity and malaria transmission [211]. 
Seven samples that were positive by microscopy in this study were found negative 
by PCR. Because PCR diagnostic method is more precise than standard microscopy 
[212], we would expect that a malaria sample found positive by microscopy would 
also be positive by PCR. The observation above could be attributed to a number of 
factors including malaria infection due to other Plasmodium species and insufficient 
DNA extraction.  A negative PCR test result may be an outcome if the amount of 
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blood collected on filter paper was less than 25µl, coupled with low parasitaemia. 
Negative PCR results for microscopic positive samples have been noted in other 
studies [98, 99]. 
The prevalence of malaria infection by microscopy was very similar to the prevalence 
of parasitaemia observed in children less than five-years-old in 2012 (32.1%, 
114/356) in the MIS in Luapula Province [189].  Another study conducted in the same 
area among children less than 10 years-of-age reported a similar parasite 
prevalence, 30.2% (236/782) by microscopy [188].  The prevalence of placental 
malaria in the current study, 40.9% (95% CI, 37.3-44.6), is comparable to what was 
found in another study, 37% (95% CI: 32.5-41.5), conducted within Luapula province 
in Mansa District [90].  
Analysis of monthly-reported district-level malaria cases among pregnant women 
showed that MiP in Zambia decreased between 2010 and 2013, although persistent 
hot spots were reported in the southeast and northeast of the country [213]. 
The prevalence of malaria among 375 pregnant women in the study conducted in 
Nchelenge District between February and April 2013 by Siame et al. was much lower 
than what was observed in the current study, 15.0% by microscopy and 22.0% by 
PCR [115].  The observed difference in malaria prevalence in the two studies could 
be attributed to a number of factors. Firstly, in the current study women attending 
the Nchelenge and Kashikishi health centres were recruited, whereas in the study by 
Siame et al. a third health centre, Kabuta, was included in addition to these two.  
Secondly, in the study by Siame et al. pregnant women who sought ANC services 
were included, regardless of visit number; in this study, only first ANC attendees who 
had not taken antimalarial treatment in the previous month before recruitment 
were enrolled.  Some of the participants who were included in the study by Siame et 
al. had received IPTp-SP during their earlier ANC visit(s) as well as antimalarial 
treatment before enrolment, and it is unclear what time period may have elapsed 
between treatment and subsequent screening.  The prevalence of malaria is likely 
lower in a group of women exposed to any IPTp-SP because even one dose of IPTp-
SP has been shown to protect against maternal parasitaemia [154]. Furthermore, the 
last IRS exercise before the current study was conducted in November 2012 and no 
IRS was conducted in the community by the district health office between October 
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2012 and April 2014 [186]. The study by Siame et al., was conducted in April 2013 a 
period during which the insecticide residue in the houses in the community would be 
expected to be more effective against mosquitoes in comparison to recruitment 
period of the current study which commenced about 11 months after the IRS 
exercise (November 2013 to April 2014). 
The coverage of bed nets in this study was lower than that observed in the study by 
Siame et al., (74% versus 49.2%). In the study by Siame et al., bed net ownership 
among pregnant women was used to characterise the percentage of households 
with at least one bed net while in the current study bed net ownership describes the 
percentage of pregnant women who slept in a protected space. It is therefore 
expected that ownership of at least one bed net in a household would be higher 
than that observed when bed net ownership is limited to the participant’s sleeping 
spaces. No association between malaria infection and bed net ownership was 
observed in the study by Siame et al., just like in the current study.   
There was a difference in malaria infection and parasite densities among HIV-
uninfected and HIV-infected women, a finding similar to other studies [214-220].  
The proportion of malaria infection detected by microscopy and by PCR in this study 
was consistently higher in HIV-infected than HIV-uninfected women.  HIV-infected 
women had a 46% increased risk of malaria infection detected by PCR at first ANC 
visit (P = 0.045).  However, the association between HIV and malaria infection was 
not statistically significant. 
Previous studies have reported stronger association between HIV and peripheral 
malaria detected by microscopy in pregnant women.  A hospital based study in 
Zimbabwe in 2000-2001 reported a high odds of malaria parasitaemia in HIV-
infected women compared to HIV-uninfected women (OR 3.96; 95% CI, 2.42-6.46) 
[219]; a study in Rwanda conducted between 1992 and 1993 reported that the risk 
of parasitaemia was moderately higher in HIV-infected compared to HIV-uninfected 
women (RR 1.4; 95% CI, 1.1-1.6, P = 0.016) [216]; a similar finding was reported from 
Kenya in a study conducted between 1996 and 1999 among HIV-infected women in 
the third trimester ( RR  1.70; 95% CI, 1.52-1.90) and at delivery  (RR 1.56; 95% CI, 
1.34-1.81)  [220].  The prevalence of malaria parasitaemia among HIV-infected 
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women at first ANC visit was higher than among HIV-uninfected women in a study in 
Malawi conducted between 1987 and 1990 (56.6% versus 43.6%, P < 0.001) [218].   
The use of antiretroviral therapy was not stated in all the studies above and, 
considering the years in which these studies were conducted, it can be assumed that 
coverage of antiretroviral therapy among pregnant women should have been very 
low if not non-existent.  In the current study, however, the coverage of antiretroviral 
therapy at first ANC visit was 42.7% among all HIV-positive women, newly-tested and 
known HIV-positive cases.  Some of the women who were screened in the current 
study were receiving cotrimoxazole prophylaxis although coverage data of 
cotrimoxazole at recruitment was not collected.  However, data from delivery 
showed that 37% of HIV-infected study participants had received cotrimoxazole 
prophylaxis during pregnancy. Thus, the relatively a weaker association between 
HIV-infected status and malaria parasitaemia observed in the current study 
compared to the previously reported studies could be due to the fact that most HIV-
infected women were on ARV therapy and/or cotrimoxazole prophylaxis. 
There was no difference in the distribution of parasite counts in HIV-infected women 
on antiretroviral therapy and women who were not on treatment.  This could be 
because HIV in women who were not on antiretroviral therapy had not progressed 
to a state of highly compromised immunity since some women tested positive for 
the first time.  Furthermore, eligibility to receive antiretroviral drugs in this 
community was linked to CD4 count.  Therefore, if women known to be HIV-positive 
were not on therapy, it was likely that their CD4 count was above 500 cells per cubic 
millimetre of blood. 
 
7.2.2 Prevalence of curable STIs/RTIs 
The combined prevalence of STI/RTIs (64.6%) was higher than that of malaria as was 
suggested in the review by Chico et al., [6]. Estimates of individual STIs/RTIs in the 
current study fall within the 95% upper and lower limits of pooled estimates for East 
and Southern Africa reported in the study by Chico et al., except in the case of 
syphilis which was estimated at syphilis 4.5% (95% CI, 3.9-5.1). Although the 
prevalence of syphilis (7.1%) obtained in this study is higher than the estimated 95% 
CI upper limit for East and Southern Africa (3.9-5.1), it falls within the range of 
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estimates (lowest to highest prevalence, 0-14.6) obtained from studies conducted in 
Zambia and neighbouring countries.  
There are a few published studies on STIs/RTI in Zambia. Two papers were published 
from the HIV Preventions Trials Network (HPTN) 024 study, one reported on syphilis 
and the other was on the rest curable STI/RTI [135, 140]. The HPTN-024 study 
(conducted between 2001 and 2003) showed a high prevalence of individual 
STIs/RTIs in HIV-infected pregnant women (N = 642) of Lusaka. The prevalence 
estimates of the same STIs/RTIs infections among HIV-infected pregnant women (n = 
143) of Nchelenge district in this study were higher than those found in the HPTN-
024 study. Comparison of the prevalence of infection in pregnant HIV-infected 
women of Lusaka in the HPTN-024 study versus what was observed in HIV-infected 
pregnant women in the current study are as follows; Chlamydia, 6.1% versus 7.0%; 
gonorrhoea, 1.6% versus 6.3%; trichomoniasis 20.9% versus 23.8%; syphilis, 13.0% 
versus 15.8% and BV, 40.0% versus 66.4%. The diagnostic tools that were used in the 
HPTN-024 study were Gram stain microscopy using the Nugent score, wet mount, an 
enzyme immunosorbent assay kit, culture (then gram stain appearance and positive 
oxidase reaction) and RPR (as well as Treponema pallidum particle agglutination or 
TPHA confirmation) for diagnosis of BV, trichomoniasis, Chlamydia, gonorrhoea and 
syphilis respectively.  The methods that were used for BV and syphilis diagnosis in 
the current study were the same as in the HTPN-024 study and the other infections 
(Chlamydia, gonorrhoea and trichomoniasis) were detected using PCR. It is likely that 
the prevalence of STIs/RTIs was higher in the current study population than in the 
HTPN-024 study population but the differences can partially be attributed to the 
diagnostic tool (PCR) with higher sensitivity that was used for the detection of some 
of the infections in the current study.  
The fact that high levels of asymptomatic STIs/RTIs exist in this population is not 
surprising because literature shows that high proportions of STIs/RTIs in women are 
asymptomatic [166, 221]. The number of women who complained of at least one 
symptom associated with STIs/RTIs among women with at least one curable STI/RTI 
was low (14.0%). The proportion remained unchanged when only curable STIs 
(excluding BV) were considered. Among 374 women who tested positive for at least 
one STI, only 14.2% (n = 53) indicated that they were experiencing at least one STI 
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symptom at recruitment. This implies that a large proportion of (86.8%) of curable 
STI-infected women were asymptomatic in agreement with what has been observed 
from literature. High proportions of gonococcal (80%) and Chlamydial (70-75%) 
infections have been shown to be asymptomatic [164] and approximately 60-70% of 
asymptomatic T. vaginalis infection and BV have been reported [165, 166].  
The high burden of STI/RTI that are asymptomatic in this study population is a clear 
demonstration of missed treatment opportunities. Although the current ANC 
package for the management of STI/RTIs is partially effective, it is clear that a huge 
burden of STI/RTI remains untreated. In the interest of reducing STI/RTI morbidity, 
there is need to devise alternative strategies for the management of STIs/RTIs in 
pregnant women.   
Provision of point of care tests for STI/RTIs would be beneficial for the reduction of 
STI/RTI morbidity in this setting. This is crucial especially when the role of STI/RTI in 
HIV transmission is considered. Different STIs/RTIs, BV [222-226], trichomoniasis 
[227-232], Chlamydia [233, 234], gonorrhoea [233, 235]  and syphilis [233, 235, 236] 
have been individually identified as risk factors for HIV acquisition and/or 
transmission. Furthermore, studies have shown that treatment of Chlamydia, 
gonorrhoea and trichomoniasis reduced genital shedding of HIV in women [237, 
238]. In this context screening and treatment of STI/RTI would reduce HIV 
transmission. In the current study higher proportions of syphilis, Chlamydia, 
gonorrhoea and BV were found among HIV-infected women than HIV-uninfected 
women although this was only statistically significant in the case of BV, gonorrhoea 
and syphilis. A statistically significant higher proportion of composite STI/RTI was 
also observed among HIV-infected women. In this context good diagnostics and 
appropriate treatment of STIs/RTIs have the potential to impact the incidence of HIV.  
The fact that the prevalence of STIs/RTIs was high in this resource poor setting 
supports calls for the development of a vaccine against five common STI pathogens 
(herpes simplex virus, C. trachomatis, N. gonorrhoea, T. vaginalis and T. pallidum) 
[239].  
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7.2.3 Prevalence of malaria and STI/RTI coinfection 
This is the first study to report malaria and curable STI/RTI coinfection in pregnancy. 
The estimated prevalence of malaria and STI/RTI coinfection in this study was 
considerable, irrespective of whether malaria was diagnosed by PCR or microscopy, 
38.7% and 21.4% respectively. Before this the only report of coinfection was from a 
sub-analysis of results from a study in Tanzania which showed that 48.3% of RPR-
positive women had placental malaria [6, 36]. 
The prevalence of STIs/RTIs and their coinfection with malaria represent an 
important finding in the context of the ongoing search for alternative drugs to 
replace SP for use in IPTp necessitated by the emergence of SP resistant parasites in 
some settings. The study provides evidence in support of antimalarial and 
antibacterial drug combinations that may offer the added benefit of reducing the 
burden of curable STIs/RTIs in pregnancy, especially in poor resource settings such as 
this where STIs/RTIs are highly prevalent and routine screening may not be 
sustainable.  
 
7.3 Risk factors for malaria, curable STIs/RTIs and their coinfection 
7.3.1 Risk factors for malaria infection 
In the univariate analysis, the risk of infection was strongly associated with gravidity 
and age, but this was not observed in the multivariate analysis. Studies have shown 
that in malaria-endemic areas, the prevalence of malaria, both clinical and 
asymptomatic, is highest in young women and primigravidae and paucigravidae 
(primigravidae and secundigravidae combined) [47, 240, 241]. This is due to 
acquisition of semi-immunity that is gravidity-dependent such that malaria infection 
tends to be less prevalent and less severe among multigravidae [42, 47, 240]. 
However, HIV infection has been shown to impair the ability of multigravidae to 
manage malaria infection [214, 220]. The fact that HIV prevalence was highest 
among multigravidae in this study population is a plausible explanation for the fact 
that there was no association between parity and malaria infection in multivariate 
analysis. 
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The low coverage of IRS and bed net use in an area of intense transmission may 
partially explain the high prevalence of malaria infection.  Despite the progress that 
has been made in scaling-up malaria control interventions, a high burden of malaria 
still remains in Nchelenge District [108, 242]. Several reasons may underlie this 
observation including population movements from high endemic areas (internally 
and across borders), increasing parasite resistance to insecticides [188, 242], as well 
as homes having been built close to water sources that serve as breeding grounds for 
Anopheles mosquitoes.  
The risk of malaria infection was higher among women at Nchelenge health centre 
compared to Kashikishi health centre.  Since there was no difference in socio-
demographic characteristics and HIV infection at the two sites, this difference in the 
risk of malaria infection may be attributable to the intensity of malaria transmission 
within the catchment areas of Kashikishi and Nchelenge health centres.  
Apart from providing health services to the people living close to the Lake Mweru, 
Nchelenge health centre also provides health services to people in villages that are 
close to a rubber plantation, the Kenani River, and other in-land water bodies in the 
Robert Mutepuka village area which provide more breeding sites for mosquitoes. 
Malaria transmission intensity is known to decrease during the winter months, April 
to August, in Nchelenge District [18].  Thus, the estimated prevalence of malaria in 
pregnancy from this study conducted during the hot rainy season from November to 
April is probably higher than the prevalence at other times of the year.    
Zambia has different malaria transmission zones ranging from very low, to low-
moderate and moderate-high [109].  Thus, the prevalence of malaria estimated in 
this study can only be cautiously extended to areas with similar transmission 
patterns.  
 
7.3.2 Risk factors for curable STIs/RTIs infection 
In the current study infection with any STI was associated with BV but not with HIV. 
Several studies have associated STIs with HIV [230, 235, 243]. Trichomoniasis[223], 
Chlamydia [223],  gonorrhoea [223, 235, 244]  and syphilis [156, 244] have been 
individually associated with HIV infection.  In contrast to this, other studies have 
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found no such association between trichomoniasis [245], or Chlamydia [246], or 
gonorrhoea [246]  or syphilis [226, 246] or  composite STIs [247] and HIV. The lack of 
association between STIs and HIV in the current study can be partially explained by 
the fact that infection with any STI was more common in younger women (≤ 25 
years) while HIV was concentrated in women aged above 25 years.  
Bacterial vaginosis was associated with STIs and HIV infection in the current study. 
The association of BV with Chlamydia [248, 249], gonorrhoea [248, 249], 
trichomoniasis [250, 251] and HIV [222, 223, 252, 253] has been observed in other 
studies. Furthermore, HIV-infected women may have more severe or persistent BV 
[254, 255].  
The number of life-time sexual partners, younger age at sexual debut and parity 
have been associated with STIs [130, 181, 256], however, these associations were 
not observed in the current study.  Factors that relate to sexual behaviour were also 
not associated with STIs. This lack of association can be explained by the fact that in 
this study the number of sexual partners that was queried was that of a life time 
count rather than for a limited period of time (e.g. past one year or during 
pregnancy).  
 
7.3.3 Risk factors for malaria and STI/RTI coinfection 
Malaria and STIs/RTIs have both been associated with HIV infection [214-217, 219, 
230, 235, 243, 257].  Consequently, it is not surprising that HIV was a risk factor for 
malaria and STI/RTI coinfection in this study population. Although the sample size 
was not large enough to conclude that the risk of malaria infection among HIV-
infected women was statistically significant, HIV infection was associated with 
malaria and STI/RTI coinfection.  
The fact that HIV was strongly associated with malaria and STI/RTI coinfection 
suggests that management and prevention of these infections in pregnant HIV-
infected women should be prioritised in this setting through provision of point of 
care tests and aggressive treatment of infected women. This is particular true for 
syphilis as RPR results were not available on the same day as the ANC visit. The 
proportion of women testing positive for syphilis who receive treatment could be 
increased by the use of point of care tests rather than laboratory-based RPR tests as 
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demonstrated in several countries including Zambia [258]. The facilities relied on 
pregnant women returning to the facility for treatment with their partners, 
prompted by a note with their test results.  However, among 729 delivering women 
only 52 of the 81 women who were RPR reactive at enrolment actually returned to 
the facility for care.  It is likely that a higher proportion of these women could have 
received timely treatment if point of care tests for syphilis, now recommended by 
the WHO [259] for use in the ANC package, had been used.  Overall, clinicians and 
staff involved in the provision of ANC services in this setting need to be proactive in 
the management of STIs/RTIs, especially in HIV-infected women. Furthermore, 
community education on the ways that infection with malaria, HIV and STIs/RTIs can 
be prevented cannot be over emphasised.  
 
7.4 Prevalence of point mutations associated with parasite resistance to SP 
Point mutations associated with resistance to SP in this study were highly prevalent. 
The prevalence of both the quintuple and the sextuple mutants was moderate but 
higher than what has been recorded in earlier studies both in Luapula Province and 
around Zambia [114]. In a study conducted in 2006 in the southern part of Zambia, 
the prevalence of the quintuple mutant was 6.5% in the general population. In 
another study conducted by Siame et al., in 2013 in Nchelenge District the 
prevalence of the quintuple and sextuple mutant among pregnant women was 
17.0% and 3.0% respectively  [115]. Another study, which documented the sextuple 
mutant for the first time in Zambia, conducted among  pregnant women at two 
health centres in Mansa District (which is also located in Luapula province) between 
January 2010 and May 2011 reported the prevalence of the quintuple and sextuple 
mutant at 63.0% and 2.0%, respectively [114]. In the current study the prevalence of 
the quintuple and sextuple mutant was 68.8% and 9.4%, respectively. This suggests 
that there has been an increase in the prevalence of the 581G mutation in this 
population which has the potential to compromise the efficacy of IPTp-SP in this 
population.  A systematic review and meta-analysis of IPTp-SP found that > 2 doses 
of IPTp-SP no longer protected against the incidence of LBW among multigravidae  
where the prevalence of 581G was > 10.1% among children [260]. It is therefore 
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important to monitor the prevalence of SP-resistance markers and the in vivo 
efficacy in Zambia especially in high transmission areas.  
 
7.5 Therapeutic and prophylactic failure of sulphadoxine-pyrimethamine 
There was 14.6% treatment failure among pregnant women of Nchelenge district 28 
days post-IPTp-SP in this area with a moderate prevalence of the highly resistant 
quintuple mutant (68.8%) and presence of the sextuple mutant (9.4%).   
Sulphadoxine-pyrimethamine retained some efficacy in parasite clearance among 
pregnant women with asymptomatic malaria in this study population. Similar 
observations have been has been made elsewhere i.e. SP retaining some efficacy 
despite a moderate to high prevalence of the quintuple mutant and presence of the 
sextuple mutant [114, 261].  
The risk of having parasitaemia at both day 0 and day 28 was higher among 
primigravidae than secundigravidae and multigravidae. This can be explained by the 
fact that malaria prevalence is highest in younger women and primigravidae [47, 
240, 241].  
Prophylactic failure could not be estimated accurately because it is impossible to 
know the number of women who tested negative by microscopy at day 0 and were 
later exposed to the malaria parasite after IPTp-SP administration. Some women 
may have been infected and SP cleared the parasitaemia and others may never have 
been infected. Nonetheless, estimating prophylactic failure based on the number of 
malaria positive women among those who tested negative at day 0 is a good proxy 
for the estimate of prophylactic failure. 
Less than half of the cases (47%) with positive malaria outcome on both day 0 and 
day 28 were due to recrudescence by MSP2 genotyping. Only MSP2 genotyping was 
carried out to distinguish recrudescence from reinfection in the current study. 
Although genotyping for the three genes (MSP1, MSP2 and GLURP) was not done in 
this study, the results from MSP2 genotyping are reliable since MSP2 provides a 
more accurate measure of treatment outcomes in comparison to MSP1 and GLURP 
[262]. 
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7.6 Characteristics of delivering women, Prevalence of adverse birth 
outcomes and risk factors for adverse birth outcomes  
7.6.1 Characteristics of women according to follow-up 
The distribution of characteristics between women who were followed up to delivery 
and those who were lost were similar except in the case of gravidity. The proportion 
of primigravidae was higher among women followed to delivery than among those 
lost to follow-up. This is contrary to what has been observed in other studies where 
women lost to follow-up to delivery were more likely to be primigravidae [36, 263, 
264]. The observation of a higher proportion of primigravidae among women 
followed up than among those who were lost to follow-up in the current study can 
partially be explained by the fact that younger Zambian women prefer to deliver at a 
health facility due to lack of birthing experience and for fear of labour complications 
[175].  
 
7.6.2 Prevalence of adverse birth outcomes 
There was considerable prevalence of ABO (35.0%) in this study population. The 
prevalence of stillbirth and LBW in the current study was 1.7% (95% CI, 1.0-2.9) and 
21.9% (95% CI, 19.2-25.3), respectively.  This is similar to what was recorded in 2013  
at St Paul’s Hospital, the only hospital in the district where prevalence estimates of 
stillbirth and LBW were 2.4% (95% CI, 1.8-3.0%) and 21.5% (19.9-25.3%), 
respectively. The routine data system at the hospital does not contain estimates of 
PD nor IUGR. The rate of stillbirths observed in this study (1.7%) was also 
comparable to what was observed in the ZEPRS (24 per 1000 births). Differences in 
individual ABO between results from this study and others conducted in Zambia 
were noted in the prevalence of LBW and PD. In this study the prevalence of LBW 
was 21.9% which was much higher than what was reported in the 2013-14 ZDHS and 
the ZEPRS, both of which reported 10% prevalence. And the prevalence of PD 
recorded in the ZEPRS was 54% higher than what was recorded in this study (34% 
versus 22.1%). The estimate for the prevalence of LBW reported in the ZDHS survey 
was obtained from Lusaka, Copperbelt and Southern Provinces while the ZEPRS was 
conducted in 25 health facilities across Lusaka. The results seem to suggest 
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differences in the prevalence of these ABO in different regions of Zambia. 
Understanding factors that are associated with ABO in different regions is required in 
order to target the most affected populations with efforts aimed at reducing the 
prevalence of ABO. 
 
7.6.3 Risk factors for adverse birth outcome 
There was no difference in the proportions of women who delivered in the different 
places (hospital, health centre or home) between the two recruitment sites, but a 
higher proportion of women recruited at Nchelenge were assisted by TBAs than 
women at recruited at Kashikishi health centre. The simple explanation for this is 
that at the time of the study Nchelenge Health Centre did not offer maternity 
services and the alternative place of delivery besides St. Paul’s Missionary Hospital 
for women who attend ANC at Nchelenge was Kabwali Health Centre, which was the 
other centre where some of the study participants delivered. In comparison to 
Kashikishi Health Centre, Kabwali was under staffed (six midwives versus one) and 
relied on TBAs to a greater extent to perform some of the deliveries at the health 
centre. In the current study adverse ABO was associated with short stature and 
primiparity. Both short stature [36, 265, 266] and primiparity [36, 265-268] have 
been associated with ABO in other studies. 
In the current study peripheral malaria was diagnosed at first ANC attendance and 
placental malaria was diagnosed at delivery. No association between malaria (both 
peripheral and placental), STIs/RTIs or their coinfection and ABO was observed in the 
current study. Studies have associated malaria [36, 49, 50, 55-58] and individual 
STIs/RTIs of interest in the current study  i.e BV [12, 23, 24, 37-41, 65, 66], 
trichomoniasis [19-21, 33], Chlamydia [11, 12, 28-31, 33-35, 62-64], gonorrhoea[17, 
18, 32, 33] and syphilis[9, 10, 17, 18, 26, 69] with ABO. Interestingly, women who 
indicated that they had received antimalarial treatment besides IPTp-SP at the time 
of delivery were at a higher risk of experiencing LBW. It is assumed that women who 
were treated with antimalarial drugs experienced clinical malaria at some point 
during pregnancy which may have had an impact on the weight of the babies.   
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In this study no association was found between composite STIs/RTIs (BV, 
trichomoniasis, Chlamydia, gonorrhoea and syphilis) and composite ABO (PD, LBW, 
IUGR and stillbirth). Similarly, no association was found between individual STIs/RTIs 
or malaria and PD or LBW or IUGR. The similarity in these finding underscores the 
observation that there was no association between STIs/RTIs or malaria or their 
coinfection and ABO in this study population. 
Although the prevalence of ABO was high in the study population (35%), the 
difference in the proportions of ABO between unexposed and exposed (infected with 
at least one curable STI/RTI and/or malaria diagnosed at first ANC) women was 
minimal (31.8% versus 36.2%).; a larger sample size of 4,469 pregnant women would 
be required to detect a statistically significant difference between unexposed and 
exposed women under the prevailing conditions. This study was underpowered for 
the detection of such a small difference in the outcome between infected and 
uninfected women. 
Various ANC activities contributed to the reduction of ABO attributable to curable 
STIs/RTIs and malaria in pregnancy. The lack of association between infections and 
ABO could partially be attributed to the interventions in the ANC package including 
IPTp-SP, iron and folic acid supplementation and syphilis treatment. Administration 
of IPTp-SP reduces the adverse effects of malaria in pregnancy including third-
trimester maternal anaemia, placental parasitaemia and the incidence of LBW [150, 
153, 217, 261]. In the current study IPTp-SP coverage of at least one dose was high 
with 99% among women who were followed to delivery. The coverage for at least 
one dose of IPTp-SP was higher than the recorded provincial coverage of 89.7%. The 
increase in the coverage of IPTp-SP among participants can be attributed to the fact 
that one of the objectives of the study was to assess the in vivo efficacy of SP and, 
thus, the administration of SP at the first and second visit as well as attendance of 
ANC may have influenced the IPTp-SP coverage. 
 It was noted that 36.4% of the 88 HIV-infected women who took IPTp-SP also took 
cotrimoxazole during the pregnancy duration. It is unclear whether these women 
took both cotrimoxazole and SP at the same point in time. However, clinicians in this 
setting are aware of toxicity concerns of administration of both drugs at the same 
time.  
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Treatment of BV [23, 68, 73-76], trichomoniasis [75], Chlamydia [70, 71], syphilis [60, 
61] and composite STIs/RTIs[67] has been shown to improve birth outcome. 
Conflicting results have been observed in the case of treatment of BV [23, 73, 74, 
76].  Studies in the US showed that treatment of BV reduced PD [23, 73, 74] and 
similar results were found in a study in the UK [76]. However, no benefit of treating 
asymptomatic BV was observed in a review [77]. Results from two studies looking at 
treatment of trichomoniasis and BV in pregnancy showed no benefit in terms of 
reducing ABO [75, 78]. Others found increased risk of ABO in treated women 
compared to untreated women [79, 80]. In contrast to this, a sub-analysis of data 
from another study showed that women randomised to the antibiotic arm were not 
more likely to deliver a preterm infant or to deliver an infant with a lower mean birth 
weight [84].  
The coverage of syphilis treatment among RPR reactive women (64%) was quite low. 
All the participants were followed up within three days of screening and given a slip 
to return to the health centre together with their sexual partner for treatment. 
Counsellors were involved in the note delivery process to ensure that those who had 
doubts were given adequate information on the benefits of seeking treatment. 
However, some of the participants did not return for treatment after being given the 
first note or at day 28 follow-up or after a second note was delivered to them/their 
homes inviting them to return to the health centre for treatment. The success of the 
treatment exercise was partially dependent on the cooperation of individual 
participants. Unfortunately, the reasons for choosing to stay away are unknown but 
establishing this would be useful in future. The proportion of women testing positive 
for syphilis who receive treatment could be increased by the use of point of care 
tests rather than laboratory-based RPR tests as demonstrated in several countries 
including Zambia [258], therefore the  Zambian Ministry of Health should consider 
amending the practise of syphilis screening during ANC. 
In this study the prevalence of STIs/RTIs was high and treatment of participants 
based on syndromic management was low due the fact that a high proportion of 
infections (86%) were asymptomatic. Furthermore, only a small proportion (12.8%) 
of the 467 who tested positive for at least one STI/RTI and 18.6% of 248 STI-infected 
women received antibacterial treatment during the pregnancy duration. Some of the 
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women who were treated based on syndromic management received antifungal 
drugs. It is important to note that the assessment of participants who presented 
with one or more symptoms indicative of an STI/RTI for the decision on treatment 
was not part of this study. In this study all the participants were asked via the 
questionnaire if they were experiencing any signs or symptoms associated with 
STIs/RTIs at the time of recruitment. Those who responded positively were directed 
to their regular clinician for further assessment and decisions on treatment. The 
drugs that were given were recorded on the ANC cards and for the purpose of the 
study drugs taken throughout the pregnancy duration were recorded at delivery. As 
a result of this arrangement, it is difficult to comment on the performance of the 
syndromic management since the study did not assess how this was done or the 
competence of the clinicians who were attending to the participants.  
The administration of antifungal drugs to women who tested positive for at least one 
STI/RTI suggests that some of the women may have had fungal infections which may 
have been much more obvious than the STI/RTI in terms of signs and/or symptoms.  
 
It was surprising that infection with at least one STI/RTI, which was highly prevalent 
in this study population, was not associated with ABO despite a low proportion of 
infected women being treated. One possible explanation is the fact that the uptake 
of SP was high in the study population. Studies have suggested that SP could offer 
additional protection against infections other than malaria resulting in the protective 
effect against ABO which becomes more apparent in areas where parasites have lost 
sensitivity [260, 269]. 
Aside from being underpowered, this study differs from other studies that have 
associated STIs/RTIs with ABO in several ways. Firstly, some of the prior studies were 
conducted in the year 1990 or earlier [11-13, 20, 24]. Under the circumstances, one 
might expect that STIs/RTIs in pregnancy were not managed as well at that time 
compared to more recent years as interventions and implementation have evolved. 
Therefore, differences in proportions of ABO among infected and uninfected women 
may have been greater historically and, consequently, more easily be detected. 
Secondly, among the prospective studies involving screening of women and follow-
up to delivery [20, 24, 30, 37] or record based retrospective studies, much larger 
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groups of women/records ranging between 3540 and 354200 were 
enrolled/included in the studies. Thirdly, studies from both the developing and 
developed world used the case-control design [17, 19, 33, 35].  
Syphilis was associated with ABO in Kenya at a time when screening and treatment 
was policy in many countries but was not implemented in poor settings [60]. In a 
study in Tanzania by Watson-Jones et al., syphilis was strongly associated with 
stillbirth, PD and LBW [10]. Notable differences in relation to syphilis between the 
study by Watson-Jones et al.  and the current study include; (i) the women in the 
study in Tanzania had not been previously screened and treated for syphilis while in 
the current study screening was done and about 64% of delivering participants who 
tested positive to RPR received treatment, (ii) although the prevalence of RPR-
positives in the study by Watson-Jones et al., was slightly lower than that observed 
in the current study (8% versus 10.9%), the proportions of high-titre active syphilis 
among RPR-seropositive women in the study by Watson-Jones et al., was higher than 
that observed in the current study (52.9% versus 36.7%). High-titre active syphilis 
was shown to pose the greatest risk to the foetus in the same study in Tanzania [10].  
 
Malaria was strongly associated with LBW, PD and IUGR but not stillbirth in a study 
conducted between 1997 and 2000 in Mwanza, Tanzania [36]. The Mwanza study 
was conducted before the WHO recommended IPTp-SP and therefore participants 
did not receive IPTp-SP unlike in the current study. Another study, conducted in 
November to December 2006 in Ghana, found an association between malaria and 
stillbirth [50]. The coverage of IPTp-SP among 746 delivering women was low in 
comparison to what was observed in this study; 47.3% of delivering women had 
taken two or more SP doses during the pregnancy duration, while in the current 
study 82.1% of participants had received two or more doses of SP. In another study 
in Sudan carried out between November 2006 and February 2008, malaria was  
associated with stillbirth, however, the coverage of IPTp-SP was not mentioned [49]. 
 
Although placental malaria diagnosed by histology at delivery was not associated 
with ABO, the proportions of PD and LBW were significantly higher among women 
with chronic placental malaria infection (pathology class 2) than in active, past and 
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no infection groups. Furthermore, in comparison to the uninfected women, those 
with chronic placental malaria infection had the lower mean maternal Hb, a lower 
median gestational age and the mean birthweight of the babies was lower as 
observed previously [191]. 
 
Infection with HIV indirectly affects birth outcomes as it is a risk factor for maternal 
anaemia [270]. Infection with HIV was associated with LBW in the current study.  No 
association was found between HIV and composite ABO or the other individual ABO 
(IUGR and PD). Other studies also conducted in sub-Saharan Africa have associated 
HIV with ABO [271, 272] in contrast to others [36].   In the current study 42.7% of 
participants were on ARV therapy at recruitment and the coverage increased to 
61.7% by the time of delivery. Studies have associated highly active antiretroviral 
therapy with higher rates of ABO [273-276], others found no association [271, 277, 
278] or recorded favourable pregnancy outcome [279].  
Having taken two or more doses of IPTp-SP was protective against ABO in the 
current study demonstrating the effectiveness of this strategy in this setting with 
moderate prevalence of the quintuple mutant. Previous studies in areas of high 
prevalence of the quintuple mutant have shown declining protective effect of IPTp-
SP or that it is harmful [2, 280, 281]. However, in areas of low and moderate levels of 
SP resistance, IPTp-SP has been shown to be effective in reducing the incidence of 
ABO [90, 282]. In the same province where the current study was conducted, in 
Mansa District, an area of moderate prevalence of the quintuple mutant [114], each 
dose of IPTp-SP contributed to a 46% and 37% decrease in the frequency of LBW 
among paucigravidae and multigravidae women presenting for delivery at a rural 
health clinic between December 2009 and December 2010 [90]. 
In the univariate analysis hypertension was strongly associated with ABO (OR 3.36, 
95% CI 1.1-10). Blood pressure readings were taken at recruitment and before 
delivery and hypertension was defined as two high BP readings.   It was not always 
possible to take BP readings before delivery due to some deliveries occurring at 
home or in cases where women made it to the hospital so close to delivery resulting 
in a large number of missing values. However, the risk factors for ABO that were 
identified when hypertension was included were the same as when hypertension 
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was excluded in the multivariate model. Urine testing was not conducted and 
therefore preeclampsia was not adjusted for in this study.  
This study demonstrates the existence of high prevalence of malaria and curable 
STIs/RTIs as well as their coinfection in a sub-Saharan setting. In this setting two or 
more doses of IPTp-SP was associated with a decrease in the risk of ABO. Although 
IPTp-SP continues to offer protection against the effects of malaria in some settings, 
the emergence of parasites resistant to SP has undermined the efficacy of SP to 
protect against the malaria attributable fraction of LBW [157]. Given the existence of 
malaria and curable STIs/RTIs confection, the high levels of asymptomatic curable 
STIs/RTIs, the limited accuracy of syndromic management and emerging parasite 
resistance warrants trials to explore antibacterial and antimalarial combinations for 
the replacement IPTp-SP. A review of studies on the efficacy of azithromycin against 
curable STIs/RTIs concluded that azithromycin-based combination therapy therapies 
are among leading potential candidates to replace SP for IPTp owing to the 
effectiveness of azithromycin against T. pallidum, N. gonorrhoea and C. trachomatis 
[283]. In a study in Malawi, adding azithromycin to monthly SP regimen appeared to 
offer further benefit to foetal and neonatal growth [284]. Such a regimen is likely to 
benefit pregnancy outcomes as well as reduce STI/RTI morbidity. 
 
7.7 Potential study biases, limitations, Conclusions and recommendations 
 7.7.1 Potential study biases and limitations 
Non-attendance of ANC may be a potential source of bias if the women who stayed 
away from ANC had a different profile from those that attended ANC. However, it is 
unlikely the results would differ much because in this part of Zambia ANC coverage is 
about 95% and refusal rate among eligible women was less than 1%.  
The general follow-up of study participants was lower than was expected and this is 
a source of concern when bias resulting from losses to follow-up is considered. 
However, women who were followed-up to delivery were generally similar to those 
who were lost to follow-up with respect to socio-demographic characteristics and 
exposure to infection and thus were representative of the study population.  
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Although malaria transmission occurs all year-round, higher numbers of malaria 
cases are recorded in the rainy season, which was the season in which this study was 
conducted. Therefore, the estimated prevalence observed of malaria alone and 
malaria and STI/RTI coinfection may be higher than it would have been had the study 
been carried out at another time of the year.  
Classification of participants as infected or uninfected was based on results for 
malaria diagnosed by PCR and all the STIs/RTIs at first ANC visit.  Repeat reading of a 
proportion of slides for BV and RPR/TPHA testing were conducted for quality control. 
In the case of Chlamydia, gonorrhoea and trichomoniasis PCR was repeated using a 
different assay (Seeplex® STI Master Panel 1 by Seegene). The results obtained from 
repeat diagnosis/reading were virtually reproducible (> 95%). Therefore, it is 
expected that bias due to misclassification was minimal in this context. On the other 
hand, misclassification of some of the infected participants as uninfected was 
reduced by diagnosis of malaria and some curable STIs/RTIs by PCR methods which 
generally have higher sensitivities than traditional methods.  
Diagnosis of STIs/RTIs was limited to the first ANC visit and women were classified as 
infected or uninfected based on results from the screening done at first ANC. This 
potentially may have resulted in the misclassification of individuals who were 
classified as uninfected but acquired an infection later in pregnancy and which may 
have resulted in the reduction of the association between infection and ABO 
towards the null.  A second screening for STIs/RTIs later in pregnancy is 
recommended in future studies although this would be much more expensive and 
labour intensive.   
Gestation age was determined using ultrasound which is a reliable method for 
establishing the length of pregnancy. One of the inclusion criteria in the current 
study was women with gestation ≤ 32 weeks. The measurements of gestational age 
by ultrasound in the second part of pregnancy are less reliable than in the first 
trimester due to normal biological variation [285]. Under/over estimation of 
gestational age at recruitment would result in misclassification of participants in 
terms of outcomes that are dependent on gestational age i.e. PD and IUGR. Although 
the recruitment period would be substantially increased, setting a lower gestation 
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age as an exclusion criterion would minimise the level of misclassification in this 
respect and is therefore suggested for future studies.  
Another study limitation is in the kind of information that was required for the study. 
Some of the questions that were posed to the women especially those on sexual 
behaviour required sharing of information that can be considered confidential and as 
a result the responses to these questions may not be reflective of the truth. 
Furthermore some of the responses to questions on socio-economic status, 
utilisation of malaria interventions, sexual behaviour etc. may have been influenced 
by social desirability.   
The study was under powered to detect risk factors with ORs > 2 and was therefore 
limited in this respect. 
  7.7.2 Conclusions 
The prevalence of P. falciparum malaria detected by PCR in pregnant women of 
Nchelenge District was high.  HIV infection increased the risk of malaria infection, 
although the sample size was not large enough to conclude this risk was statistically 
significant. The high prevalence of malaria infection that was observed in this 
population suggests that past prevention efforts have had limited impact in pregnant 
women.  
The combined prevalence of STIs/RTIs was higher than that of malaria and was 
concentrated in younger and HIV-infected women. The prevalence of malaria and 
STI/RTI coinfection was considerable in this study population and the risk of infection 
was higher in HIV-infected women.  
Both quintuple and sextuple mutants were observed in this study population. 
Sulphadoxine-pyrimethamine retains partial efficacy in clearing parasites in pregnant 
women in this area with moderate prevalence of the highly resistant quintuple 
mutant.  
The prevalence of ABO was considerable and was higher in shorter and primiparous 
women. However, there was no association found between infection with malaria, 
STI/RTI or both and ABO in this study. Two or more doses of IPTp-SP was protective 
against ABO, therefore IPTp-SP remains a viable option for Zambia in this context. 
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However, there is need to investigate alternative drugs that are effective against 
malaria and common STI/RTIs to replace SP for IPTp.  
7.7.3 Recommendations 
The findings from this study are not enough to influence change of policy; however 
they can be used to recommend better coverage of the current policy.  
The prevalence of malaria and STIs/RTIs in this study group was generally high and 
ownership of bed nets and usage were also observed to be low. Malaria control 
policies should therefore focus on providing uninterrupted interventions such as 
robust vector control, distribution of bed nets, yearly IRS spraying, IPTp-SP provision 
and sensitising of the community about the importance of using available 
interventions which are vital to reducing the malaria burden in pregnancy. Health 
service provision administrators should ensure uninterrupted availability of test kits 
for syphilis and treatment drugs. Further sensitisation of community members on 
the effects of syphilis in pregnancy could improve the numbers of women and their 
partners who seek appropriate treatment for syphilis since effective treatment 
requires commitment from infected pregnant women. Provision of point of care 
tests for syphilis and prompt treatment of infected women and their partners should 
be considered in this setting especially among HIV positive women. Provision of 
point of care tests for syphilis has the potential to increase the proportion of women 
receiving treatment among those testing positive. Increased frequency of 
community education on the prevention of infection with STIs via safe sex practises 
and behaviour change such as the use of condoms and maintaining one sexual 
partner can help reduce the burden of STIs/RTIs. Dissemination of information to the 
community can be enhanced via other channels such as the community radio and in 
schools. 
 
7. 8 Future work 
The results in the current thesis show that the prevalence of malaria and STI/RTI 
coinfection is considerable. Although this has only been demonstrated in one setting, 
the fact that malaria and STI/RTI have overlapping prevalence in sub-Saharan Africa 
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implies that a number of settings have cases of malaria and STI/RTI coinfection. 
Evidence suggesting that IPTp-SP may not be beneficial and that it may be harmful in 
areas where parasites express the 581G DPHS mutation has emerged in Muheza, 
Tanzania [2],  but this has not observed elsewhere  [286]. It has been reported that 
IPTp-SP was not associated with decreased odds of placental malaria or with 
increased mean maternal haemoglobin or mean birthweight. Furthermore IPTp-SP 
was associated with decreased cord haemoglobin level and increased foetal 
anaemia. Given the compromised efficacy of IPTp-SP [2, 13, 157, 280] coupled with 
and the limitations of syndromic management in the detection of STIs/RTIs, there is 
need for trials for antibiotic and antimalarial combinations for IPTp. Therefore, 
future work will involve evaluation of the effect of an antibiotic and antimalarial 
combination on birth outcomes in an environment with high prevalence of SP 
resistance markers in comparison to the current strategy of IPTp-SP.    
A possible combination of an antimalarial and antibiotic is that of azithromycin and 
dihydroartemisinin–piperaquine.  This is because azithromycin has been shown to 
efficacious against T. pallidum, C. trachomatis and N. gonorrhoea and azithromycin 
combination therapies are among the leading candidates to replace SP for IPTp and 
may offer the added benefit of reducing morbidity and the effects of STIs/RTIs on 
pregnancy outcome [283]. In the case of an antimalarial, research has shown that 
dihydroartemisinin-piperaquine could be a good replacement for SP as IPTp. Two 
trials have evaluated the use of dihydroartemisinin–piperaquine for the prevention 
of malaria in pregnancy. One was conducted in an area of western Kenya with high 
levels of resistance to SP.  In this trial, HIV-uninfected pregnant women were 
randomly assigned to receive intermittent screening and treatment with 
dihydroartemisinin–piperaquine or IPTp with a median of three doses of either 
dihydroartemisinin–piperaquine or SP [269]. Intermittent screening and treatment 
with dihydroartemisinin–piperaquine was not found to be a suitable alternative to 
IPTp-SP. However, IPTp with dihydroartemisinin–piperaquine was associated with a 
lower prevalence of malaria infection at delivery (15 [3%] of 457 versus 47 [10%] of 
459 of women; relative risk 0·32, 95% CI 0·18-0·56; P < 0·0001); a lower incidence of 
malaria infection (19.2 versus 54·4 events per 100 person-years; incidence rate ratio 
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0·28, 95% CI, 0·22-0·36;  P < 0·0001) and clinical malaria during pregnancy (37·9 
versus  6·1 events; 95% CI, 0·16, 0·08-0·33;  P < 0·0001) than was for SP.  
The second trial conducted in Tororo, Uganda, an area of high malaria-transmission 
and intensity, was a double-blind, randomised, three-group controlled trial 
comparing SP, three-dose dihydroartemisinin–piperaquine, and monthly 
dihydroartemisinin–piperaquine as IPT for malaria in pregnancy [287]. Participants 
were HIV-uninfected pregnant adolescents or women at least 16 years of age 
(primigravid or multigravid), who were between 12 and 20 weeks of gestation. In this 
trial the prevalence of histopathologically confirmed placental malaria was 
significantly higher in the SP group (50.0%) than in the three-dose 
dihydroartemisinin–piperaquine group (34.1%, P = 0.03), or the monthly 
dihydroartemisinin–piperaquine group (27.1%, P = 0.001). The prevalence of 
composite ABO was marginally lower in the monthly dihydroartemisinin–
piperaquine group (9.2%) than in the SP group (18.6%, P = 0.05) or the three-dose 
dihydroartemisinin–piperaquine group (21.3%, P = 0.02). 
Adding an antibiotic to dihydroartemisinin–piperaquine is likely to be more 
beneficial than using this antimalarial alone. As earlier mentioned, studies have 
suggested that SP could offer additional protection against infections other than 
malaria resulting in the protective effect against ABO [260, 269]. In view of this, it is 
likely that if SP is withdrawn and replaced by an efficacious antimalarial without any 
antibacterial activities, it may not be as effective as IPTp-SP has been noted to be in 
reducing ABO. 
Given that malaria and STI/RTI co-infections are very common and both infections 
are associated with ABOs, future interventions to reduce ABOs should be effective 
against both infections.  As mentioned earlier a combination of azithromycin and an 
antimalarial could be considered. A clinical trial to assess the effect of SP alone, SP + 
azithromycin or dihydroartemisinin-piperaquine + azithromycin on ABOs is needed.  
In addition, as the most common RTI is BV a trial to evaluate the effects of adding 
metronidazole to SP or SP is also needed to inform the future guidelines to control 
adverse birth outcomes attributable to malaria and STI/RTIs. 
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7.9 Reflexivity 
According to socially constructed knowledge claims, personal, cultural and historical 
experiences of the researcher influence the interpretation hence the need for the 
researcher to acknowledge this and account for it in their study [288-290]. 
Specifically, there is need for reflexivity from the researcher on how their socio-
cultural and historical contexts shape their theories and research practises. Although 
this was not qualitative research, this section was included to give the reader some 
understanding of my background which shapes the way in which the research was 
conducted and my interpretation of the results.  Reflexivity helps “researchers to 
recognise that their own background shapes their interpretation and ‘position 
themselves’ in research to acknowledge how their interpretation flows from their 
own personal, cultural and historical background” [291]. 
This section identifies the role of my personal experiences in the study which may be 
in the design, conduct, analysis, interpretation of results and writing of the research 
results [292]. I have written this section in first person to show my perspectives, 
experiences and roles in certain aspects of the research project.  
I know that my personal experience influenced the design of this study in one way or 
another. A good example is in how my decision on the study design was influenced 
by my personal experience as a mother. I was faced with deciding whether to 
conduct a case-control study in which samples were to be collected from delivering 
women or find an alternative design. I knew that obtaining cervico-vaginal samples 
from delivering women might be inappropriate although I had come across a study 
in which vaginal and cervical samples were collected within 24 hours of delivery and 
at 7 days postpartum for identification of organisms including Chlamydia 
trachomatis and Neisseria gonorrhoeae by the culture method [17]. This was 
because I strongly felt that this would be too much to ask from a participant during 
such an intimate time and that I would personally find it difficult to agree to such a 
thing having gone through the birthing process. I also thought about collection of 
cervico-vaginal samples a week after delivery which I dismissed for the same reason. 
Due to my experience in molecular diagnostic methods (which I acquired during my 
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Master of Science training in Medical Parasitology), I was aware of possible 
challenges I would have faced if I had opted to isolate genetic material from cervico-
vaginal swabs stained with blood. As a result of this background I settled for a cohort 
study in which samples were collected at first antenatal care attendance and 
participants were followed up to delivery. My past training and experience also 
made other aspects of the study manageable. For instance my undergraduate 
training in Microbiology made the processing, reading of slides for diagnosis of BV 
and interpretation easy for me. 
Having grown up in both the rural and urban settings of Zambia, I understood the 
importance of recognising community leaders which was cardinal to the success of 
the study. As a result of this I made courtesy calls on the chief and the village head 
men in the areas where the two recruitment sites were located.  I also recognised 
the authority of the administrators at the district health office and the district 
commissioner who appreciated this and were supportive to the project throughout 
the period that I worked in the area. 
Furthermore, I decided to engage the local people as much as possible in the 
research activities. The regular ANC staff, midwives and TBAs were trained and 
involved in the project because I understood that the local people were likely to co-
operate with a research team that included people within their community based on 
information I had gathered prior to the commencement of the project.  I was also 
aware of the fact that involving members of community who were familiar with 
participants might result in participants withholding certain information during one-
on-one interviews while completing the study questionnaire. To deal with this, 
research team members administering questionnaires were instructed to declare 
personal knowledge of or familiarity with the participants and pass on such 
participants to another member of the team. 
Some of the community members thought I was linked to the Tropical Disease 
Research Centre which has been conducting research in the area for several years 
and has a good reputation in the community.  I believe this also influenced the 
willingness of women to take part in the study to some extent. 
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My gender and the fact that I had a few months old baby at the time I started my 
field research may also have influenced the attitude of expecting mothers towards 
me. Women seemed comfortable talking to me and seeking clarification on certain 
aspects of the study. Based on some of their questions and comments, it was clear 
that some of the community members thought that I am a powerful person or 
someone connected to politically powerful people.  This may have influenced some 
of their responses to questions bordering on economic status or bed net ownership 
and usage to some extent as some may have wanted to portray a slightly different 
picture with the hope of getting help or may have wanted to be desirable.  
The field work also had a personal impact on me as I leant to relate to and engage 
the community. Visiting the homes of participants was made much easier by the 
warmth of community members who were generally welcoming.  Co-ordinating the 
day to day running of project activities also helped me to build my interpersonal 
skills. A good example of a time when I had to closely deal with the community is 
when the project vehicle was involved in an accident involving a drunken cyclist and 
two children. Our driver tried to avoid a drunken cyclist who hit his bicycle on the 
front passenger’s door by swerving to the opposite side of the road into an area with 
tall grass along the road. Sadly, two little girls were playing in the grass and both 
were hit. One sustained injuries and the other died instantly. The people who 
witnessed the accident understood what happened. After about an hour while 
waiting for the police some youths who were not at the scene at the time of the 
accidents got excited and set the vehicle ablaze. This brought the project to a 
temporal halt. As the principle investigator I had to deal with the police, the 
insurance company, the community leaders, the district commissioner’s office, the 
family of the deceased and the injured girl and cyclist. However, in dealing with all 
these people, I generally received support from the community including the 
community radio station staff that contacted me and gave me an opportunity to 
explain our side of the story as well as inform the community about the project 
progress and the way forward. I had some community leaders who came to 
apologise for the behaviour of the youths who took the law into their own hands and 
they also offered to help the police to bring the perpetuators to justice. In no time 
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the project was up and running and I found alternative transport under very difficult 
circumstances. This whole experience taught me the importance of recognition of 
authority when working with communities. Managing the field activities and team 
members financially was also crucial to the project. Despite the limited budget that I 
had to work with, I managed to achieve most of the objectives for the study. 
Fieldwork did not always run as smoothly as I would have liked but I did everything 
to the best of my ability under the circumstances, I believe that a good job was done. 
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9.0 Appendices 
  Appendix 1.1a: Search terms for studies reporting malaria and/or STIs/RTIs and birth outcomes 
Organism/infection Medical subject heading terms Free test terms 
Treponema pallidum Treponema pallidum OR syphilis AND “ 
birth outcome”  
Treponema pallidum and  birth outcome 
Treponema pallidum and   pregnancy outcome 
Syphilis and   birth outcome 
Syphilis and   pregnancy outcome 
Treponema pallidum and stillbirth 
Treponema pallidum and IUGR 
Treponema pallidum and Preterm delivery 
Treponema pallidum and low birth weight 
Treponema pallidum and PROM 
Syphilis and stillbirth 
Syphilis and IUGR 
Syphilis  and Preterm delivery 
Syphilis and low birth weight 
Neisseria gonorrhoea Neisseria gonorrhoeae OR Gonorrhoea 
OR Gonorrhoea AND “ birth outcome” 
Neisseria gonorrhoeae and  birth outcome 
Gonorrhoea and  birth outcome 
Gonorrhea and birth outcome 
Neisseria gonorrhoeae and pregnancy outcome 
Gonorrhoea and pregnancy outcome 
Gonorrhea and pregnancy outcome 
Neisseria gonorrhoeae  and stillbirth 
Gonorrhoea  and stillbirth 
Gonorrhea  and stillbirth 
Neisseria gonorrhoeae and IUGR 
Gonorrhoea and IUGR 
Neisseria  gonorrhoeae and Preterm delivery 
Gonorrhoea and Preterm delivery 
Neisseria gonorrhoeae and low birth weight 
Gonorrhoea and low birth weight 
Gonorrhea and low birth weight 
Neisseria gonorrhoeae and PROM 
Gonorrhoea and PROM 
Gonorrhea and PROM 
Chlamydia trachomatis Chlamydia trachomatis AND “ birth 
outcome” 
Chlamydia trachomatis and  birth outcome 
Chlamydia trachomatis and   pregnancy outcome 
Chlamydia trachomatis and stillbirth 
Chlamydia  trachomatis and IUGR 
Chlamydia trachomatis and Preterm delivery 
Chlamydia  trachomatis and low birth weight 
Chlamydia trachomatis and stillbirth 
Chlamydia trachomatis and PROM  
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Appendix 1.1a: Search terms for studies reporting malaria and/or STIs/RTIs and birth outcomes continued 
Organism/infection Medical subject heading terms Free text terms 
Trichomonas vaginalis Trichomonas vaginalis and  birth outcome Trichomonas vaginalis and  birth outcome 
Trichomonas vaginalis and   pregnancy outcome 
Trichomonas vaginalis and stillbirth 
Trichomonas vaginalis  and IUGR 
Trichomonas vaginalis and Preterm delivery 
Trichomonas vaginalis and low birth weight 
Trichomonas vaginalis and stillbirth 
Trichomonas vaginalis and PROM 
Trichomoniasis and  birth outcome 
Trichomoniasis and   pregnancy outcome 
Trichomoniasis and stillbirth 
Trichomoniasis  and IUGR 
Trichomoniasis and Preterm delivery 
Trichomoniasis and low birth weight 
Trichomoniasis and PROM 
Bacterial vaginosis Bacterial vaginosis and  birth outcome Bacterial vaginosis and  birth outcome 
Bacterial vaginosis and   pregnancy outcome 
Bacterial vaginosis and stillbirth 
Bacterial vaginosis  and IUGR 
 Bacterial vaginosis  and Preterm delivery 
Bacterial vaginosis and low birth weight 
Bacterial vaginosis and PROM 
Malaria Malaria and  “ birth outcome” Malaria and  birth outcome 
Malaria  and   pregnancy outcome 
Malaria and stillbirth 
Malaria  and IUGR 
Malaria and Preterm delivery 
Malaria and low birth weight 
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  Appendix 1.1b: Search terms for studies reporting point prevalence for malaria and STIs/RTIs 
Organism/infection Medical subject heading terms Free text terms 
Treponema 
pallidum 
Treponema pallidum OR syphilis AND “pregnant women” 
AND Africa 
Treponema pallidum and pregnant and Africa 
Treponema pallidum and pregnancy and Africa 
Syphilis and pregnant and Africa 
Syphilis and pregnancy and Africa 
Screen and syphilis and pregnant and Africa 
Screen and syphilis and pregnancy and Africa 
Test and syphilis and pregnant and Africa 
Test and syphilis and pregnancy and Africa 
Neisseria 
gonorrhoea 
Neisseria gonorrhoeae OR Gonorrhoea OR Gonorrhoea AND 
Pregnant women AND Africa 
Neisseria gonorrhoea and pregnant and Africa 
Neisseria gonorrhoea and pregnancy and Africa 
Gonorrhoea and pregnant and Africa 
Gonorrhea and pregnancy and Africa 
Screen and gonorrhoea and pregnant and Africa 
Screen and gonorrhea and pregnant and Africa 
Test  and gonorrhoea and pregnant and Africa 
Test and gonorrhea and pregnant and Africa 
Chlamydia 
trachomatis 
Chlamydia trachomatis and Pregnant women AND Africa Chlamydia trachomatis and pregnant and Africa 
Chlamydia trachomatis and pregnancy and Africa 
Screen and Chlamydia and pregnant and Africa 
Screen and Chlamydia and pregnancy and Africa 
Test and Chlamydia and pregnant and Africa 
Test and Chlamydia and pregnancy and Africa 
Trichomonas 
vaginalis 
Trichomonas vaginalis and Pregnant women AND Africa Trichomonas vaginalis and pregnant and Africa 
Trichomonas vaginalis and pregnancy and Africa 
Trichomoniasis and pregnant and Africa 
Trichomoniasis and pregnancy and Africa 
Screen and Trichomoniasis and pregnant and Africa 
Screen and Trichomoniasis and pregnancy and Africa 
Test and Trichomoniasis and pregnant and Africa 
Test and Trichomoniasis and pregnancy and Africa 
Bacterial vaginosis Bacterial vaginosis and Pregnant women AND Africa Bacterial vaginosis and pregnant and Africa 
Bacterial vaginosis and pregnancy  and Africa 
Screen and Bacterial vaginosis and pregnant and Africa 
Screen and Bacterial vaginosis and pregnancy  and Africa 
Test and Bacterial vaginosis and pregnant and Africa 
Test and Bacterial vaginosis and pregnancy  and Africa 
Malaria Malaria and Pregnant women AND Africa Malaria  and pregnant and Africa 
Malaria and pregnancy  and Africa 
Screen and malaria  and pregnant and Africa 
Screen and malaria and pregnancy  and Africa 
Test and malaria and pregnant and Africa 
Test and malaria and pregnancy  and Africa 
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Appendix 1.2a: Peripheral malaria point prevalence estimates among pregnant women in Zambia and surrounding countries 
Site 
Year study conducted 
Reference No. 
women 
positive 
No. tested Prevalence 95% CI Diagnostic method 
Chikwawa, Malawi (1993-94) 
Chikwawa, Malawi (1993-95) 
Blantyre, Malawi (1997-98) 
Blantyre, Malawi (1997-98) 
Kigoma, Tanzania (NR) 
Manhica, Mozambique (1998) 
Blantyre, Malawi (2000) 
Sofala, Mozambique (2003-04) 
Morogoro, Tanzania (2001-02) 
Multicenter, Mozambique (2003-04) 
Multicentre, Mozambique (2004) 
Southern Malawi (2004-05) 
Mongochi, Malawi (2003-04) 
Blantyre, Malawi (1997-2001) 
300 DHS geographic clusters, DRC 
Sambizanga and Ingombota, Angola 
(2006-2007) 
Manhica, Mozambique (2003-04) 
Manhica, Mozambique (2003-2005) 
Luanda, Angola (2008) 
Nchelenge, Zambia (2013) 
Mansa , Zambia (2009-2010) 
Machinga, Malawi (2010-2011) 
 
Verhoeff, 1998 [293] 
Verhoeff, 1999 [294] 
Rogerson, 2000 [141] 
Rogerson, 2000 [88] 
Mnyika, 2000[295] 
Saute 2002 [296] 
Mankhambo, 2002[297] 
Montoya, 2006 [298] 
Wort,2006 [142] 
Brentlinger,2007 [299] 
Lujan,2008 [300] 
Van Den Broek, 2009[301] 
Rantala,  2010 [95] 
Feng, 2010 [1]* 
Taylor, 2011 [144]*                   
valente, 2011[89]* 
 
Serra-Casas, 2011 [143] 
Mayor, 2012 [302]* 
Campos,2012 [145] * 
Siame, 2015[115]* 
Mace, 2012 [90]* 
Gutman, 2015 [261]* 
109 
743 
2034 
85 
66 
158 
70 
78 
493 
255 
52 
571 
51 
798 
193 
49 
 
120 
26 
74 
83 
21 
760 
575 
3913 
4764 
339 
705 
686 
135 
587 
1684 
684 
1117 
2297 
475 
7671 
520 
567 
 
399 
272 
679 
375 
419 
2,566 
18.9 
19.0 
42.7 
25.1 
9.4 
23.0 
51.9¥¥ 
13.3 
29.3 
37.3 
4.7
¥
 
24.9 
10.7       
10.4 
37.2 
8.6 
 
30.0 
9.5
 
10.9 
22 
5.0 
29.6 
 
15.7-22.1 
17.8-20.2 
41.3-44.1 
20.5-29.7 
7.3-11.6 
19.8-26.2 
43.5-60.3 
10.6-16.1 
27.1-31.5 
33.7-40.9 
3.5-5.9 
23.1-26.7 
7.9-13.5 
9.7-11.1 
33.3-41.7 
6.3-10.9 
 
25.5-34.5 
6.0-13.0 
8.6-13.2 
17.8-26.2 
2.9-7.1 
27.8-31.2 
Giemsa stain microscopy 
Giemsa stain microscopy 
PCR 
Giemsa stain microscopy 
Giemsa stain microscopy 
Giemsa stain microscopy 
PCR 
Giemsa stain microscopy 
Giemsa stain microscopy 
Giemsa stain microscopy 
Giemsa stain microscopy 
Giemsa stain microscopy 
PCR  
Giemsa stain microscopy 
PCR 
PCR 
 
PCR 
Giemsa stain microscopy 
Giemsa stain microscopy 
PCR 
Giemsa stain microscopy 
RDT 
 
PCR: polymerase chain reaction 
*Studies that did not contribute to the pooled prevalence estimates in the meta-analysis by Chico et al. 2012 [6] 
¥¥
 Highest prevalence estimate 
¥
Lowest prevalence estimate 
Rapid diagnostic test 
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Appendix 1.2b: Placental malaria point prevalence estimates among pregnant women in Zambia and surrounding countries 
 
Site 
Year study conducted 
Reference No. women 
positive 
No. 
tested 
Prevalence 95% CI Diagnostic method 
North Kivu, DRC (NR) 
Blantyre, Malawi (1997-99) 
Blantyre, Malawi (NR) 
Kinshasa, DRC (2004) 
Chikwakwa, Malawi (2004-05) 
Muheza, Tanzania (2002-05)  
Muheza, Tanzania (2002-05) 
Blantyre, Malawi (1997-2001) 
Luanda,Angola 
Manhica, Mozambique (2003-05) 
Manhica, Mozambique (2003-05) 
Mansa, Zambia (2009-2010) 
Rufiji, Tanzania (2012) 
Moshi, Tanzania (2012) 
Meuris, 1993[303] 
Rogerson, 2000[88] 
Rogerson, 2003 [104] 
Lukuka, 2006 [304] 
Senga, 2007[305] 
Mwangoka, 2008 [306] 
Kabyemela, 2008 [146]  
Feng, 2010 [1] 
Valente, 2011 [89]* 
Serra-Casas, 2011 [143]  
Mayor, 2012 [302]* 
Mace, 2012 [90] * 
Mosha, 2014 [147]*  
Mosha, 2014 [147] 
242 
77 
124 
41 
124 
100 
55 
1058 
99 
110 
156 
161 
29 
4 
461 
232 
464 
196 
636 
1,022 
445 
7671 
567 
342 
272 
435 
175 
175 
52.5 
33.2 
26.7 
21.0 
19.5 
9.8 
12.4 
13.8 
17.5 
32.1 
57.4
¥¥
 
37.2 
16.6 
2.3
¥
 
 
47.9-57.1 
27.1-39.3 
22.6-30.7 
15.3-26.7 
16.4-22.6 
8.0-11.6 
9.3-15.5 
13.0-14.4 
14.4-20.6 
27.2-37.1 
51.5-63.3 
32.7-41.7  
11.1-22.1 
0.1-4.5 
Placental histology 
Placental impression and  blood  smear  with microscopy 
Placental histology, impressions, smear with microscopy 
Placental impression and  blood  smear  with microscopy 
Placental histology and  blood smear with microscopy  
Placental blood microscopy 
Placental impression and  blood  smear  with microscopy 
Placental blood microscopy 
PCR 
PCR 
Placental histology 
Placental  histology 
PCR 
PCR 
PCR: polymerase chain reaction 
*Studies that did not contribute to the pooled prevalence estimates in the meta-analysis by Chico et al. 2012 [6] 
¥¥
 Highest prevalence estimate 
¥
Lowest prevalence estimate 
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Appendix 1.2c: Syphilis point prevalence estimates among pregnant women in Zambia and surrounding countries 
Site 
Year study conducted 
Reference No. 
women 
positive 
No. 
tested 
Prevalence 95% CI diagnostic method 
Vilanculos, Mozambique (1991-92) 
Umzigwana, Zimbabwe (1991) 
Zambiazai, Mozambique (1992-93) 
Mwanza, Tanzania(1992-93) 
Dar es Salaam, Tanzania (1993) 
Rwandan Camp, Tanzania (1994) 
Mwanza, Tanzania (NR) 
Mwanza, Tanzania (1994) 
Blantyre, Malawi (1995) 
Blantyre, Malawi (1996) 
Murewa, Zimbabwe 
Murewa, Zimbabwe 
Mwanza,Tanzania (2002) 
Gutu, Zimbabwe (NR) 
Harare, Zimbabwe (NR) 
Sofala, Mozambique (2003-04) 
Gaborone, Botswana (2000-01) 
Multicentre, Tanzania (2003-04) 
ZDHS sites, Zambia 
Blantyre, Malawi (2000-04) 
Kinshansa, DRC (2004) 
Multicentre, Mozambique (2004)  
Rural Tanzania (2003-04) 
Manhica, Mozambique  
Moshi, Tanzania (2002-04) 
Southern Malawi (2004-05) 
Manhica, Mozambique (2000) 
Harare, Zimbabwe (2002-03) 
Harare, Zimbabwe (2002-04) 
Sentinel sites, Congo DR (2011) 
Multiple, Tanzania (2008-2010) 
Mwanza, Tanzania (2012) 
Multicentre, Tanzania (2011) 
Kalomo, Zambia (2012) 
Vuylsteke, 1993[307] 
Rutgers, 1993[308] 
Cossa, 1994[131] 
Mayaud, 1995 [126] 
Mwakagile, 1996 [129] 
Mayaud, 1997[309] 
Mayaud, 1997 [310] 
Mayaud, 1998[311] 
Taha, 1998 [312] 
Taha, 1999 [313] 
Kambarami, 1998 [314] 
Kambarami, 1998 [314] 
Watson-Jones,2002 [10] 
Majoko, 2003 [315] 
Pham, 2005[132] 
Montoyo, 2006[298] 
Romeron, 2006 [316] 
Swai, 2006 [136] 
CSO, 2007  [317] 
Kwiek, 2008 [137]  
Kanoshita-Moleka, 2008[318]  
Lujan, 2008 [300] 
Yahya-Malima 2008 [133] 
Menendez 2008 [319] 
Msuya, 2009[221]* 
Van Den Broek, 2009 [301] 
Menendez, 2010 [139] 
Kurewa, 2010 [128] 
Mapingure, 2010 [320] 
Taylor, 2014 [321]* 
Chiduo, 2012 [322]* 
Hokororo, 2015 [130]* 
Manyahi, 2015 [138]* 
Bonawirz, 2015 [323]* 
 31 
198 
211 
97 
31 
2 
174 
45 
98 
1005 
36 
28 
106 
9 
74 
33 
35 
92 
5 
199 
0 
52 
21 
122 
24 
163 
31 
8 
8 
742 
284 
21 
973 
50 
 
201 
1433 
1728 
964 
777 
100 
2380 
628 
808 
9309 
366 
308 
1809 
85 
2969 
381 
703 
1,265 
128 
3824 
529 
1117 
1296 
1030 
2654 
2297 
258 
678 
662 
17,669 
25,802 
403 
38,920 
1868 
14.6
¥¥
 
13.8 
12.2 
10.1 
4.0 
2.0 
7.3 
7.2 
12.1 
10.8 
9.8 
9.2 
5.9 
10.6 
2.5 
8.6 
5.0 
7.3   
4.1 
5.2 
0.0
¥
 
4.7 
1.6 
11.8 
0.9 
7.1 
12.0 
1.2 
1.2 
4.2 
1.1 
5.2 
2.5 
2.7 
9.7-19.5 
12.0-15.6 
10.7-13.7 
8.2-12.0 
2.6-5.4 
0.7-4.7 
6.2-8.4 
5.2-9.2 
9.8-14.7 
10.2-11.4 
6.8-12.9 
6.0-12.4 
4.8-7.0 
4.1-17.1 
1.9-3.1 
5.8-11.4 
3.4-6.6 
5.9-8.7 
2.9-5.3 
4.5-5.9 
0-0 
3.5-5.9 
0.9-2.3 
9.8-13.8 
0.5-1.3 
6.1-8.2 
8.0-16.0 
0.4-2.0 
0.4-2.0 
3.9-4.5 
1.0-1.2 
3.0-7.4 
2.3-2.7 
2.3-3.4 
 
RPR and TPHA 
RPR only 
RPR and MHA-TP 
RPR and TPHA 
RPR and TPHA 
RPR and TPHA 
RPR and TPHA 
RPR and TPHA 
RPR and TPHA 
RPR and TPHA 
RPR and TPHA 
VDRL and TPHA 
RPR and TPHA 
RPR only 
RPR and TPHA 
RPR and TPHA 
RPR and TPHA 
RPR only 
RPR and TPHA 
RPR and TPHA 
RPR and TPHA 
RPR and TPHA 
RPR and TPHA 
RPR only 
RPR and Determine Syphilis TP 
VDRL only 
RPR and enzyme immunoassay 
RPR and TPHA 
RPR and Determine Syphilis TP 
RPR and Determine Syphilis TP 
RPR and TPHA 
RPR and TPPA 
RPR only 
Rapid syphilis test 
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Appendix 1.2c: Syphilis point prevalence estimate among pregnant women in Zambia and surrounding countries continued 
RPR: Rapid plasma reagin 
TPHA: Treponema pallidum haemagglutination assay 
TPPA: Treponema pallidum particle agglutination 
VDRL: Venereal disease research laboratory 
FTA-Abs-Fluorescent treponemal antibody absorption  
MHA-TP: Micro heamagglutination assay-Treponema pallidum 
CSO-Central statistical Office. 
*Studies that did not contribute to the pooled prevalence estimates in the meta-analysis by Chico et al. 2012 [6] 
¥¥
 Highest prevalence estimate 
¥
Lowest prevalence estimate 
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Appendix 1.2d: Chlamydia trachomatis point prevalence estimates among pregnant women in Zambia and surrounding countries 
Site 
Year study conducted 
Reference No. 
women 
positive 
No. 
tested 
Prevalence 95% CI Diagnostic method 
Vilancolus, Mozambique (1991-92) 
Kinshasa, DRC (1990) 
Mwanza,Tanzania  (1992) 
Mwanza, Tanzania (1994) 
Harare, Zimbabwe  
Gaborone, Botswana (2001-01) 
Multicentre, Mozambique (2004) 
Kinshasa, DRC (2004) 
Moshi, Tanzania (2002-04) 
Manhica,Mozambique (2000) 
Mwanza, Tanzania (2012) 
Vuylsteke, 1993 [307] 
Vuylsteke, 1993 [324] 
Mayaud, 1995 [126] 
Mayaud,  1998 [311] 
Latif, 1999 [125]* 
Romoren, 2004 [325] 
Lujan, 2008 [300] 
Kanoshita-Moleka, 2008 [318] 
Msuya, 2009 [221]* 
Menendez, 2010 [139] 
Hokororo, 2015[130]* 
11 
75 
64 
39 
88 
42 
51 
9 
183 
15 
48 
 
141 
1,160 
964 
660 
1656 
557 
835 
521 
1048 
151 
403 
 
7.8 
6.5 
6.6 
5.9 
5.3
¥ 
 
7.5 
6.1 
1.7 
17.5¥¥ 
9.9 
11.4 
 
3.4-12.2 
5.1-7.9 
5.0-8.2 
4.1-7.7 
4.2-6.4 
5.1-9.5 
4.8-7.7 
0.6-2.8 
15.2-19.8 
5.1-14.7 
8.2-14.4 
Culture 
EIA 
EIA 
EIA 
EIA 
LCR cervical swab 
LCR cervical swab 
PCR cervical swab 
ELISA 
DNA ID-assay cervical swabs 
PCR 
PCR: polymerase chain reaction 
*Studies that did not contribute to the pooled prevalence estimates in the meta-analysis by Chico et al. 2012 [6] 
¥¥
 Highest prevalence estimate 
¥
Lowest prevalence estimate 
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Appendix 1.2e: Neisseria gonorrhoeae point prevalence estimates among pregnant women in Zambia and surrounding countries  
Site 
Year study conducted 
Reference No. women 
positive 
No. 
tested 
Prevalence 95% CI Diagnostic method 
Kinshasa, DRC (1990) 
Vilanculos, Mozambique (1991-92) 
Mwanza, Tanzania (1992-93) 
Dar es Salaam, Tanzania (1993) 
Mwanza, Tanzania (1994) 
Blantyre, Malawi (1993) 
Blantyre, Malawi (1995) 
Harare, Zimbabwe 
Blantyre, Malawi (1995) 
Gaborone, Botswana (2000-01) 
Multicentre, Mozambique (2004) 
Moshi, Tanzania (2002-04) 
Manhica, Mozambique (2000) 
Mwanza, Tanzania (2012) 
Vuylsteke,1993 [324] 
Vuylsteke,1993[307] 
Mayaud,1995 [126] 
Mwakagile 1996 [129] 
Mayaud, 1998 [311] 
Taha, 1998 [312] 
Taha, 1998[312] 
Latif 1999 [125]* 
Taha, 1999 [313] 
Romeron, 2007  [127] 
Lujan, 2008 [300] 
Msuya, 2009 [221]* 
Menendez, 2010 [139] 
Hokororo, 2015 [130]* 
19 
14 
20 
28 
15 
54 
20 
65 
373 
21 
21 
13 
27 
27 
1,160 
201 
964 
777 
660 
2161 
808 
1656 
9104 
703 
835 
2555 
145 
403 
1.6 
7.0 
2.1 
3.6 
2.3 
2.5 
2.5 
3.9 
4.1 
3.0 
2.5 
0.5
¥
 
18.6¥¥ 
6.7 
0.9-2.3 
3.5-10.5 
1.2-3.0 
1.9-4.3 
1.2-3.4 
1.8-3.2 
1.4-3.6 
3.0-4.8 
3.2-5.0 
1.7-4.3 
1.4-3.6 
0.2-0.8 
12.2-24.8 
4.3-9.1 
Culture 
Culture 
Culture 
Culture 
Culture 
Culture 
Culture 
Culture 
LCR cervical swab 
Culture 
PCR urine     
Culture and gram stain 
Culture and gram stain 
PCR 
 
PCR: polymerase chain reaction 
*Studies that did not contribute to the pooled prevalence estimates in the meta-analysis by Chico et al. 2012 [6] 
¥¥
Highest prevalence estimate 
¥
Lowest prevalence estimate 
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 Appendix 1.2f: Trichomonas vaginalis point prevalence estimates among pregnant women in Zambia and surrounding countries 
Site 
Year study conducted 
Reference No. women 
positive 
No. tested Prevalence 95% CI Diagnostic method 
Kinshasa, DRC (1990) 
Vilancolus, Mozambique (1991-92) 
Dar es Salaam, Tanzania (1993) 
Rwadan camp, Tanzania (1994) 
Mwanza, Tanzania (1994) 
Blantyre, Malawi (1993) 
Harare, Zimbabwe 
Blantyre, Malawi (1994) 
Gaborone, Botswana (2000-01) 
Moshi, Tanzania (2002-2004) 
Ndola, Zambia (NR) 
Manhica, Mozambique (2000) 
Moshi, Tanzania (2002-04) 
Harare, Zimbabwe (2002-04) 
Harare, Zimbabwe (2000) 
Mwanza, Tanzania (2012) 
Vuylsteke,1993 [324] 
Vuylsteke 1993[307] 
Mwakangile 1996[129] 
Mayaud, 1997[309] 
Mayaud, 1998 [311] 
Taha, 1998 [312] 
Latif,  1999 [125] 
Taha, 1999 [313]  
Romoren, 2007[326] 
Msuya, 2009 [221]* 
Crucitti, 2010 [327]* 
Menendez 2010 [139] 
Mapingure, 2010 [320] 
Mapingure, 2010 [320] 
Kurewa, 2010 [128] 
Hokororo, 2015 [130]* 
213 
46 
176 
31 
108 
19 
22 
215 
132 
128 
99 
78 
128 
80 
80 
54 
1,160 
201 
777 
100 
660 
808 
1656 
9137   
 703 
2555 
307 
254 
2555 
680 
678 
403 
18.4 
22.9 
22.7 
31.0 
16.4 
2.4
¥
 
13.0 
31.1 
18.8  
5.0 
32.2¥¥ 
30.7 
5.0 
11.8 
11.8 
13.4 
16.2-20.6 
17.1-28.7 
19.8-25.7 
21.9-40.1 
13.6-19.2 
1.3-3.5 
11.4-14.6 
30.1-32.1 
15.9-21.7 
4.2-5.8 
27.0-37.4 
25.0-36.4 
4.2-5.9 
9.4-14.2 
9.4-14.3 
10.1-16.7 
Wet-mount microscopy 
Wet-mount microscopy  
Wet-mount microscopy 
Wet-mount microscopy  
Wet-mount microscopy 
Wet-mount microscopy 
Wet-mount microscopy 
Wet-mount microscopy 
Wet-mount microscopy 
Wet-mount microscopy 
PCR  
Wet-mount microscopy 
Wet-mount microscopy  
Wet-mount microscopy 
Wet-mount microscopy 
Wet-mount microscopy 
PCR: polymerase chain reaction 
*Studies that did not contribute to the pooled prevalence estimates in the meta-analysis by Chico et al. 2012 [6] 
¥¥
Highest prevalence estimate 
¥
Lowest prevalence estimate 
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Appendix 1.2g: Bacterial vaginosis point prevalence estimates among pregnant women in Zambia and surrounding countries 
Site 
Year study conducted 
Reference No. 
women 
positive 
No. 
tested 
Prevalence 95% CI Diagnostic method 
Rwadan camp, Tanzania (1994) 
Mwanza, Tanzania (1994) 
Harare, Zimbabwe 
Blantyre, Malawi (1993) 
Multicentre, Zimbabwe (1999-2004) 
Gaborone, Botswana (2000-01) 
Tanzania (1999-2004) 
Harare, Zimbabwe (2002-04) 
Moshi, Tanzania (2002-04) 
Harare, Zimbabwe (2002-03)  
Mwanza, Tanzania (2011) 
Mwanza, Tanzania (2012) 
Mayaud, 1997 [309]  
Mayaud, 1998 [311] 
Latif, 1999 [125]* 
Taha, 1999  [313] 
Toloso, 2006 [328] 
Romoren, 2007 [326] 
Msuya, 2009 [221]* 
Mapingure, 2010 [320] 
Mapingure, 2010 [320] 
Kurewa,2010 [128]  
Shayo, 2012[329] 
Hokororo, 2015 [130]* 
16 
159 
71 
640 
51 
264 
534 
195 
534 
221 
81 
102 
100 
660 
1656 
2077 
209 
703 
2555 
598 
2555 
678 
284 
403 
16.0 
24.1 
4.3
¥
 
30.8 
24.4 
37.6¥¥ 
20.9  
32.6 
20.9 
32.6 
28.5 
25.3 
8.8-23.2 
20.8-27.4 
3.3-5.3 
28.8-32.8 
18.6-30.2 
34.0-41.2 
19.3-22.5 
28.8-36.4 
19.3-22.5 
29.1-36.1 
23.2-33.6 
21.1-29.5 
Clue cell count  
Clue cell count 
Amsel 
Amsel 
Nugent 
Nugent 
Amsel 
Amsel 
Amsel 
Amsel 
Nugent 
Nugent 
*Studies that did not contribute to the pooled prevalence estimates in the meta-analysis by Chico et al. 2012 [6] 
¥¥
 Highest prevalence estimate 
¥
Lowest prevalence estimate 
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Appendix 1.3: Diagnostic Methods and published Sensitivity and Specificity Measures 
Infection Diagnostic method Sensitivity Specificity 
Syphilis Treponema pallidum haemagglutination assay ˷ 100 ˷100 [330] 
Rapid plasma regain (RPR) only 86-100 93-98 [116] 
Venereal disease research laboratory (VDRL) 78-100  98 [116] 
RPR or VDRL ˷ 100 ˷ 100 [6] 
RPR and TPHA  ˷ 100 ˷ 100 [6] 
RPR and Determine Syphilis TP ˷ 100 ˷ 100 [6] 
RPR and Microhemagglutination assay-Treponema pallidum (MHA-TP) ˷ 100 ˷ 100 [6] 
RPR and Immunoglobulin G (ELISA test) ˷ 100 ˷ 100 [6] 
Neisseria gonorrhoeae Gram stain 50-70 95-100 [331] 
Polymerase chain reaction (PCR) with cervical swab 36-75 98-100 [332] 
Culture ˷ 80 100 [117] 
Culture and Gram stain  ˷ 80 100 [6] 
Ligase chain reaction (LCR) with cervical swab 95-100 98-100 [117] 
PCR with cervical swab 89-97 94-100 [117] 
Chlamydia trachomatis Culture cervical swab 74-90 98-99 [117] 
Enzyme immunoassay (EIA) 71-87 97-99 [117] 
Culture cervical swab or EIA (score based on the less precise method, i.e mean of EIA) 71-87 97-99 [6] 
PCR urine 78-89 99-100 [332] 
LCR cervical culture 90-97 99-100 [117] 
PCR cervical swab 99 99-100 [117] 
Deoxyribonucleic acid identification assay-cervical swab  ˷ 100 ˷100 [6] 
Trichomonas vaginalis Wet mount microscopy 38-82 100 [117] 
In-pouch culture 96 100 [333] 
PCR 97 98 [334] 
Bacterial vaginosis Clue cells ≥ 20% of epithelium 40 97 [121] 
Amsel criteria: 3 or 4 of 4 51 98 [121] 
Nugent score ≥ 7 86-89 94-96 [122-124] 
Peripheral parasitaemia Giemsa stain microscopy 50 -90 ˷ 95 [91-93] 
PCR 91 91[95] 
Antigen  assay Reported as equal to microscopy [6] 
Rapid diagnostic test 89 76  
Placental parasitaemia Placental blood microscopy  63 98-99 [104] 
PCR 93-99 73-76 [335] 
Placental histology 91 98-99 [104] 
Placental blood microscopy and tissue histology (score based on more precise method, i.e histology 91 ˷ 100 [6] 
Placental histology, impression, smears with microscopy (score based on most precise method i.e. histology 91 ˷ 100 [6] 
Placental impression and blood smear with microscopy (score based on more precise method, i.e. impression 91 ˷ 100 [105] 
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Appendix 1.4: Risk factors for malaria and STIs/RTIs 
Infection Site,  country (year) First Author, Year of 
publication 
 
Risk factors for infection 
Treponema pallidum Vilanculos, Mozambique (1991-92) Vuylsteke, 1993[307] NR 
Umzigwana, Zimbabwe (1991) Rutgers, 1993[308] NR 
Zambiazai, Mozambique (1992-93) 
 
Cossa, 1994[131] 
 
The following factors were associated with infection; married status 
(aOR 2.5, 95% CI, 1.0-6.1), history of past STD (aOR5.6; 95% CI, 3.3-
9.4), genital ulcers (aOR 3.7; 95% CI, 1.4-9.8), vaginal discharge (OR 
1.5; 95% CI, 1.0- 2.1), genital warts (aOR 3.0; 95% CI, 1.1- 8.7), HIV 
infection (aOR 2.2; 95% CI, 1.0-5.0), and being from Nicoadala district 
(aOR 6.8; 95%CI, 1.7-58.1). 
Mwanza, Tanzania(1992-93) Mayaud, 1995 [126] NR 
Dar es Salaam, Tanzania (1993) 
 
Mwakagile, 1996 [129] 
 
Higher prevalence of syphilis, trichomoniasis and gonorrhoea  in 
teenagers  than older women (45.3% verses 29.2, P < 0.001) 
Rwandan Camp, Tanzania (1994) Mayaud, 1997[309] NR 
Mwanza, Tanzania (NR) Mayaud, 1997 [310] NR 
Mwanza, Tanzania (1994) Mayaud, 1998[311] NR 
Blantyre, Malawi (1995) Taha, 1998 [312] NR 
Blantyre, Malawi (1996) Taha, 1999 [313] NR 
Murewa, Zimbabwe Kambarami, 1998 [314]  RPR positivity was not significantly associated with the women's age 
or parity.  
Mwanza,Tanzania (2002) Watson-Jones,2002 [10] NR 
Gutu, Zimbabwe (NR) Majoko, 2003 [315] NR 
Harare, Zimbabwe (NR) 
 
Pham, 2005[132] 
 
 Increases in parity and gravidity were significantly associated with 
increased risk of syphilis infection. Prior stillbirths were associated 
with an increased risk of syphilis infection (odds ratio [aOR], 3.4; 95% 
CI, 1.61 to 7.37; P = 0.001). 
Sofala, Mozambique (2003-04) Montoyo, 2006[298] NR 
Multicentre, Tanzania (2003-04) 
 
 
Swai, 2006 
 
 
Women living in rural areas had higher prevalence than those in urban 
areas (P < 0.0001).Marital status did not appear to influence the 
prevalence of syphilis. There was a higher likelihood of having syphilis 
for women aged > 34 years compared to those less than 34 years. 
Women with no education were more likely to be infected with 
syphilis than were women with some education (P < 0.0001) 
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Appendix 1.4: Risk factors for malaria and STIs/RTIs continued 
Infection Site,  country (year) First Author, Year of 
publication 
Risk factors for infection 
Treponema palllidum ZDHS sites, Zambia CSO, 2007  [317] NR 
Moshi, Tanzania (2002-04) Msuya,  2007[336] NR 
Blantyre, Malawi (2000-04) 
 
Kwiek, 2008 [137]  
 
Syphilis seroreactivity was associated with anemia (aOR: 1.4, 95% CI 
1.0, 1.9), previous diagnosis of STI (aOR: 5.3, 95%CI: 3.5, 8.0), rural 
residence, multigravidity.  Self-reported history of miscarriage or 
stillbirth (aOR: 2.3, 95%CI: 1.6, 3.5) Syphilis seroreactivity was inversely 
associated with maternal education (χ
2
(trend)=17, P <0.0001). 
Syphilis was not associated with maternal employment, cost of 
housing material, being a Yao, or marital status.  
 
Kinshansa, DRC (2004) 
 
Kanoshita-Moleka, 2008[318] NR 
Multicentre, Mozambique (2004)  Lujan, 2008 [300] No factors were independently  associated with  syphilis infection 
 
Rural Tanzania (2003-04) 
 
Yahya-Malima 2008 [133] 
 
Women with self-reported previous spontaneous abortion were more 
likely to have a positive syphilis serology (aOR 4.3, 95% CI: 1.52–
12.02), infection with syphilis not associated with self-reported 
stillbirth (OR 2.4, 95% CI: 0.64–8.95).Odds were also higher for women 
who had more than one lifetime sexual partner, OR 5.4 (95% CI: 1.88–
15.76).  
Manhica, Mozambique  Menendez 2008 [319] NR 
Moshi, Tanzania (2002-04) Msuya, 2009[221]* NR 
Southern Malawi (2004-05) Van Den Broek, 2009[301] NR 
Manhica, Mozambique (2000) 
 
Menendez, 2010 [139]** 
 
 Being divorced/widowed (aOR 3.6; 95% CI, 0.6-21.9) 
 was  associated with syphilis infection 
Harare, Zimbabwe (2002-03) 
 
Kurewa, 2010 [128] 
 
Risk factors for a positive serologic STI* were increasing age above 30 
years ( aOR  2.61; 95% CI, 1.49-4.59), polygamy (aOR 2.16; 1.06-4.39), 
and multigravid (aOR 3.89: 1.27-11.98), number of lifetime sexual 
partners (aOR 2.8; 1.2-6.2) and partner taking alcohol (aOR 1.16; 1.01-
1.33).  
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Appendix 1.4: Risk factors for malaria and STIs/RTIs continued 
Infection Site,  country (year) First Author, Year of publication Risk factors for infection 
Treponema pallidum Harare, Zimbabwe (2002-04) Mapingure, 2010 [320] NR 
Sentinel sites, Congo DR (2011) 
 
Taylor, 2014 [321] 
 
Syphilis seropositivity was significantly higher among women 
attending rural clinics (5.0%) as compared to urban clinics (3.0%) and 
those tested in antenatal care clinics in the provinces of Equateur 
(7.6%) and Orientale (7.7%) as compared to other provinces P < 
 0.001).  
 
Mwanza, Tanzania (2012) 
 
Hokororo, 2015 [130] 
 
The presence of any STI
α
 was associated with being in a long-term 
(as opposed to short-term) relationship (aOR 2.6; 95% CI 1.4 - 4.9, 
increasing age difference between the girl and her partner (aOR 1.1; 
95% CI 1.0 -1.1 per year, and history of prior pregnancy (aOR 1.6; 
95% CI 1.0 - 2.6).  
 
Multicentre, Tanzania (2011) 
 
Manyahi, 2015 [138] The risk for syphilis infection was significantly higher among women 
attending semi-urban and rural clinics than those attending urban 
clinics and those having 3-4 (aOR 1.50; 95% CI, 1.17-1.92) and 5 (aOR 
1.70, 95% CI, 1.27-2.27) previous pregnancies. Marital status and 
level of education were not statistically significant  
Neisseria gonorrhoea Kinshasa, DRC (1990) Vuylsteke,1993 [324] NR 
Mwanza,Tanzania  (1992) 
 
Mayaud, 1995 [126] 
 
Chlamydia/gonorrhoea 
Age < 25 years (aOR=2.2, P < 0.003; Unmarried (aOR= 3.2, P < 0.003; 
in polygamous marriage (aOR  = 2.3, P < 0.003; > one sexual partner 
over the previous year (aOR = 1.7, P < 0.06; previously delivered 
more than 5 years (OR=3.2, P  <  0.01 
Dar es Salaam, Tanzania (1993) Mwakagile 1996 [129] As stated  for this paper under syphilis (infections combined) 
Blantyre, Malawi (1995) Taha, 1999 [313] NR 
Harare, Zimbabwe Latif 1999 [125] 
 
 Women with vaginal discharge: being separated from the partner 
for a month or more (P = 0.002), having had sex with a new partner 
in the previous three months (P = 0.002), current use of condoms (P 
= 0.011 presence of  a purulent vaginal discharge (P = 0.004). 
increasing educational level was inversely associated with cervical 
infection (P = 0.007).  
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Appendix 1.4: Risk factors for malaria and STIs/RTIs continued 
Infection Site,  country (year) First Author, Year of publication Risk factors for infection 
Neisseria 
gonorrhoeae 
Gaborone, Botswana (2000-01) 
 
Romeron, 2007  [127] 
 
Compared to Women aged 30 and above, women aged 20-29 (aOR 
4.0; 1.60-10.10) and below 20 (aOR 10.5; 3.59-30.72) had a higher 
risk of infection with Chlamydia and/or gonorrhoea. 
Multicentre, Mozambique (2004) Lujan, 2008 [300] No factors were independently  associated with infection 
gonorrhoea 
Moshi, Tanzania (2002-04) Msuya, 2009 [221]* NR 
Manhica, Mozambique (2000) 
 
Menendez, 2010 [139] 
 
Women with more than one lifetime sexual partner  were at a 
higher risk of being seropositive for gonorrhoea than women with 
one lifetime sexual partner (aOR 2.8; 1.2-6.3) 
Mwanza, Tanzania (2012) Hokororo, 2015 [130] As stated  for this paper under syphilis (infections combined) 
Chlamydia trachomatis Vilancolus, Mozambique (1991-92) Vuylsteke, 1993 [307] NR 
Kinshasa, DRC (1990) Vuylsteke, 1993 [324] NR 
Mwanza,Tanzania  (1992) 
 
Mayaud, 1995 [126] 
 
As stated for this paper  under gonorrhoea (the two infections 
were combined) 
Harare, Zimbabwe Latif, 1999 [125]* As stated for this paper  under gonorrhoea (the two infections 
were combined) 
Gaborone, Botswana (2001-01) Romoren, 2004 [325] NR 
Multicentre, Mozambique (2004) Lujan, 2008[300] No factors were independently  associated with infection 
Chlamydia 
Kinshasa, DRC (2004) 
 
Kanoshita-Moleka, 2008 [318] NR 
Moshi, Tanzania (2002-04) Msuya, 2009 [221]* NR 
Manhica,Mozambique (2000) 
 
Menendez, 2010 [139] 
 
Infection with chlamydia was not significantly associated with any 
social or behavioral risk factor 
Mwanza, Tanzania (2012) Hokororo, 2015 [130] As stated for this paper under syphilis (infections were combined) 
Trichomonas vaginalis Kinshasa, DRC (1990) Vuylsteke,1993[324]  NR 
Vilancolus, Mozambique (1991-92) Vuylsteke 1993 [307] NR 
Dar es Salaam, Tanzania (1993) Mwakangile 1996 [129] Prevalence was lower in pregnant women in monogamous 
marriages 
 
Rwadan camp, Tanzania (1994) Mayaud, 1997[309] NR 
Mwanza, Tanzania (1994) Mayaud, 1998 [311] NR 
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Appendix 1.4: Risk factors for malaria and STIs/RTIs continued 
Infection Site,  country (year) First Author, Year of publication 
 
Risk factors for infection 
Trichomonas vaginalis Blantyre, Malawi (1993) Taha, 1999 [313]  NR 
Gaborone, Botswana (2000-01) Romoren, 2007[326] NR 
Ndola, Zambia (NR) Crucitti, 2010 [327]* NR 
Manhica, Mozambique (2000) 
 
Menendez 2010 [139] 
 
Women with anogenital warts were at increased risk of having 
trichomoniasis (aOR 7.1, 95% CI, 1.4-36.5) 
Multicentre Mapingure, 2010 [320] NR 
Harare, Zimbabwe (2000) Kurewa, 2010 [128] 
 
For vaginal infections**  it was age at sexual debut; sexual debut 
before 20 years of age  compared to whose sexual debut was 
after 20
th
 birthday 
(aOR  1.60; 95% CI, 1.06-2.42) Being in a polygamous relationship 
was significantly associated with having Trichomonas vaginalis; 
(aOR 2.24, 95% CI, 1.09-4.56). 
Mwanza, Tanzania (2012) Hokororo, 2015 [130]  As stated  for this paper under syphilis (infections were 
combined) 
Bacterial vaginosis Rwadan camp, Tanzania (1994) Mayaud, 1997 [309] NR 
Mwanza, Tanzania (1994) Mayaud, 1998 [311] NR 
Harare, Zimbabwe Latif, 1999 [125] NR 
Multicentre, Zimbabwe (1999-2004) Toloso, 2006 [328] NR 
Harare, Zimbabwe Taha, 1999  [313] NR 
Gaborone, Botswana (2000-01) Romoren, 2007 [326] NR 
Tanzania (1999-2004) Msuya, 2009 [221]* NR 
Moshi, Tanzania (2002-04) and 
Harare, Zimbabwe (2002-04) 
Mapingure, 2010 [320] 
 
NR 
Harare, Zimbabwe (2002-03)  Kurewa,2010 [128] As stated  for this paper under T. vaginalis (infections were 
combined) 
Mwanza, Tanzania (2012) Hokororo, 2015 As stated  for this paper under syphilis (infections were 
combined) 
Peripheral Malaria Macha, Zambia (1989) Larkin, 1991[337] NR 
Chikwawa, Malawi (1993-94) Verhoeff, 1998 [293] NR 
Chikwawa, Malawi (1993-95) Verhoeff, 1999 [294] NR 
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Appendix 1.4: Risk factors for malaria and STIs/RTIs continued 
Infection Site,  country (year) First Author, Year of publication 
 
Risk factors for infection 
Peripheral malaria Blantyre, Malawi (1997-98) 
 
Rogerson, 2000 [141] 
 
 
first attendance at a clinic in the dry season relative to the wet season 
(OR 0.70; 95% CI, 0.62–0.79) and a younger age, < 20 years, (OR 0.97; 
95% CI, 0.95–0.99) were associated with the presence of parasitaemia 
but there was no significant difference in malaria prevalence with 
gravidity as a continuous variable (OR 0.96, 95% CI, 0.90–1.01) 
Blantyre, Malawi (1997-98) 
 
Rogerson, 2000 [88] Gravidity had a significant influence on malaria infection. Peripheral 
parasite prevalence was similar in primigravidae and secundigravidae, 
24.0% and 26.1% respectively but was lower in multigravidae (17.2%) 
 
Kigoma, Tanzania (NR) Mnyika, 2000[295] NR 
Blantyre, Malawi (2000) Mankhambo, 2002[297] NR 
Sofala, Mozambique (2003-04) Montoya, 2006 [298] NR 
Morogoro, Tanzania (2001-02) Wort,2006 [142] Adolescent primigravidae had higher parasite prevalence than 
adolescent secundigravidae (41.3% versus 28.1%, P > 0.05) and adult 
primigravidae (41.3% versus 31.5%, P = 0.007). 
Multicenter, Mozambique (2003-
04) 
Brentlinger,2007 [299] NR 
Southern Malawi (2004-05) Van Den Broek, 2009[301] NR 
Mongochi, Malawi (2003-04) Rantala,  2010 [95] NR 
Blantyre, Malawi (1997-2001) Feng, 2010 [1]* Bed net use protected from peripheral parasitaemia (aOR 0.47; 95% CI, 
0.37, 0.60)  
300 DHS geographic clusters, DRC 
 
Taylor, 2011 [144]*   In a multivariate model only lower wealth (all categories of wealth 
below the highest quintile) was significantly associated with higher 
prevalence of parasitaemia (P < 0.001). No association between age or 
gravidity or area of residence and malaria infection was found. 
Sambizanga and Ingombota, 
Angola (2006-2007) 
 
Valente, 2011[89]* 
 
Women ≤ 18 years old were at a higher risk of infection than women ≥ 
25 years (aOR 2.1; 95% CI, 1.1-4.2).  Women who had self-reported 
malaria infection earlier in pregnancy (aOR 2.0; 95% CI, 1.0-3.9) were at 
a higher risk of infection. No association was found between parity or 
area of residence or the level of education and placental malaria 
infection. 
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Appendix 1.4: Risk factors for malaria and STIs/RTIs continued 
Infection Site,  country (year) First Author, Year of publication Risk factors for infection 
Peripheral malaria Manhica, Mozambique (2003-04) 
 
Serra-Casas, 2011 [143] 
 
Multiparous women were at a reduced risk of peripheral infection 
compared to primiparous women (aOR 0.26; 95% CI, 0.13-0.53) and 
women who had received SP were had reduced risk of infection 
compared to women who had received placebo (aOR 0.30; 95% CI, 0.14-
0.63) 
Manhica, Mozambique (2003-
2005) 
Mayor, 2012 [302]* Prevalence of P. falciparum malaria, both by microscopy and RT-PCR, 
was equal across age and parity groups 
Luanda, Angola (2008) 
 
Campos,2012 [145] 
 
Age, parity and gestational age were not associated with malaria 
infection. Women who had previous malaria during pregnancy also had 
a higher risk of current malaria (aOR 4.86; 95% CI, 1.45-16.25) 
 
Nchelenge, Zambia (2013) 
 
Siame, 2015 [115]* 
 
Ownership of at least one net in their household was not associated 
with malaria. Age was the only factor associated with malaria; women 
aged 30-34 were 64% less likely to have malaria compared to those in 
the reference group 14-18 years old (AOR 0.36; 95% CI, Not reported). 
 
Mansa , Zambia Mace, 2012 [90] NR 
Placental malaria 
 
North Kivu, DRC (NR) Meuris, 1993[303] NR 
Blantyre, Malawi (1997-99) 
 
Rogerson, 2000[88] 
 
Gravidity had a significant influence on malaria infection. Placental 
parasite prevalence was similar in primigravidae and secundigravidae, 
2.5% and 36.2% respectively but was lower in multigravidae (16.0%) 
Blantyre, Malawi (NR) Rogerson, 2003 [104] NR 
Kinshasa, DRC (2004) Lukuka, 2006 [304] No association between parity or IPTp-SP and placental malaria infection 
Chikwakwa, Malawi (2004-05) Senga, 2007[305] NR 
Muheza, Tanzania (2002-05) Mwangoka, 2008 [306] NR 
Muheza, Tanzania (2002-05)  
 
Kabyemela, 2008 [146] Iron deficiency (aOR 0.20; 95% CI 0.11-0.36) and multigravidity (aOR 
0.32; 0.15-0.66) were independently associated with a decreased risk of 
placental malaria. The following factors were not independently 
associated with placental malaria infection; Use of intermittent 
presumptive therapy, insecticide-treated bed nets and delivering during 
seasons of low malaria transmission   
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Appendix 1.4: Risk factors for malaria and STIs/RTIs continued 
Infection Site,  country (year) First Author, Year of publication Risk factors for infection 
Placental malaria Blantyre, Malawi (1997-2001) 
 
Feng, 2010 [1] Number of sulphadoxine-pyrimethamine doses received correlated 
inversely with placental parasitaemia (aOR 0.79; 95% CI, 0.68, 0.91). 
Bednet use protected from placental parasitaemia (aOR 0.41; 95% CI, 
0.31, 0.54). 
 
Luanda, Angola 
 
Valente, 2011 [89] 
 
Women ≤ 18 years old were at a higher risk of placental malaria 
infection than women ≥ 25 years (aOR 2.2; 95% CI, 1.1-4.5). Women 
who had self-reported malaria infection earlier pregnancy (aOR 1.7; 95% 
CI, 1.1-2.8) and those residing in the peripheral areas of Luanda (aOR 
1.7; 1.0-30) were at a higher risk of infection. No association was found  
between parity or the level of education and placental malaria  
 
Manhica, Mozambique (2003-05) 
 
Serra-Casas, 2011 [143] 
 
Multiparous women were at a reduced risk of placental infection 
compared to primiparous women (aOR 0.30; 95% CI, 0.16-0.57) and 
women who had received SP had a lower risk of infection compared to 
women who had received placebo (aOR 0.42; 95% CI, 0.22-0.63) 
 
Manhica, Mozambique (2003-05) Mayor, 2012 [302] NR 
Mansa , Zambia Mace, 2012 [90] NR 
Rafiji and Moshi, Tanzania Moshi, 2015 Primigravidity (aOR 2.4; 95% CI, 1.1-5.0; P = 0.025) and residing in a high 
transmission area (aOR 9.4; 95% C,I 3.2-27.7; P < 0.001) were significant 
risk factors for placental malaria. IPTp was associated with a lower risk 
of placental malaria (aOR 0.3; 95% C,I 0.1-1.0; P = 0.044). 
 
aOR; Adjusted odds ration; BV: Bacterial vaginosis; HSV: herpes simplex  virus;  NR: Not reported 
Serological STI: human immunodeficiency virus, HSV-type 2 and syphilis 
Vaginal infection: Trichomoniasis, bacterial vaginosis and candidiasis  
α
Any STI: HSV-type 2, trichomoniasis, Chlamydia, gonorrhoea, syphilis and HIV 
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Appendix 2.1: Information Sheet 
You are being invited to take part in a research study.  It is important for you to understand 
why the research is being done and what it will involve before you decide.  Please take time 
to read the following information carefully and discuss it with others if you wish.  Feel free 
to ask us if there is anything that is not clear or if you would like more information.  Take 
time to decide whether or not to take part. Please understand that participation in this 
study is voluntary and that you are free to withdraw at any time, without giving any reason 
and without your medical care or rights being affected.  
About the study 
The study is on the malaria and reproductive tract infections in pregnancy. The principle 
investigator in this study is a lecturer of Parasitology at the University of Zambia and a PhD 
student at the London school of Hygiene and Tropical medicine. The study will be conducted 
under the supervision of experienced epidemiologists from the both the London School of 
Hygiene and Tropical Medicine and The University of Zambia. 
Malaria, curable sexually transmitted infections (STI) and non-sexually transmitted 
infections of the reproductive system of women put the health and lives of pregnant 
women and their babies at risk. All of these diseases are present in our communities.  In 
Zambia women receive pills at antenatal care that are meant to prevent malaria. Women 
are also screened for syphilis and treated if necessary. This is all in the interest of protecting 
them and their babies. However, these are not the only diseases that are common among 
pregnant women. Other diseases also affect the lives and health of women and their babies.  
Through this study we hope to find out the burden of malaria and the other infections that 
affect pregnant women when they occur together.   
Purpose of the project 
We hope to use the information from the study to contribute to improved health policies to 
ensure that women receive appropriate testing and/or treatment of other infection that 
affect them and their babies.  This study will also examine to what extent malaria and 
reproductive tract infections occur together among pregnant Zambian women. The Ministry 
of Health can use this information to make more effective recommendations for 
management of common infections that occur in pregnant women. 
Procedure 
 The nurses/research assistants will collect some personal information and collect a blood 
sample from you by pricking your finger and another one by drawing blood from your arm. 
They will also collect a vaginal sample from you and you will be given the first dose of 
sulphadoxine-pyrimethamine for protection of you and your baby against malaria. You will 
be asked to return to the clinic after four weeks. It is very important that you return after 
four weeks for a second malaria screening and the second dose of sulphadoxine-
pyrimethamine.  
When you come back to have your baby, the nurses will get a small piece of tissue from your 
placenta (the extra tissue that comes out after the baby) and ask you a few more questions. 
A 2cm by 2 cm by 1 cm piece will be sampled from the placenta. The baby will be weighed 
only; no blood will be taken from the baby.    
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All blood, vaginal swabs and tissue samples will be labelled with an identification number, 
not your name.  Your name and ID number will be recorded on a list kept only by the study 
coordinator.  This list will be kept only to help us to report back to you on your results and 
to follow up with you if you are found to have any of the infections that we will test you for.  
After the study is over, this list will be destroyed. 
Number of women required 
We need about 1100 pregnant women to take part in this study and women will be 
recruited consecutively as they come for their first antenatal visit. We are inviting anyone 
who is willing to take part provided that:  
1. The person is attending antenatal for the first time. 
2. She has not taken antibiotics or antimalarial agents in the previous 4 weeks.  
3. She is less than 32 weeks pregnant. 
Risks or discomforts 
We expect the risks for you being in this study to be rare.  You may feel a sting when a vein 
is punctured or when your figure is pricked to obtain blood from you.  If enough blood is not 
taken from one prick, a second prick may be done.  We may also ask you a few personal 
questions and you may feel uncomfortable answering these questions.  You may choose to 
not answer any questions that you do not feel comfortable answering.   
Benefits 
This study will benefit pregnant women in Zambia, their children.  We intend to share the 
results of this study with the Ministry of Health so that they can have evidence for the need 
to improve their recommendations on management and control of malaria and other 
infections that put the lives of pregnant women and their unborn babies at risk.  This study 
has the potential to contribute to the improvement of health care which pregnant women 
and babies born to them receive.  
Confidentiality 
Any information or samples that leave the health centre will have an identification number 
(ID) not your name.   Your name and ID number will be recorded on a list kept only by the 
study coordinator.  We intend to use this list to report back to you on your results so that 
you can get the required treatment.  After the study is over, all forms and your blood 
samples will be destroyed.  Only the final results of the study, without names, will be shared 
with others. 
Cost/Payment: 
Your participation in this study will not cost you any money.  The only cost to participating in 
this study is your time.  This should take up to an extra hour (in addition to period you will 
spend for the normal ANC activities) of your time today in order for us to collect samples 
and information about you. The project has no money to compensate you for the time you 
will spend for the study.  
Persons to Contact 
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If you have any questions about this study, please contact the principle investigator at P. O. 
Box 33528, Lusaka or call mobile: “Mobile number for the principle investigator was 
inserted here”. If you feel that you have been harmed as a result of being part of this study, 
please contact the University of Zambia Biomedical Research Ethics Committee at the 
following address: 
University of Zambia 
Ridgeway Campus 
P.O. Box 50110, Lusaka, Zambia 
Telephone 260-1-250753 
 If you agree to take part in this study you will be asked to sign two copies of the consent 
form and you will keep one together with this information sheet.  
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Appendix 2.2: Eligibility screening form 
If a potential participant’s gestational age by last menstrual period and fundal height 
determination is less than 32 weeks please fill out this form.  
  
1. Have you taken any antimalarial treatment in the past one month     No [  ]   Yes [  ] 
2. Have you taken any antibacterial medication in the past one month No [  ]   Yes [  ] 
3. Are you willing to allow   a member of our team to record your  
HIV test results. No [  ]   Yes [  ] 
 
 
Indicate to a potential participant that the results will not be recorded with their name but 
with an identification number that they will be given if they decide to take part in the study 
  
       
If the response to question 1 and to question 2 is “NO” and that to question 3 is “Yes” please 
ask for consent using the consent form. 
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Appendix 2.3: Consent Form 
Patients ID Number for study: _____________________________ (for official use) 
Title of project: The Epidemiology of malaria and sexually transmitted infections and 
reproductive tract infections in pregnant women in Ndola district, Zambia 
Name of researcher: Mrs. Enesia Chaponda Ngulube 
Please tick appropriately 
1. I confirm that I have read and understand the information sheet for the above study 
and have had the opportunity to ask questions.  Yes [  ]  No [  ]    
 
 
2. I understand that my participation is voluntary and that I am free to withdraw at any 
time, without giving any reason and without my medical care or rights being 
affected. Yes [  ]  No [  ] 
 
3. I understand that a vaginal samples and blood form my arm and from my finger will 
be collected from today. Yes [  ]  No [  ] 
 
4. I understand that a piece of my placenta will be taken from me at delivery Yes [  ]  
No [  ]      
       
 
5. I understand that sections of any of my medical notes that are of interest to the 
project may be read by the researchers.  I give permission for these individuals to 
have access to my records. 
Yes [  ] No [  ] 
 
6. I agree to take part in the above study Yes [  ]  No [  ] 
 
 
________________________________   _________________  
Participant’s signature      Date 
 
Thumb print (if unable to sign) 
 
________________________________  
 _______________________  
Name of person taking consent form    Signature 
(If different from principle investigator) 
 
1 for participant; 1 for researcher 
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Appendix 2.4: Questionnaire 
Participant’s ID Number: /___/___//___/___/ 
Demographics and Socio-economics 
1. Date of interview:………………………(dd/mm/yyyy) 
Village/area of residence ………………………………………. 
Name of Health centre ………………………………………….. 
2. HIV status 
[0] Negative [1] Positive 
 
3. Are you on antiretroviral therapy?  
[0] No [1] Yes 
 
4. What is your age? …………………. 
Measure and record weight, height and blood pressure at first antenatal visit 
5. Weight: ..................................... 
6. Height: ...................................... 
7. Systolic blood pressure ………………………mmHg 
8. Diastolic blood pressure …………………….mmHg 
9. What is your marital status? 
[1] Single    
[2] Married   
[3] Separated/divorced  
[4] Widowed 
[5] Other, Please specify ___________________ 
[99] Not answered 
 
10.  What is the highest level of schooling you completed?  
[Indicate number of years as 1, 2, 3… etc. count should include repeated years and 
years spend in tertiary education where applicable] 
____________ 
11. What is your main source of income? 
[1] Working for wages 
[2] Selling items 
[3] Self-employed (other than selling items) 
[4] None 
[5] Other, please specify_________________ 
[99] Unknown/not answered 
 
12. What is your husband’s main source of income? 
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[1] Working for wages 
[2] Selling items 
[3] Self-employed (other than selling items)  
[4] None 
[5] Other, please specify_________________ 
[6] Not applicable (single/widowed)  
Does your household have any of the following? 
13. Television  
[0] No   [1] Yes  
 
14. Electricity 
[0] No   [1] Yes  
15. Radio 
[0] No   [1] Yes  
16. Freezer/Fridge 
[0] No   [1] Yes  
 
17. What type of fuel does your household mainly use for cooking? 
 [1] Firewood 
[2] Charcoal 
[3] Gas 
[4] Electricity 
[5] Other, please specify__________________ 
[99] Not known 
18. What type of floor is in the house? 
[1] Earth/sand 
[2] Wooden/Bamboo 
[3] Vinyl/Tiles 
[4] Cement 
[5] Other, _________________ 
[99=] Not known 
19. What type of roof is on the main house? 
[1] Plastic/tarpaulin 
[2] Thatch/grass 
[3] Iron sheets/tiles/Asbestos 
[4] Other _________________ 
[99] Not known 
 
B. Indoor residual spraying and bed net ownership 
20. Do you have a bed net? (If not, go to question 23) 
[0] No   [1] Yes   
21. Is your net factory treated (long lasting net)? If ‘yes’ go to question 22 
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[0] No   [1] Yes  [99] Unknown 
22. If your net is not factory treated, when was the last time it was treated? 
[1] Treated in the last 6 months 
[2] Treated 6-12 months ago 
  [3] Treated more than 12 months ago 
 [4] Never been treated 
[99] Unknown 
23. Did you sleep under the bed net last night? 
[0] No   [1] Yes  
24. Has your house been sprayed for malaria control in the last 12 months? 
[0] No   [1] Yes  [99] Unknown 
C. Medical History          
25. Is this your first pregnancy? (If yes, enter 0 in question 26 and go to question 30) 
[0] No   [1] Yes 
 
26. If no, how many previous pregnancies have you had? (include all pregnancies resulting 
in live births, stillbirths, abortions/miscarriages) 
Number of previous pregnancies (1, 2, 3… etc) Pregnancies with twins count as 1 
pregnancy. 
 
 
 
27. Have you ever experienced a miscarriage (lost a baby before it could survive 
independently)? (Based on assessment by a medical practitioner) 
 [0] No   [1] Yes  
 
28. Have you ever experienced a stillbirth (given birth to a dead child)? (Based on 
assessment by a medical practitioner) 
[0] No   [1] Yes  
 
29. Have you ever given birth to a premature baby? (Based on assessment by a medical 
practitioner) 
[0] No   [1] Yes  
 
30. Have you ever experienced itching or/and burning session when urinating and/or 
vaginal discharge and/or had sores on your private parts during this pregnancy? (if ‘no’ 
go to 33) 
[0] No   [1] Yes 
  
31. If your answer to 25 is ‘yes’, did you receive treatment?  
 [0] No   [1] Yes 
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32. Are you currently experiencing any of the symptoms mentioned in 30? 
 [0] No   [1] Yes 
 
33.  Have you been treated for malaria during this pregnancy so far?  
[0] No   [1] Yes 
 
34.  Have you ever been treated for a sexually transmitted or reproductive tract infection 
this pregnancy 
[0] No   [1] Yes 
 
D. Sexual behaviour 
35. How old were you when you started your period (menstruation)? 
Enter age in years. If unanswered/unknown enter 99 
   
 
36. How old were you when you had your first sexual encounter? 
Enter number of years. If unanswered enter 99  
  
 
37. How many sexual partners have you had in your life time? 
     Enter number of partners. If unanswered enter 99 
  
 
 
To be administered after delivery. 
Patients ID Number: /___/___//___/___/ 
E. Birth characteristics and medical History 
38. Have you been treated for malaria during this pregnancy? 
[0] No   [1] Yes  [99] Not sure 
 
39. Did you take iron supplementation for blood building? 
[0] No   [1] Yes  [99] Not sure 
 
40. Have you taken or used any medicines/gel for the treatment of an STI or itchiness during 
this pregnancy? If no go to 41  
 [0] No   [1] Yes  [99] unknown/not sure 
 
41. If yes in which trimester1 was the medicine taken?  
[0] First Trimester 
[1] Second trimester 
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[2] Third trimester 
[99] Unknown 
 
11st trimester = in the first 3 months of pregnancy 
2nd trimester = in the 4th to 6th month after the last menstruation 
3rd trimester = in the 7th to 9th month after the last menstruation 
42. Indicate the name(s) of the drug(s) taken for STI/RTI treatment as recorded on the ANC 
card. 
....................................................................................................................................................
....................................................................................................................................................
.................................................................................................................................................... 
Questions 43-60 to be filled in by or with the help of the attending nurse and patients 
records 
 
43. Date of delivery (dd/mm/yyyy)  /___/___//___/___/___/ /___/___/____/    
 
44. Place of delivery 
[1] Hospital 
[2] Health centre/clinic 
[3] Home  
[4] Other.................................................................. 
 
45. Who performed delivery?   
[1] Family member  
[2] Traditional birth attendant (TBA) 
[3] Midwife 
[4] Doctor 
[5] Other 
 
46. Delivery induced/spontaneous   
[1] Induced 
[2] Spontaneous 
[99] Not known  
 
47. Type of delivery? 
[1] Vaginal 
[2] C-section 
[3] Assisted  
[4] Other 
 
48. How was the baby born? 
[1] Alive 
[2] Dead 
[3] Unknown 
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49. Sex of baby 
 
[0] Female [2] Male 
 
50. Birth weight: .......................grams. 
 
51. Delivery gestational age: ......................weeks [For official use, to be recorded based 
earlier assessment by ultrasound] 
 
52. Number of babies delivered  
[0] Singleton 
[1] Twins  
[2] Triplets 
 
 
53. Birth outcome  
[0] Live birth 
[1] Stillbirth 
[99] Unknown 
  
 (If live birth, go to F) 
  
54. For stillbirths, was the baby moving at the start of labour? 
[0] No  
[1] Yes 
[99] Unknown 
If yes go to F 
 
55. If the baby was not moving before delivery, how many days before delivery did the 
foetal movements stop?(Enter number of days 1, 2, 3, 8 etc) 
 
  
 
F.  Drug History 
56. HIV status 
[0] Negative   [1] Positive 
 
57. Has the participant been on ART? 
[0] No   [1] Yes  [99] Unknown 
 
 
58. Has the participants taken cotrimoxazole (commonly known as pyriton) during this 
pregnancy?  
[0] No   [1] Yes  [99] unknown 
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59. Has the Participant taken Sulphadoxine-pyrimethamine (Fancidar) for malaria 
prevention during this pregnancy?  
 
[0] No   [1] Yes  [99] Unknown 
 
60. If yes to question 59 indicate the number of doses as indicated by participant/recorded 
on the participants ANC card/record. 
 
 
 
Appendix 2.5: Study completion or drop out record form 
Participant’s ID number: \____\____\____\_____\ 
1. Date of enrolment dd/mm/yyyy /__/__/__/__/__/__/___/__/ 
2. Date of 28 day 
follow-up 
dd/mm/yyyy  
/__/__/ __/___/___/___/___/___/ 
3. Did the participant 
attend the 28 day 
follow-up 
 
[0] No   [1] Yes    
/___/ 
4. Was the 
participant lost to 
follow-up 
[0] No   [1] Yes   /___/ 
5. If yes give reason Reasons 
[1] Moved 
[2]cannot be traced 
[3] withdrew consent/refused 
[4]Other (To give reason go to 
6)  
 
6. If other reason  
Other________________________________________________ 
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Appendix 2.6: Laboratory Record/Reporting forms  
F1: Blood smear record form 
Participant’s ID number: \____\____\____\_____\  
Date of collection: dd/mm/yy \____\____\____\ 
Sample collected at day 0  Day 28  (Tick appropriately as indicated on slide) 
ID number Result No. of 
parasites 
No. of white blood 
cells 
Parasites/µl of blood 
     
 
F2: Record form for Chlamydia, trichomoniasis and gonorrhoea test results. 
Participant’s ID number: \____\____\____\_____\    
Organism Test result 
 
Chlamydia trachomatis 
 
Positive □      Negative □  
 
Neisseria gonorrhoea 
 
Positive □      Negative □ 
 
Trichomonas vaginalis 
 
Positive □      Negative □ 
 
F3: Record form for bacterial vaginosis diagnosis. 
Record form based on Nugent criteria 
ID Number Gram 
variable 
coccobacilli 
 
Gram 
negative 
curved 
bacilli 
Lactobacilli Total  score Classification 
      
      
 
F4: Placental Histology Results Reporting Form 
ID NO Parasite Pigment  Inflammation  Pathology class 
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Appendix 2.7: Names and sequences of primers that were used for detection of 
chlamydia, gonorrhoea, trichomoniasis and malaria infection 
 
Organism 
 
Primer name 
 
Sequence 
 
Chlamydia 
trachomatis 
 
KL1 
 
5'-TCCGGAGCGAGTTACGAAGA-3'  
KL2 5’AATCAATGCCCGGGATTGGT 3' 
 
Neisseria 
gonorrhoeae 
 
Ngu1 
 
5'-CAA CTA TTC CCG ATT GCG A-3' 
Ngu2 5'-GTT ATA CAG CTT CGCCTG AA-3' 
 
 
 
Trichomonas 
vaginalis 
 
TV3  
 
5′ – ATTGTCGAACATTGGTCTTACCTC –3 ′ 
 
TV7  
 
5′ – TCTGTGCCGTCTTCAAGTATGC –3′ 
 
 
Plasmodium 
falciparum 
 
 
 
 
1ST  
reaction 
 
 
rPlus 5 
 
 
 
5’-CCTGTTGTTGCCTTAAACTTC-3’ 
 
rPlus 6 
 
5’-TTAAAATTGTTGCAGTTAAAACG-3’ 
 
2nd  
reaction 
 
rFAL1 
 
5’-TTAAACTGGTTTGGGAAAACCAAATATATT-3’ 
rFAL2 5’-ACACAATGAACTCAATCATGACTACCCGTC-3’ 
Sources of primer sequences:  
C. trachomatis- Schachter 1997 [193] 
N. gonorrhoeae-  Chaundry 2002 [192] 
T. vaginalis- Kengne et al., 1994 [197] 
P falciparum-  Snounou et al., 1993 [201] 
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Appendix 2.8: Polymerase chain reaction parameters   
Organism  
(gene) 
Reaction Initial 
Denaturation 
0C, Time  
Denaturation 
 
0C, Time 
Annealing 
 
0C, Time 
Extension 
 
0C, Time 
Final 
Extension 
0C, Time 
No. of cycles 
Chlamydia trachomatis 
Chlamydial ribosomal 
plasmid 
Single PCR 
reaction 
95, 10 min 95, 10 min 62, 2 min 72, 1:30 
min 
72, 7 min 45 
Neisseria gonorrhoea 
(Orf1) 
 
Single PCR 
reaction 
95, 10 min 
 
95, 1 min 
 
55, 2 min 
 
72, 1:30 
min 
 
72, 7 min 
 
45 
 
Trichomonas vaginalis 
(repeat DNA sequence) 
single PCR 
reaction 
95, 10 min 95, 1min 60, 2 min 72, 1:30 
min 
72, 7 min 45 
Plasmodium falciparum 
(MSP2) 
Primary and 
secondary 
94, 2 min 94 for 45 sec 61.1, 45 
sec 
65, 1 min 65, 2 min 25 
Plasmodium falciparum 
(Dhfr and Dhps) 
Primary and 
secondary 
 
94, 2 min 94, 45 sec 43.4, 45 65,1 min 65,2 min 25 
Plasmodium falciparum 
small subunit ribosomal 
RNA 
primary 94,3 min 94,1 min 60, 2min 
 
72, 2min 72, 7min 30 
secondary 94,3 min 94, 1min 55,2min 
 
72, 2min 72,7 min 30 
MSP2-Merozoite surface protein 2 
DHFR-Dihydrofolate reductase 
DHPS-Dihydropteroate synthase 
DNA- Deoxyribonucleic acid 
RNA-Ribonucleic acid 
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Appendix 2.9: Primer names and sequences for detection of DHFR and DHPS mutations 
Polymorphism 
 
Primer                               Sequence 
Pf DHFR 
1st 
reaction 
M1              5’-TTTATGATGGAACAAGTCTGC-3’ 
 
Pf DHPS 
M5 
 
R2 
             5’-AGTATATACATCGCTAACAGA-3’ 
 
              5’-AACCTAAACGTGCTGTTCAA-3’ 
R1               5’-AATTGTGTGATTTGTCCACAA-3’ 
Pf DHFR 
 
2nd 
reaction 
 
 
M3 
 
 
              5’-TTTATGATGGAACAAGTCTGCGACGTT-3’ 
F/               5’-AAATTCTTGATAAACAACGGAACCTttTA-3’ 
F               5’-GAAATGTAATTCCCTAGATATGgAATATT-3’ 
 
M4               5’-TTAATTTCCCAAGTAAAACTATTAGAgCTTC-3’ 
Pf 
DHPS 
 
K 
 
              5’-TGCTAGTGTTATAGATATAGGatGAGcATC-3’ 
K/               5’-CTATAACGAGGTATTgCATTTAATgCAAGAA-3’ 
 
J               5’TGCTAGTGTTATAGATATAGGTGGAGAAagC-3’ 
L               5’-ATAGGATACTATTTGATATTGGAccAGGATTcG-3’ 
L/               5’-ATTACAACATTTTGATCATTCgcGCAAccGG-3’ 
Source of primer sequence: Duraisingh 1998 [203], Pf-Plasmodium falciparum 
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Appendix 2.10: Restriction fragment length polymorphisms analysis of DHFR and DHPS 
polymorphisms 
Appendix 2-10a RFLP analysis of DHFR polymorphisms 
Substrate Codon Enzyme RFLP Residue 
M3-F/ DHFR 16 NlaIII 93bp, 376bp Ala 
146bp, 376bp Val 
DHFR 51 Tsp509I 120bp, 154bp Asn 
120bp, 218bp Ile 
DHFR 108 AluI 196bp, 326bp Ser 
522bp (no cut) Other 
BsrI 190bp, 322bp Asn 
522bp Other 
BstNI 196bp, 326bp Thr 
522bp Other 
F-M4 DHFR 59 XmnI 137bp, 189bp Cys 
137bp, 163bp Arg 
DHFR 108 AluI 119bp, 180bp Ser 
299bp Other 
BsrI 146bp, 180bp Asn 
326bp Other 
BstNI 145bp, 181bp Thr 
326bp Other 
Appendix 2-10b RFLP analysis of DHPS polymorphisms 
Substrate Codon Enzyme RFLP Residue 
K-K/ 436 MnlI 121bp, 278bp Ser 
121bp, 317bp Other 
MspA1I 406bp Ala 
438bp (no cut) Other 
437 MwoI 387bp Ala 
419bp Other 
AvaII 404bp Gly 
438bp Other 
540 FokI 85bp, 320bp Glu 
405bp Other (Lys) 
J-K/ 436 HindIII 406bp Phe 
438bp Other 
HhaI 406bp Ala 
438bp Other 
L-L/ 581 BstUI 105bp Ala 
138bp Other 
BslI 128bp Gly 
161bp (no cut) Other 
613 MwoI 128bp Ala 
161bp Other 
BsaWI 131bp Ser 
161bp Other 
AgeI 128bp Thr 
161bp Other 
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Appendix 2.11: Sequences of oligonucleotide primers that were employed for the 
differentiation of recrudescence from re-infection 
Merozoite Surface Protein 2: msp2 
Reaction Primer name Sequence 
First reaction: M2-OF  5- ATGAAGGTAATTAAAACATTGTCTATTATA -3 
 M2-OR  5- CTTTGTTACCATCGGTACATTCTT -3 
Second reaction:   
FC27-type M2-FCF  5- AATACTAAGAGTGTAGGTGCARATGCTCCA -3 
 M2-FCR 5- TTTTATTTGGTGCATTGCCAGAACTTGAAC -3 
IC3D7-type M2-ICF   5- AGAAGTATGGCAGAAAGTAAKCCTYCTACT -3 
 M2-ICR  5- GATTGTAATTCGGGGGATTCAGTTTGTTCG -3 
Source: Snounou et al, 1999 [205] 
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Appendix 2.12: Letter of notification of Ethical Clearance 
 
 
 
